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Preface 
 
Drug abuse has devastating consequences on individual abusers, their 
families, their communities, and our Nation.  The phenomenon is dynamic, 
constantly changing, and complex. Like other diseases, it is important to 
identify and assess the nature and extent of drug abuse and emerging drug 
abuse problems as soon as possible. It is also important to closely monitor 
drug problems within and across communities.  Epidemiology is one of the 
first lines of defense.  It enables researchers to… 
 Assess the causes, determinants, and distribution of drug problems 
 Discover, identify, and track drug problems   
 Identify questions, issues, and research hypotheses 
 Plan appropriate intervention strategies 
 Launch public information campaigns 
 Alert communities 
  
The National Institute on Drug Abuse (NIDA) supports research on all aspects 
of drug abuse and addiction, ranging from studies of the brain to the nature 
and extent of drug abuse in different populations.  A considerable body of 
knowledge has been produced through the research supported by NIDA over 
the years.  The research has led to… 
 A greater understanding of the nature of drug addiction as a chronic 
disease 
 Knowledge on how to prevent and treat drug abuse and drug addiction  
 
NIDA has also supported the Community Epidemiology Work Group 
(CEWG) since 1976. The CEWG monitors and assesses drug abuse patterns, 
trends, and emerging problems across 21 sentinel areas in the United States 
using multiple sources of data.  
 
One of NIDA’s goals is to develop science-based tools and assist communities 
in using them to identify and assess drug problems, so communities, in turn, 
can provide the information to planners, policymakers, and interventionists 
who are involved in the prevention and treatment of drug abuse. 
 
In an effort to foster this goal, we are pleased to offer our newest edition of 
Assessing Drug Abuse Within and Across Communities, Second Edition.  The 
publication provides updated guidelines on how to effectively establish and 
maintain drug abuse epidemiology surveillance networks. We also invite you  
Preface 
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to visit our Web site at <www.drugabuse.gov> where this publication and 
other materials related to the consequences, prevention, treatment, and 
monitoring of drug abuse patterns and trends are offered.  We hope that 
communities and States will find this guide useful and helpful in their work. 
 
The strategies suggested in this guide are based on methods that have been 
applied in communities throughout our Nation and in other countries.  Many 
of the examples provided on uses of different drug abuse indicators are from 
the CEWG and other epidemiology work groups.  
 
 
Nora D. Volkow, M.D. 
Director 
National Institute on Drug Abuse 
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Introduction 
 
In 1998, the National Institute on Drug Abuse (NIDA) published the first 
edition of Assessing Drug Abuse Within and Across Communities: Community 
Epidemiology Surveillance Networks on Drug Abuse to share information on 
establishing drug abuse epidemiology networks at community and State 
levels.  The first edition was widely distributed and well received, with 
ongoing requests for a reprint of the publication. However, it was clear that an 
update and not a reprint would be of most value to the fields of drug abuse 
epidemiology, research, and intervention. Since 1998, the expansion of the 
Internet has greatly enhanced access to relevant drug abuse information.  
Also, since 1998, there have been substantial changes in drug abuse data 
sources used by epidemiology networks. This second edition addresses these 
changes, but the purpose of this edition remains the same: to provide 
guidelines for establishing epidemiology networks to monitor and assess drug 
abuse patterns and trends and emerging drug problems at community and 
State levels to provide a foundation of information for public health response.  
 
NIDA’s Division of Epidemiology, Services and Prevention Research has 
continued to support epidemiology networks, including the Community 
Epidemiology Work Group  (CEWG) consisting of 21 sentinel metropolitan 
areas, the Border Epidemiology Work Group in coordination with the 
Ministry of Health of Mexico, and State Epidemiology Work Groups.  
International epidemiology networks, modeled after the CEWG, often present 
data at CEWG meetings on drug abuse patterns and trends in other nations. 
Years of experience with these groups are testimony to the contributions of 
epidemiology work groups in advising public health response in our Nation as 
well as other countries. 
 
This second edition differs from the first in format.  For each data source, 
there is a description of the source and database, followed by guidelines on 
how to access the data (including Web sites) and what to request, and 
examples of how the data have been used by epidemiology work groups or 
Federal agencies.  NIDA hopes that this revised guide is helpful to agencies, 
organizations, and researchers that are involved in or wish to establish 
epidemiology networks in their communities or States.
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PART I. COMMUNITY EPIDEMIOLOGY 
SURVEILLANCE NETWORKS ON 
DRUG ABUSE  
 
 
What Are Community Epidemiology Surveillance Networks? 
 
 
Community Epidemiology Surveillance Networks are multiagency work 
groups with a public health orientation that study the spread, growth, or 
development of drug abuse and related problems. The networks have a 
common aim––the assessment of drug abuse patterns, trends, and emerging 
problems to provide the foundation of information for public health response. 
The ultimate goal is the elimination or reduction of drug abuse and its related 
consequences.  
 
To achieve this goal, network members access existing information from 
multiple sources, including drug abuse treatment agencies, public health 
offices, law enforcement agencies, hospital emergency departments, medical 
examiner and coroners' offices, and local school and household surveys. Much 
useful data are available in published reports. Furthermore, the Internet has 
greatly facilitated access to many data sources and published reports.  
 
Members meet periodically to review, compare, and draw inferences from the 
data. The data are reported in a standardized format to facilitate the review 
and comparative analyses. Qualitative studies may be conducted to help 
members understand the quantitative findings from existing data sets.  
 
The primary objectives of the network members are to…  
 Identify drug abuse patterns in defined geographic areas  
 Identify changes in drug abuse patterns over defined time periods to 
establish trends  
 Detect emerging substances of abuse 
 Communicate and disseminate the information to appropriate community 
agencies and organizations so it can be used in developing policies, 
practices, prevention strategies, and research studies 
 
Network members are individuals who are in a position to access and assess 
information about drug use in specific geographic areas. They may represent 
agencies and organizations that have some responsibility for addressing drug 
abuse problems or that benefit directly from acquiring information about drug 
abuse. Researchers and other individuals who have special knowledge about a 
particular issue or drug-abusing population also may participate. Regularly 
…network members 
access existing 
information from 
multiple sources… 
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scheduled network meetings provide a forum for members to share, review, 
and analyze information on the epidemiology of drug abuse.  
 
This guide focuses on practical ways of accessing and analyzing diverse 
indicator data from a variety of data sources and on effective ways of 
reporting such data.  
 
 
Where and How Did Surveillance Networks Get Started? 
 
 
The first national level surveillance network was established in 1976 by the 
National Institute on Drug Abuse (NIDA), National Institutes of Health, to 
assess current drug use patterns in major metropolitan areas across the country 
and to identify emerging trends within and across these areas. This network, 
called the Community Epidemiology Work Group (CEWG), has been meeting 
semiannually since 1976 to fulfill its role as a drug abuse surveillance system. 
CEWG members represent Atlanta, Baltimore, Boston, Chicago, Denver, 
Detroit, Honolulu, Los Angeles, Miami/Ft. Lauderdale, Minneapolis/St. Paul, 
Newark, New Orleans, New York City, Philadelphia, Phoenix, St. Louis, San 
Diego, San Francisco, Seattle, the State of Texas, and Washington, DC. 
Names and contact information for CEWG representatives are presented in 
Appendix A of this publication, in each semiannual CEWG Volume II report, 
and on the NIDA Web site <http://www.nida.nih.gov> (see About 
NIDA/Organization/Community Epidemiology Work Group for both CEWG 
contact information and meeting reports).  CEWG representatives are useful 
contacts for information specific to their cities and for additional advice on the 
organization of a local community surveillance network. 
 
Based on the NIDA CEWG model, State Epidemiology Work Groups 
(SEWGs) have been organized in many States. Other countries also have 
adopted the model. Similar work groups have been organized or are under 
development in Asia, Australia, Canada, Central America, Europe, Mexico, 
and South Africa.  
 
National CEWG information is disseminated by the Division of Epidemiology, 
Services and Prevention Research, NIDA, through its biannual report series 
entitled Epidemiologic Trends in Drug Abuse. Information on the national 
CEWG, its reports, and other important data sources can be accessed from the 
NIDA Web site (specified above).  By clicking on “organization,” you will find 
it listed under Division of Epidemiology, Services and Prevention Research.  
 
 
Why Are Networks Established? 
 
Drug abuse and dependence strain resources at local, State, and national levels 
and threaten the well-being of drug abusers and their significant others.  The 
…the Community 
Epidemiology Work 
Group (CEWG) has 
been meeting 
semiannually since 
1976… 
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types of drugs used and the populations using a particular drug or drugs at a 
particular period in time change, and drug abusers continue to be an elusive 
population that is not fully captured in prevalence studies. Drug abusers often 
remain “hidden” until they seek medical care, are arrested, or come into 
contact with social and criminal justice agencies. 
To best understand the problem, planners, policymakers, and practitioners 
need timely information on a regular basis so human, financial, and medical 
resources can be allocated appropriately. The research community also needs 
such information so studies can be planned and implemented to provide more 
indepth and definitive data to help guide policy and prevention and treatment 
interventions. 
In Chapters 1–8 of this publication, descriptions are provided of major types 
of data sources used by a network, with examples of how these data have been 
used.  Many of the examples are provided by representatives of the CEWG. In 
the description of different data sources, the reader is referred to relevant Web 
sites. Information about relevant Web sites is also provided in Appendix B. 
Note, however, that Web site addresses sometimes change, and it may be 
necessary to search by the name of an agency or organization. 
The primary purpose of a local surveillance network is to share timely and 
reliable information about drug abuse. Surveillance networks help define and 
determine the magnitude of drug problems and provide an early warning for 
emerging problems. What types of drugs are being used in particular 
communities? Who is using them? How are they being used? What are the 
consequences of use? How are the patterns of use changing?  
 
Information of this type is essential to many agencies and organizations, 
especially those with responsibility for planning and allocating resources to 
address drug abuse and related problems. Too often, agencies plan strategies 
and commit resources without having up-to-date information about the nature 
and extent of drug abuse problems. These efforts can be wasteful and 
counterproductive.  
 
Patterns of drug use are determined not only by the availability and cost of 
different substances, but also by the dynamics and differences within groups, 
cultures, and communities. Drug abuse patterns are complex, dynamic 
phenomena that can quickly spread through and across communities. Drug 
abuse has been associated with increasing rates of crime and violence, as well 
as health problems such as human immunodeficiency virus (HIV) infection, 
which causes the acquired immunodeficiency syndrome (AIDS); other 
sexually transmitted diseases (STDs); and other infectious diseases such as 
hepatitis B and C. If a pattern is identified early, appropriate action can be 
taken to control its spread.  
 
By monitoring drug abuse over time, it also is possible to evaluate whether 
programs are having any impact on particular aspects of drug abuse problems.   
The primary 
purpose…is to share 
timely and reliable 
information… 
…drug abusers 
continue to be an 
elusive population… 
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It is important for members to understand the specific purposes, advantages, 
organization, and limitations of the network. Through this understanding, 
local networks are more likely to be successful and contribute to needs 
assessments.  
 
 
What Are the Advantages of a Network? 
 
 
The surveillance network model has many advantages for planning purposes...  
 It uses a practical formula.  
 It is not costly.  
 It makes use of existing resources.  
 It provides immediate feedback.  
 It works on many different levels (e.g., local, State, national, 
international).  
 The information is useful to many agencies and organizations.  
 It provides input from different perspectives.  
 It establishes a network of people who share information and work 
together on common problems.  
 It builds an infrastructure for further research.  
 
Often, people who are sought as members of a network already are engaged 
by agencies or organizations involved in the drug abuse field and may be 
currently collecting data from or about drug-using populations. In addition, 
their agencies would probably recognize the short- and long-term benefits to 
be derived from participation in a surveillance network.  
 
Optimally, meetings should be regularly scheduled about twice each year. 
This time frame provides a sufficient time gap (6 months) to assess changes in 
drug use patterns and keep the groups active without placing a heavy burden 
on participants. At least 1 full day should be set aside for each meeting.  
 
 
It is important for 
members to 
understand the 
specific purposes… 
Often, people who 
are sought as 
members of a 
network already are 
engaged by 
agencies or 
organizations 
involved in the drug 
abuse field… 
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What Sources of Information Do Networks Access and Use? 
  
 
Epidemiology networks make use of multiple sources of information, such as 
those described above and elaborated upon in the chapters that follow. Each 
source has the potential to provide data/information about particular drug-
using populations and/or different facets of the behaviors and outcomes of the 
same or similar populations.  The data/information obtained from each source 
is considered a drug abuse indicator.  The direction of changes in indicators 
across time is a measure of relative change in drug-abuse behaviors and 
related problems rather than a measure of absolute change. Indicators do not 
provide estimates of the number (prevalence) of drug abusers at any given 
time.  Rates (e.g., per 100,000 population) at which drug-abusing populations 
may be increasing or decreasing in size are sometimes reported and help 
standardize data.  However, indicators do help identify different types of drug 
abusers, such as those who have been arrested, treated in hospital emergency 
departments, discharged from hospitals, admitted to drug abuse treatment 
programs, involved in accidents, diagnosed with HIV/AIDS, or died with 
drugs found in their bodies.   
Survey data can be used to complement indicator data.  Most surveys can 
provide estimates of the prevalence of drug use in particular populations (e.g., 
general household and school populations), including the prevalence of use of 
specific substances. However, the populations covered in surveys may not 
provide information on many groups at high risk for drug abuse (e.g., 
homeless persons, school dropouts). Methodologically sound surveys provide 
valuable prevalence estimates of the population groups that are sampled. 
By comparing information from different sources concurrently, network 
members can identify and learn more about different drug-using populations, 
the similarities and differences across groups, and perhaps emerging patterns 
and trends. One source can complement and support another and help to 
validate information on drug use patterns. Networks, at all levels, use many 
data sources. 
 
 
How Are Local Networks Organized? 
 
 
Generally, the impetus for organizing a surveillance network comes from an 
agency that recognizes the need for up-to-date information about drug abuse 
patterns and trends. The agency may be one that coordinates drug abuse data 
sources or a health planning organization. Sponsoring a network can be of 
great benefit to an agency, as it provides that agency with important infor-
mation about drug trends, knowledge about street use, and a network of 
sources to answer questions. Any agency that deals with the general public, 
…indicators help 
identify different 
types of drug 
abusers… 
One source can 
complement and 
support another and 
help to validate 
information on drug 
use patterns. 
Each source has the 
potential to provide 
data/information 
about different drug-
using populations… 
Sponsoring a 
network can be of 
great benefit to an 
agency… 
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answers questions about drugs, or provides public information will find the 
investment in sponsoring a local network worthwhile. In addition, it will be 
possible to provide education and information materials and press releases to 
inform the public of current trends.  
 
For practical reasons, it is important to have someone assume the role of 
Network Coordinator, a member who will serve as the key point person to 
ensure that all members are informed of the time and place of each meeting, 
that a meeting agenda is finalized and disseminated to all participants, and that 
each member is fully aware of the roles that he or she should assume at each 
meeting. In some networks, members have shared this role, since it is 
demanding and requires ongoing coordination and communication. The 
Network Coordinator may be someone who works for a lead agency (e.g., a 
drug abuse treatment agency) and is given the time and resources to carry out 
this role.  The Coordinator also assumes the lead role at network meetings, 
briefly reviewing findings and issues raised at the prior meeting, the 
objectives for the current meeting, and the plans for the next meeting. 
It is best to plan and maintain small work groups so that all participants have 
an opportunity to contribute to the process. Try to get members from different 
organizations and with different perspectives. Include the medical examiner, 
treatment program personnel, HIV street outreach workers, health planners, 
university researchers, and local police officers. If the network is comprised of 
representatives of different towns, cities, or counties, the reporting process 
should be standardized so that comparisons can be more easily made across 
different jurisdictions.  
 
Initially, one or two staff members can be assigned to review and report on 
potential benefits, other potentially valuable participants, and accessible 
sources of information. Representatives of other agencies can be contacted to 
determine how the information might be useful to them, their level of interest, 
and who from their agencies might meet the qualifications to participate in the 
network. This type of review should be completed within a 1–2 month period.  
 
If, on the basis of the information, it is decided to begin efforts to organize a 
surveillance network, arrange a small planning meeting of staff from key 
agencies. This meeting should include researchers and agency representatives 
who are familiar with drug abuse issues and sources of data and who are 
interested in the possibility of establishing a network. The meeting should be 
structured to… 
 Establish the rationale for and the purpose of a network  
 Identify potential sources of data/information  
 Identify agencies and individuals with access to information  
 Identify individuals who could contribute in other ways to the network  
 Develop an agenda for the first meeting  
…arrange a small 
planning meeting of 
staff from key 
agencies. 
…it is important to 
have someone 
assume the role of 
Network 
Coordinator… 
It is best to plan and 
maintain small work 
groups… 
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 Determine who should be invited to participate in the first meeting and 
what they should be asked to contribute  
 Establish a time and place for the first meeting  
 Develop a plan for the second meeting, including the date, place, and 
general themes to be covered 
 
A preliminary step that has proven useful is to hold a preplanning meeting 
with officials of selected organizations or agencies to discuss the purpose and 
goals of the network; how the agency or organization can contribute; the staff 
capabilities, knowledge, skills, and experience required to contribute; and the 
benefits to the agency of belonging to the network.  
 
While it is unlikely that an agency official will be a working member of the 
local network, enlisting the official's support may increase the agency's 
participation in and contribution to the network. Unless the official 
understands the value of the network, he or she may not be willing to support 
the initiative and the investment of time by the agency. In addition, the official 
may help identify the most qualified person(s) from the agency to serve on the 
network. In some instances, it is beneficial to invite both the official and his or 
her data person to the meeting so the official can become informed of the 
benefits of the group and the data person can be involved from the beginning 
in identifying needed information.  
 
 
How Should the First Network Meeting Be Organized? 
 
 
The first meeting is very important because it sets the stage for what the 
surveillance network will be, how it will function, and how it will be 
perceived by participants and others. Two interrelated objectives should 
always be kept in mind…  
 Obtaining knowledge about drug abuse 
 Developing and strengthening the work group  
 
Care should be taken to avoid common pitfalls that others have encountered in 
planning initial network meetings. Four principles should be observed…  
 
1. Start small. Be selective in inviting individuals to attend. It is easy to add 
individuals once the needs and sources have been identified and to change 
individuals based on the strengths and interests of the members.  
 
2. Have clear, attainable objectives for the meeting. Avoid trying to 
overachieve at the beginning.  
 
Have clear, attainable 
objectives for the 
meeting. 
…enlisting the 
official’s support 
may increase 
the agency’s 
participation and 
contribution… 
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3. Establish the agenda in coordination with other participants so they feel 
invested from the beginning.  
 
4. Give each participant a role to play and a contribution to make.  
 
The first meeting should be organized to accomplish several objectives…  
 Identify known and potential sources of data and information. Selected 
participants can be asked to describe particular data sets and to prepare 
and briefly present data from sources to which they have access.  
 Review the types of data sources (indicators) accessed by other 
epidemiologic networks to determine if they might be available in your 
area. If they are, determine what steps should be taken to identify agencies 
and individuals who can provide access to each of these sources.  
 Assign participants to follow up (after meetings), and, if appropriate, make 
contacts to find out what types of data are available, how the data can be 
made available, and who is most knowledgeable about the data and the 
data sources.  
 Determine how the information from the meetings should be recorded, 
reported, and disseminated, including to whom it should be sent. A full 
report with all the information will prove useful for agency planners, grant 
writers, and staff associated with the network member agencies. An 
executive summary that brings all the information together in a quick-
reference format will prove very popular with the press and the general 
public.  
 Identify current and potential sources of support for organizing and 
conducting the meeting and producing and disseminating meeting reports. 
The full report should be based largely on the papers prepared and 
presented by participants, along with data tables.  
 
Surveillance networks need to remain focused on questions such as: What 
drugs are currently being used? Who is using them? Are drug use patterns 
changing from year to year? If so, how?  
 
 
What Types of Problems Are Encountered by Networks? 
 
 
As in any network, individuals who participate in the meetings are likely to 
have different backgrounds and different frames of reference. It may not 
always be clear to them what is expected. If each member is sent the specific 
format for the presentation in advance, it will be easier to keep the meetings 
on track and to get the information in a form that is comparable with that 
submitted by other members.  
 
Surveillance net-
works need to  
remain focused 
on questions… 
…determine what 
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It must be kept in mind that there is limited time to address the key questions 
and achieve the network's objectives. It is therefore important for the persons 
coordinating or chairing network meetings to define carefully what 
information participants need to present and to keep the meetings focused. 
Tell each member in advance the time limit for the oral presentation.  
 
Another problem is the turnover in members and finding members who are 
interested in the network and willing to commit to the process and collect and 
report on the information on a continuing basis. The Network Coordinator will 
occasionally confront the need to search for new members and persons who 
have the time to participate. It is good policy to routinely call the agency 
directors to thank them for the past participation of their staff, inform them 
that another meeting is planned, and explain the importance of their agency's 
participation and the benefit to the agency. At times, unless informed, the 
director will not know that a meeting has been scheduled, and the local 
network member may be unable to attend the meeting or not have time to 
gather the needed data.  
 
 
Who Should Be Invited to the First Network Meeting? 
 
 
The first meeting should be considered a planning session. The organizers 
should emphasize that the individuals who attend this meeting will not 
necessarily be permanent members and they are not obligated to attend future 
meetings. One of the primary objectives of the first meeting is to identify 
individuals who are in the best position to contribute information to the 
network planning process. If a national CEWG representative is located in 
your State, or if there is a planner at the State Substance Abuse Agency 
(SSAA) who is knowledgeable about sources of data, invite them to the first 
meeting.  
 
The first meeting should include individuals who are capable of providing 
information about different sources of data, including the following:  
 
Survey Data  
 
If not yet known, find out if any relevant local surveys have been or are 
currently being conducted or planned. These would include household, school, 
and special population surveys that provide information about substance use. 
In addition, some States have contracts from Federal agencies to perform 
surveys. In some instances, the State agency has conducted the surveys, while 
in other States, surveys are done by a university or survey research firm. If a 
relevant survey has been or is being conducted, invite the Principal 
Investigator or another person who can describe the data collected.  
 
One of the primary 
objectives of the first 
meeting is to identify 
individuals who are in 
the best position to 
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Drug Abuse Treatment Data  
 
If not yet known, find out which agencies collect information about drug 
abusers entering, undergoing, and/or leaving treatment. Every treatment 
program that receives funds from the SSA is required to report data to the 
State. Which local drug abuse treatment programs participate in the State 
system, and which are required to report client data to county and city 
coordinating agencies? Find out who in the different agencies is responsible 
for coordinating these efforts. Contact these individuals to find out who would 
be the most appropriate person to participate in the first network meeting. 
Treatment facilities can be found at <http://findtreatment.samhsa.gov>. 
 
Law Enforcement Data  
 
If not yet known, find out which agencies, departments, or offices collect drug 
use data on local arrestees charged with criminal offenses, including drug 
violations. Drug violations, including arrests for possession and/or trafficking, 
are reported by counties and States. Several different State offices can be 
contacted to determine sources of arrest data. These include the Uniform 
Crime Report Office, the Statistical Analysis Center, the Law Enforcement 
Planning Office, and the Attorney General's Office. In some instances, the 
same arrest will be reported by the local police, the State police, and Federal 
agents, so inquire about possible duplicate reporting and overlap. Other law 
enforcement data that can be very useful include information on price and 
purity of drugs confiscated. Try to find out which levels of law enforcement 
agencies are included in a report. State Statistical Analysis Centers (SACs) 
assemble statewide criminal justice statistics, act as a clearinghouse for 
statewide crime information and statistics, and issue periodic reports. Contact 
names, addresses, and telephone numbers for the SAC office in each State can 
be found at <http://www.jrsa.org/sac>.  
 
Hospital Data Pertaining to Drug Use  
 
If not yet known, contact the State, county, and city health departments to 
identify individuals who can provide information about relevant hospital data 
sources. If the geographic area covered by the network is relatively small, it 
may be appropriate to contact administrators of each hospital to find out what 
types of data related to drug use are collected and who coordinates such 
efforts within or outside the hospital.  
 
AIDS Cases and HIV Seroprevalence Data  
 
HIV/AIDS is a reportable condition in all States and territories in the United 
States. The HIV/AIDS Surveillance System, established by the Centers for 
Disease Control and Prevention (CDC), monitors the incidence and 
demographic profile of AIDS cases and describes the modes of HIV 
transmission among infected persons. Information can be found at 
<http://www.cdc.gov/hiv/surveillance.htm>. State and local health 
…drug use data on 
local arrestees… 
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departments conduct active surveillance. Standardized case report forms and 
software (HIV/AIDS Reporting System) are used to produce local tabulations 
and to report cases monthly to the CDC. All 50 States, U.S. territories and 
possessions, and some major cities report to the CDC surveillance system.  
 
One of the objectives of surveillance is to identify changing patterns in the 
modes of HIV transmission. The local health department office responsible 
for HIV/AIDS surveillance should be contacted to find out who is the best 
person to report relevant information at the first network meeting, such as 
information on the percentage of injection drug users who have contracted the 
virus.  
 
Other Health Data  
 
Since substance abuse is also related to numerous health consequences, such 
as tuberculosis and sexually transmitted diseases, the State, county, or city 
health departments will have information on the number of individuals who 
have these diseases and the prevalence rates for these diseases in your local 
area. Contact the health department to get the statistics and to obtain 
information from the street outreach workers who seek out persons with these 
diseases. In some instances, certain outreach workers concentrate on drug-
using populations, while others will concentrate on prostitutes and commercial 
sex trade workers.  
 
School Data  
 
Local and State school systems may fund surveys of drug use among students. 
If a relevant survey has been or is being conducted in your area, invite the 
Principal Investigator or another person who could describe the data collected. 
 
School survey data may be available in a network’s area from the Youth Risk 
Behavior Survey (YRBS), supported by CDC and conducted in coordination 
with State and local educational entities (see Chapter 1).  
 
Community-Level Data Sources  
 
At the community or neighborhood level, data/information sources can be 
obtained from smaller entities. Be careful to check that this information is not 
already included in reports from the various State agencies. The following are 
some suggested local sources of data: 
 Drug abuse treatment and intervention programs (both public and private) 
 Local hospitals and hospital associations 
 State, county, and local health departments and agencies/clinics  
 Medical examiners and coroners offices 
 Poison control centers 
 Drug helplines 
Local and State school 
systems may fund 
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 Community mental health centers 
 HIV and STD outreach programs 
 Pharmaceutical associations 
 State and county forensic laboratories 
 Criminal justice and correctional agencies that report arrest data (e.g., 
police, sheriff) 
 Agencies that collect and report data on drug seizures and the price and 
purity of different drugs 
 Drug courts 
 Education offices and departments and schools 
 Recreation facilities 
 University researchers who conduct surveys or studies on drug abuse 
 
There may be many other potential sources of information, depending on the 
community. 
 
Network members may also review the Computer Retrieval of Information on 
Science Projects (CRISP) to determine if any studies are relevant to their area.  
CRISP is a searchable database of federally funded biomedical research 
projects being conducted at universities, hospitals, and other research 
institutions.  CRISP, maintained by the National Institutes of Health (NIH), 
includes NIDA grantees who are conducting drug abuse research.  The 
information may be accessed through related links on NIDA’s Web site 
(<www.nida.nih.gov>; see Appendix B). 
Over time, the network can identify individuals most likely to have data on 
drug abusers and make efforts to engage them as regular members. 
 
 
Some Basic Steps in Accessing Drug Abuse Indicator Data 
 
Many data sets can be accessed on the Internet (see Appendix B). Other 
relevant data may not be available online, and it will be necessary to access 
information through records, publications, or some other type of 
documentation.  In either case, it may be necessary to contact agencies and 
organizations to obtain needed information. However the data are accessed, 
taking the steps outlined below will prove useful. 
 
 
CRISP is a searchable 
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1. Identify the data set and its characteristics by addressing such 
questions as the following:  
¾ What are the data categories relevant to illicit drugs and to nonmedical 
use of prescribed drugs?  How is each category defined? 
¾ What populations are covered in the data set?  Are data on 
demographic and other social or behavioral characteristics of each 
drug-abusing group available?  How is each of these categories 
defined? 
¾ What geographic area(s) is covered (e.g., State, region, county)?  Can 
the data be aggregated into subareas of interest (e.g., metropolitan 
area, Zip Code)? 
¾ What time period(s) is covered?  Does each period represent a 
calendar year or a fiscal year?  For which years are comparable data 
available so that trend analyses can be conducted? 
¾ Are the raw data (numbers) available? Are the data reported as 
percentages, averages, or in some other descriptive statistic form?  Are 
the data in a format or system that can be manipulated for further 
analysis?  Access all numeric data of interest and any available 
information needed to further manipulate the data. 
2. Obtain documentation on the system (e.g., data collection instruments, 
sampling methods, analytic methods) to assist in understanding the data. 
3. Identify any privacy or confidentiality procedures that must be 
followed in analyzing and reporting the data. 
4. Identify a person(s) in the agency/organization who can answer questions 
that may arise.  Inquire if the person/agency would like to participate in 
analyses or receive a copy of your report.  Establish ongoing rapport with 
the data provider. 
Documenting information on the questions and issues summarized above will 
be important.  For example, information on the questions listed in Step 1 will 
assist not only in understanding the data from a specific data source but also in 
comparing indicators across data sources.  Agencies and organizations collect 
information relevant to their own specific mission and objectives, and there 
may be many differences across data systems in the populations covered, how 
information is categorized and defined, in the time periods represented in the 
data, and in the way the information is analyzed.  Maintaining rapport with the 
data sources is also important, especially if researchers plan multiyear studies 
of drug abuse patterns and trends.  Providing the agencies with network 
reports and findings also will further future cooperation. 
Access all numeric 
data of interest and 
any available 
information needed to 
further manipulate 
the data. 
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“Tips” on Establishing and Maintaining An Epidemiology 
Surveillance Network 
 
An epidemiology network can function as a drug abuse surveillance system at 
any jurisdictional level––national, regional, State, county, city, or community.  
The descriptions in this guide focus primarily on the local community level. 
Activities of an epidemiology surveillance network include those summarized 
in the box below. 
Planning for regularly scheduled meetings, as well as agenda items for future 
meetings, collection of data from multiple sources, data analysis and reporting, 
timely dissemination of findings, and continuity of the network  
Developing and expanding the network and updating data sources and 
contacts 
Creating a key informant network of individuals who can be contacted quickly 
for information if a drug abuse problem emerges or increases 
Networking through an ongoing group process in which members gain knowledge 
and current information about drugs of abuse, drug abuse patterns and trends, 
and emerging drug problems 
Connecting, communicating, and coordinating with one another on an 
ongoing basis, and with “data sources,” that is, agencies, organizations, and 
systems that have relevant information/data on drugs, drug-abusing populations, 
and the knowledge and skills to contribute to the network 
Accessing and compiling data at regularly scheduled times, in coordination with 
data sources 
Analyzing and reporting data systematically, based on a standardized format 
Identifying the target audiences (e.g., practitioners, administrators, 
policymakers, legislators) that can benefit from the data/information and findings 
produced by the network 
Disseminating the information to target audiences 
Providing feedback to participating agencies and organizations, including copies 
of the network’s reports 
Assessing progress and goal attainment periodically so that changes can be 
made, if necessary, to ensure continuity and expansion of the network  
Developing knowledge and skills over time.  Because drug abuse is a complex 
and changing phenomenon, network members build collective knowledge and skills 
as they work together over time. By accessing and sharing information and 
knowledge, members impart and gain an understanding of the following: 
                                                                                                   (Continued)
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• Knowledge of licit and illicit drugs and ways in which different drugs are 
abused 
• Knowledge of relevant sources of drug abuse information/data and skills in 
retrieving the information/data 
• Knowledge of their community/area and the “street savvy” and cultural 
awareness needed to ensure that relevant data are collected and that the data 
are interpreted accurately and in meaningful ways  
• Skills in analyzing and interpreting data/information gathered collectively by 
the group 
• Skills in preparing reports appropriate for different target audiences 
• The capability to disseminate reports to different target audiences 
• The skills needed to ensure continuity and effectiveness of network activities 
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PART II. ACCESSING AND ANALYZING  
DATA FROM DIFFERENT 
SOURCES 
 
1. SURVEY DATA  
 
Surveys are among the primary sources of epidemiologic data on drug abuse. 
When based on probability sampling, well-tested questionnaires, and well-
controlled field procedures, surveys of a specific population can provide 
estimates of the incidence and prevalence of drug use in that population, 
overall and by drug type, as well as by demographic subgroup (e.g., gender, 
age, race/ethnic group). Many surveys also yield information on drug-using 
behaviors (e.g., age of first use, route of drug administration, frequency of 
use), attitudes toward drug use, and health consequences associated with drug 
use.  Surveys conducted regularly over specific time periods (e.g., annually) 
provide data for trend analyses, and, thus, can show changes in overall drug 
use and the use of specific drugs by specific population groups across time 
periods.   
Three periodic national surveys that provide important drug abuse data are… 
 The National Survey on Drug Use and Health (NSDUH) 
 Monitoring the Future (MTF) 
 Youth Risk Behavior Survey (YRBS)  
Occasionally, national-level data, such as NSDUH and MTF data, can be 
compared with data from local and State surveys to determine how a 
community deviates from the drug abuse patterns in larger geographic areas. 
NSDUH estimates are available by State, although special data requests may 
be needed to obtain State-level data on a specific drug of interest. When 
comparisons between local and national surveys are of interest, the 
questionnaires must be compared to determine differences in wording of 
questions, since they may be so different as to be noncomparable.  YRBS data 
are available for several cities across the Nation, while the MTF represents 
secondary school students across the coterminous United States. 
A comparison of local versus national data could, theoretically, yield a 
number of different but useful findings. For example, a comparison of local 
versus national data in a given year may show little difference between the 
local and national prevalence rates and patterns of drug use. Conversely, a 
comparison of local and national data may show divergent drug use patterns 
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overall or for a particular drug or population group. For example, national data 
may show the emergence of a new drug of abuse that has not yet appeared in 
the local data.  Such a divergence could serve as an “alert” to local planners, 
policymakers, and providers, leading them to address such questions as:  Has 
the trend been missed in local data gathering, or is it a pattern that may 
emerge in the future?  How should local efforts be designed to determine 
whether the specific drug is or will become a substance of abuse in a confined 
geographic area? 
Knowledge of national surveys can also be useful in planning surveys at the 
local and State levels.  The national-level methods and questionnaires have 
been tested for utility and for reliability and validity.  Sampling strategies 
have been developed by expert statisticians; confidentiality and privacy 
procedures conform to Federal guidelines; and methods for training data 
collectors have been carefully developed and monitored.  Many instruments 
and methods are available to the public and can be used without cost. 
 
Accessing and Analyzing Survey Data 
 
Network members may care to first examine the national surveys described 
below. However, network members should also inquire with State and local 
educational institutions and researchers to determine whether household or 
school surveys have been or are being conducted in their local areas.  
The National Survey on Drug Use and Health 
The NSDUH is conducted annually under the sponsorship of the Office of 
Applied Studies (OAS), Substance Abuse and Mental Health Services 
Administration (SAMHSA).  The NSDUH (formerly the National Household 
Survey on Drug Abuse, NHSDA) provides information on the prevalence of 
and trends in the use of illicit drugs, alcohol, tobacco, and the nonmedical use 
of prescription-type drugs among members of the civilian, noninstitutional-
ized population age 12 and older in the United States and represents nearly 98 
percent of this population. The NSDUH also provides information about 
substance abuse and dependence, based on the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (American Psychological 
Association 1994), mental health problems, and treatment needed and 
received for substance abuse and mental health problems. 
The survey employs a 50-State sample design with an independent, multistage 
area probability sample for each of the 50 States and the District of Columbia, 
enabling the calculation of State estimates. In the eight States that constitute 
48 percent of the Nation’s population age 12 and older, SAMHSA reports 
substate area estimates.  
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The NSDUH collects data on lifetime (“ever used”), past-year, and past-30-
day use of illicit drugs, such as powder cocaine, crack cocaine, heroin, 
marijuana, methamphetamine, and various hallucinogens; psychotherapeutic 
drugs (nonmedical use, e.g., of narcotic analgesics, sedatives, tranquilizers, 
stimulants); alcohol; and tobacco (cigarettes, smokeless tobacco). As noted 
above, the survey also yields diagnostic data related to abuse or dependence 
on drugs, mental health problems (including co-occurring disorders), and 
treatment.  
Of special note is the fact that trend analyses are limited prior to 2002 because 
of the redesign of the NSDUH.  Data from 2002 onward should not be 
compared with 2001 and earlier NHSDA data to assess changes over time 
(SAMHSA 2004a). 
NSDUH publications can be obtained by contacting the National 
Clearinghouse for Alcohol and Drug Information (NCADI),1 or publica-
tions/reports can be viewed at the following Web site: <http://www.oas. 
samhsa.gov>. Public data files for the NHSDA and NSDUH for 1979, 1982, 
1985, 1988, and annually from 1990 to 2003 are currently available through 
the Substance Abuse and Mental Health Data Archive (SAMHDA Online 
Analysis) and the archive’s online data analysis system (DAS), which allows 
analysts to run statistical analyses directly from public use data files and 
obtain results online without the need to download the data file.  The Web site 
is <http://www.icpsr.umich.edu/SAMHDA/das.html>. 
Monitoring the Future Study 
The MTF survey has been conducted for nearly three decades by the Institute 
for Social Research, University of Michigan, under grant support from NIDA.  
The MTF provides data on the prevalence of drug use and related attitudes 
among students in grades 8, 10, and 12.  Data have been collected since 1975 
on high school seniors and since 1991 on students in grades 8 and 10.  The 
data represent public and private secondary schools in the coterminous United 
States. A followup panel survey is structured to collect data from a random 
sample of high school seniors biannually after high school, covering college 
students and young adults.   
Information on lifetime, past-year, and past-30-day use is collected on many 
drugs, including illicit and licit drugs.  Illicit drugs data include “any illicit 
drug,” marijuana, powder cocaine, crack cocaine, heroin, methamphetamine, 
hallucinogens, and methylenedioxymethamphetamine (MDMA or “ecstasy”).  
Nonmedical use of licit drugs covers such prescription-type drugs as narcotic 
painkillers (e.g., Vicodin, oxycodone, Ritalin), sedatives (barbiturates), 
stimulants, and tranquilizers. Alcohol and tobacco use are also covered.  
Students are also asked about the perceived risk of using specific drugs, their 
disapproval of people using each of the drugs, and their perception of the 
availability of each drug.   
                                                 
1P.O. Box 2345, Rockville, MD  20852-2345; Phone: 800-729-6686; Fax: 301-468-6433. 
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Publications may be ordered from NCADI or through the NIDA Web site 
<http://www.NIDA.NIH.gov>.  Those interested in obtaining the results and 
key findings from the MTF survey (1975–2004) can go directly to 
<http://monitoringthefuture.org> where tables and figures from the most 
recent MTF survey’s published findings can be found. 
Youth Risk Behavior Survey 
The Youth Risk Behavior Surveillance System (YRBSS), developed by the 
Centers for Disease Control and Prevention, monitors six categories of health-
risk behaviors among youth and young adults (tobacco use, unhealthy dietary 
behaviors, inadequate physical exercise, alcohol and other drug use, risky 
sexual behaviors, and behaviors that contribute to unintentional injuries and 
violence).  The system includes a national school-based Youth Risk Behavior 
Survey (YRBS), as well as State, territorial, and local school-based YRBSs 
conducted by education and health agencies. 
The YRBS covers lifetime use of many illicit drugs, including cocaine 
(powder, crack, freebase), heroin, marijuana, methamphetamine, inhalants, 
and ecstasy, as well as “current” (past-30-day) use of some drugs (e.g., 
cocaine, inhalants, marijuana), and injection of any illicit drugs.  YRBS also 
covers alcohol and tobacco use and nonmedical use of steroids. Other 
behaviors included in the survey are, as noted above, unhealthy dietary 
behaviors, inadequate physical exercise, risky sexual behaviors, and behaviors 
that contribute to unintentional injuries and violence. 
Since 1991, the national YRBS has been conducted every other year.  State 
and local school-based YRBS efforts are based on a two-stage cluster sample 
design to produce representative samples of students in grades 9–12 within 
their jurisdictions.  In 2003, 32 States were included in the YRBS, as were 18 
local jurisdictions. Data are weighted, and confidence intervals are reported. 
The YRBS city data can be obtained by contacting school districts. Findings 
are also summarized in CDC’s Morbidity and Mortality Weekly Report 
(MMWR). The YRBSS Web site is available at <http://www.cdc.gov/Healthy 
Youth/YRBS/about_YRBS.htm>. This Web site includes the most recent 
YRBS questionnaire for surveys of 9th–12th grade students, published 
reports, data files and documentation, and Youth Online, which provides 
interactive access to survey results. 
National-level estimates of drug use may mask substantial variations in local 
areas. Recent YRBS data reveal such variations in the abuse of drugs, such as 
the three stimulant drugs shown in exhibit 1 for 13 CEWG areas where the 
survey was conducted. The exhibit is based on weighted 2003 data for 
students in grades 9–12 and presents confidence intervals (CIs) by drug and 
area. 
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Exhibit 1. Lifetime Use of Cocaine, Methamphetamine, and Ecstasy Among Students in Grades 9–12 in 13  
 CEWG Areas,1 by Percent:  2003 
 
Cocaine Methamphetamine Ecstasy City Percent CI2 (±) Percent CI (±) Percent CI (±) 
Boston PS 3.3 1.1 3.6 1.4 6.2 1.7 
Broward Co., FL PS 5.9 1.4 4.5 1.1 7.8 1.6 
Chicago PS 5.6 1.6 3.7 1.7 5.3 1.9 
Dallas ISD 11.9 1.8 5.2 1.2 NA3 – 
DeKalb Co., GA PS 3.4 1.2 2.9 0.8 4.7 1.3 
Detroit PS 2.3 0.8 2.6 1.0 NA – 
Los Angeles USD 9.9 2.2 8.0 1.7 4.7 2.0 
Miami-Dade Co., FL PS 6.3 1.1 3.8 1.0 8.2 1.6 
New Orleans PS 3.4 1.3 5.8 1.8 7.2 1.9 
New York City PS 3.5 0.6 2.4 0.5 5.0 0.8 
Philadelphia SD 2.9 0.9 2.0 0.9 4.9 1.5 
San Diego USD 7.7 1.7 7.6 1.5 9.0 1.6 
Wash., DC PS 6.2 1.5 5.7 1.5 8.8 2.0 
 
1PS=Public school; SD=school district; ISD=independent school district; USD=unified school district. 
2At the 95 percent confidence level. 
3NA=Not available. 
SOURCE:  Centers for Disease Control and Prevention, Youth Risk Behavior Survey 
As shown in exhibit 1, estimates of lifetime use of cocaine among high school 
students ranged from a low of 2.3 percent in Detroit to 11.9 percent in Dallas. 
Lifetime use of methamphetamine varied from 2 percent in Philadelphia to 8 
percent in Los Angeles. Ecstasy use, reported from 11 CEWG areas, also 
shows variation, with a low of 4.7 percent in the Atlanta area (DeKalb 
County) and a high of 9.0 percent in San Diego. 
Other Surveys  
Network members should check with education departments, public health 
departments, and universities in their area to determine whether other surveys 
on drug use have been or will be conducted in their local area or State.  For 
example, in Texas, a school survey is conducted every other year, and data 
can be accessed from school districts in different parts of the State.  Exhibit 2 
shows data from four different survey years on students in grades 7–12 in two 
Independent School Districts in Webb County, Texas, as reported by Jane 
Maxwell, Ph.D. (2003), at the September 2003 Border Epidemiology Work 
Group meeting.  
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Exhibit 2. Substance Use Among 7th–12th Grade Students in Webb County (Laredo), Texas, ISDs,1 by Year2  
 and Percent:  1993–2002 
 
ISD Lifetime Substance Use (Percent) Past-Month Substance Use (Percent) 
United ISD 1993 1998 2000 2002 1993 1998 2000 2002 
Tobacco 61 56 54 47 28 28 27 21 
Alcohol 75 74 76 73 43 44 45 41 
Inhalants 21 17 19 18 3 8 8 8 
Any Illicit Drug 19 28 29 31 7 14 15 15 
Marijuana 17 25 25 27 6 11 12 12 
Cocaine/Crack 7 11 13 13 2 6 6 5 
Laredo ISD 1993 1994 1998 2002 1993 1994 1998 2002 
Tobacco 56 56 55 44 25 25 25 21 
Alcohol 75 76 75 71 40 42 42 40 
Inhalants 13 13 18 16 4 4 7 8 
Any Illicit Drug 18 20 30 26 8 8 14 12 
Marijuana 16 17 26 22 7 7 10 9 
Cocaine/Crack 7 8 13 12 3 3 6 4 
 
1ISD=Independent School District. 
2Laredo ISD did not participate in the 2000 survey. 
SOURCE: Texas Commission on Alcohol and Drug Abuse and Public Policy Research Institute of Texas A&M University 
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2. DRUG ABUSE TREATMENT DATA 
 
Data collected by programs that treat substance abusers can be another 
important indicator of substance abuse patterns and trends in particular 
geographic areas.  These data, generally collected uniformly at admission and 
reported to State and Federal agencies, include the numbers and types of 
substances used by drug abusers entering treatment.  They also include the 
characteristics (e.g., gender, age, ethnicity/race) of the treatment admissions 
by specific drug.  For example, it is possible to determine how many 
admissions report cocaine as their primary drug at treatment entry during a 
specific time period and the characteristics of the cocaine abusers.  What 
percent were male and female?  African-American, White, Hispanic, or of an 
other racial/ethnic group?  What were the specific age categories for these 
admissions?  Based on these variables alone, many comparisons can be made.  
The characteristics of primary cocaine abusers, for example, can be compared 
with the characteristics of those who reported other types of primary drugs 
during the same admission period.  Consequently, network members can 
quickly make comparisons between the different types of drug abusers and 
draw some important inferences. Many other reported data elements collected 
at admission could be analyzed to learn more about the drug-abusing 
population.  These elements will be presented later in this chapter of the 
guide.  The chapter includes information on… 
 Advantages of treatment data 
 Major limitations of treatment data 
 How to locate/identify treatment programs in specific geographic areas 
 Obtaining information about treatment programs and their facilities, 
including data from local programs, State agencies, and the Federal 
Government 
 Examples of how treatment data can be analyzed and reported 
 
Advantages of Treatment Data  
Some of the advantages of using treatment data are as follows: 
 Treatment data are generally a good indicator of the types of drugs being 
used in geographic areas; these data also show changes in patterns of drug 
use over time. 
 Treatment admissions data are collected and reported by all publicly 
funded and some privately funded substance abuse treatment programs, 
based on standardized questions. 
 Data on the specific drugs (primary, secondary, and tertiary) used and the 
characteristics of the users are collected systematically at intake by trained 
staff. 
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 These data are relatively easy to access and analyze. 
 These data can be analyzed over time (e.g., years) to assess changes over 
time and trends. 
 These data may show emerging drugs or drug problems that require 
treatment. 
 Comparisons can be made with treatment data from other areas within a 
State or across States. 
 
Major Limitations of Treatment Data 
The limitations of treatment data include… 
 Treatment data cannot be used to make drug abuse prevalence estimates 
for or by geographic area.  These data only represent drug abusers who 
enter particular types of treatment programs and exclude the majority of 
drug abusers who are unable to access treatment or who do not seek the 
treatment services that are available. An unknown number of drug abusers 
obtain treatment from private programs that are not required to report data. 
 There is a gap between the time when a person starts using a drug or drugs 
and the time when that individual seeks or is referred to treatment.  By the 
time an individual enters treatment, it is likely that s/he had been using 
drugs for some time. The data are unlikely to reflect the newest drug 
patterns on the street. 
 A drug abuser can enter treatment more than one time in a calendar year 
and is most likely to be counted each time s/he was readmitted. However, 
some programs can provide unduplicated counts, and network members 
should request unduplicated data.  Multiple admissions by the same person 
are more likely in short-term outpatient programs.   
 The substances reported at treatment admission are the substances that led 
individuals to seek or be referred to treatment at that particular time. 
Therefore, treatment data often do not provide a complete history of all 
substances used. 
 In seeking treatment, drug abusers may not be totally honest in reporting 
their primary drug problem.  For example, some may be afraid of 
reporting an illicit drug problem that has more serious legal implications.  
Interviews with active methamphetamine abusers in Ohio suggest that 
some may conceal their use of the drug from treatment providers or avoid 
treatment altogether because of heightened media attention and increased 
law enforcement efforts focused on methamphetamine (Wright State 
University 2005). 
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Where to Start:  How to Locate/Identify Treatment Programs 
in Specific Geographic Areas 
 
The first step is to identify treatment programs in your area. The yellow pages 
of the telephone directory may be useful in identifying substance abuse 
treatment programs in your area or areas for which the network is attempting 
to assess drug abuse patterns and trends. Network members may also contact 
the local Chamber of Commerce for this information. 
A useful online source is the Substance Abuse and Mental Health Services 
Administration’s Treatment Facility Locator, which is based on facility 
responses to SAMHSA’s National Survey of Substance Abuse Treatment 
Services (N-SSATS) and periodically updated.  New facilities are added 
monthly, if facilities inform SAMHSA of changes.  
For a listing of programs on the Treatment Facility Locator go to:      
<findtreatment.samhsa.gov>.  
1. Click to enter the drug abuse and alcoholism Treatment Facility Locator. 
2. A Quick Search with Map It page will appear.  Click on the State or 
Territory of interest to the network. 
3. On the next page, to search for programs in your area, type in the City 
name and the Search Radius (e.g., 30 miles), that is, the geographic area of 
network interest.  Optional choices are available for Zip Code areas and 
Street Address. 
4. Continue, and a map of the area (e.g., 30 miles around your city) will 
appear that identifies the geographic areas where programs are situated. 
Scroll down, and the following information will be provided on each 
program:  facility number (corresponding to the map number), name of the 
facility, address, and phone number. Other information summarizes the 
program’s focus (e.g., mix of mental health and substance abuse services), 
services provided, type of care (e.g., residential, outpatient), special 
programs (e.g., women, adolescents), and forms of payment accepted. 
Some programs also list their Web sites. 
 
What to Request 
 
Network members need to carefully consider the types of information that will 
be most useful.  If State or local data are not easily accessible, network 
members may wish to use data from SAMHSA’s Treatment Episode Data Set 
(TEDS), which is described later in this chapter. Some useful types of 
information for a specified geographic area or areas, which should be 
accessible from your State or TEDS, include the following: 
…SAMHSA’s 
National Survey of 
Substance Abuse 
Treatment Services 
(N-SSATS). 
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 The primary drug of abuse (the drug the client feels caused him/her to 
enter treatment) as well as the secondary and tertiary drugs of abuse 
 Sociodemographic characteristics of different primary drug-abusing 
groups (e.g., gender, age, race/ethnicity, educational level, employment 
status, criminal justice system involvement) 
 Frequency of drug use (e.g., daily, several times a week or month) 
 Route of drug administration (e.g., injection, smoking, inhalation) 
 The demand for treatment generated by referral source (e.g., the criminal 
justice system) 
Other data that may be important for analysis, especially if discharge data are 
used, include date of admission and type of service provided at admission. If 
discharge data are requested and available, the following types of information 
can be accessed for the 20 or more States that provide such data to TEDS: 
 Type of service at discharge 
 Date of last contact 
 Date of discharge  
 Reason for discharge, transfer, or discontinuance of service 
If network members contact drug abuse treatment programs directly to access 
client data, the following things should be kept in mind: 
 Do not request information that would potentially make it possible to 
identify an individual client; such information cannot be divulged under 
penalty of Federal law.  Programs can only provide data at aggregate or 
summary levels. 
 The primary responsibility of treatment programs is treating clients.  As 
appropriate, staff see treatment as their primary obligation, and are likely 
to be less interested in the potential benefits of research.  Some may feel 
that any attempt to obtain client data is another demand on their limited 
time.   
Obtaining Information about Treatment Programs and Facilities 
Substance abuse treatment programs differ in many ways, e.g., by area, 
modality, services provided, length of treatment, and treatment philosophy.  In 
the National Directory of Drug and Alcohol Abuse Treatment Programs, 
SAMHSA uses the codes shown in the box below to distinguish between 
types of providers, services, and care and specialized programs by agency. 
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Codes for Providers, Services, Care, and Special Programs 
Primary Focus of Provider 
¾ Substance abuse treatment services 
¾ Mental health services 
¾ Mix of mental health and substance abuse services 
¾ General health services 
 
Type of Care 
¾ Outpatient 
¾ Partial hospitalization 
¾ Hospital inpatient 
 
Services Provided 
¾ Substance abuse treatment 
¾ Detoxification 
¾ Methadone/LAAM 
¾ Halfway house 
Special Programs/Groups Offered 
¾ Adolescents 
¾ Dually diagnosed 
¾ Persons with HIV/AIDS 
¾ Gay and lesbian 
¾ Seniors/older adults 
¾ Pregnant/postpartum women 
¾ Other women’s groups 
¾ Groups of men only 
¾ DUI/DWI offenders 
¾ Other criminal justice groups 
 
 
 
The most recent National Directory of Drug and Alcohol Treatment Programs 
can be accessed through the Internet at <http://findtreatment.samhsa.gov>.  
Hard copies of the directory can be obtained from the NCADI by calling 1-
800-729-6686.  
Obtaining Treatment Data from Local Programs 
It may be possible to obtain treatment data directly from substance abuse 
treatment agencies.  To release data, the Executive Director would have to be 
informed about the reasons for requesting the data, how the data would be 
used, and the goals and makeup of the network.  The Executive Director 
would have to be convinced that the data would be used appropriately and for 
a good purpose. It may be that the Executive Director is already familiar with 
the network and knows some of the members.  Following an introductory 
telephone call to the Executive Director, the network should follow up with a 
formal letter, making the request in writing.  It might be helpful to invite the 
Executive Director, or his/her representative, to the next network meeting to 
discuss the possibility of obtaining the data, how the data can be obtained, and 
how the information produced by the network can be of use to the agency.   
If the network covers a large geographic area where many substance abuse 
treatment agencies are located, the process involved in acquiring the data 
directly from agencies would obviously be more difficult.  However, there are 
many advantages in getting data directly from each treatment agency rather 
than from the State or Federal agencies. First, it is possible to obtain insight 
and understanding from program staff about the different types of clients 
admitted to treatment and the patterns of drug use.  Second, local programs 
can identify more specifically the geographic areas where clients reside.  They 
cannot identify specific addresses of clients, but by using "mapping" software 
they can show the general locations where client addresses are clustered. 
When done by type of drug used by clients, mapping can identify even more 
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information about the geographic areas where specific types of drug abuse 
problems are clustered.  Third, treatment program staff (e.g., counselors) are 
often able to help surveillance networks answer questions that emerge from 
the quantitative admissions data. Treatment staff often serve as "key 
informants" for CEWG representatives, providing insight on issues that 
emerge from the data. 
Obtaining Treatment Data from State Agencies 
Those who wish to obtain data for their area from their State Substance Abuse 
Agency will find a link on Treatment Facility Locator that lists SSAAs in each 
State and U.S. Territory.  This listing provides the name, address, and telephone 
number for each SSAA. Network members are likely to find SSAAs useful in 
providing the most recent treatment data. 
Obtaining Treatment Data from the Federal Government 
Characteristics of clients entering publicly funded programs (and some private 
programs) are collected at admission and reported to the State Substance 
Abuse Agency, which in turn, forwards the data in a standardized “Minimum 
Data Set” to SAMHSA for inclusion in TEDS. Some States also submit a 
more detailed Supplemental Data Set on admissions, and all States will be 
submitting discharge outcome data in the future. The TEDS Minimum Data 
Set is collected in a standardized way within each State, which permits 
comparisons across geographic areas (e.g., counties, cities, States) and also 
provides information on the types of clients served in publicly funded 
programs. 
The Treatment Episode Data Set was established through the 1988 
Comprehensive Alcohol Abuse, Drug Abuse and Mental Health Amendments 
(Public Law 100-690), which mandates that data be collected and reported on 
clients receiving treatment from publicly supported programs for either 
alcohol or drug abuse.  Some States also voluntarily collect and report data 
from private programs.  TEDS is an exceptionally large treatment data set, so 
caution must be taken in interpreting the data. 
Accessing TEDS Data.   The quickest way to access the most recent TEDS 
data is through the SAMHSA Web site <http://www.drugabusestatistics. 
samhsa.gov>. 
Hard copies of the most recent TEDS annual report can be obtained by calling 
NCADI at 1-800-729-6686. 
Limitations of TEDS.  TEDS does not include all substance abuse treatment 
admissions in States.  The scope of the treatment facilities included in TEDS 
is affected by differences in State licensure, certification, accreditation, and 
disbursement of Federal funds.  Crisis intervention facilities and hospital 
emergency departments are not included in TEDS.  Hospital-based substance 
abuse treatment facilities are not licensed through the State substance abuse 
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agencies.  Some State agencies include data from correctional facilities, while 
others do not. 
TEDS, an admission-based information system, does not represent 
individuals. An individual admitted to a treatment program twice within a 
calendar year would be counted as two admissions. 
Another disadvantage to using TEDS is the fact that data from a particular 
year may not be available until 1 or 2 years later. 
Standardizing Treatment Data 
Exhibit 1 on the following page illustrates how network members can record 
treatment data in a standardized way, using their own data form to collect 
information the network considers most important. It is vital to obtain the total 
number of admissions for a given time period, since the total serves as a 
denominator (e.g., to calculate the percentage of, say, primary cocaine 
admissions in a specific time period and geographic site). Network members 
may wish to add drugs to their recording form (e.g., opiates other than heroin) 
or to add other client characteristics (e.g., age of first use for each drug).  
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Exhibit 1. Standard Treatment Data Request Form 
Site: 
 
 
Characteristics of Clients Admitted to Treatment 
 
From  To  ,  (Months/Year) 
Total Number of Treatment Admissions: N= 
Characteristics 
Alcohol 
(Only  
or in 
Combo) 
Cocaine Heroin Other Opiates Marijuana 
Metham-
phetamine 
(Other) 
Stimulants1 
All 
Other 
Total n:              
Gender 
Male % % % % % % % % 
Female % % % % % % % % 
Race/Ethnicity 
White % % % % % % % % 
Afican-American % % % % % % % % 
Hispanic % % % % % % % % 
Other 
1. % % % % % % % % 
Other 
2. % % % % % % % % 
Age at Admission 
17 and younger % % % % % % % % 
18 to 25 % % % % % % % % 
26 to 34 % % % % % % % % 
35 and older % % % % % % % % 
Route of Administration 
Smoking % % % % % % % % 
Sniffing % % % % % % % % 
Intravenous % % % % % % % % 
Other/multiple % % % % % % % % 
Secondary Drug 
             
Type of Drug 
% % % % % % % % 
Tertiary Drug 
             
Type of Drug 
% % % % % % % % 
 
1Use this column if you cannot provide separate data on methamphetamine (MA) OR to document other stimulant admissions if you can 
provide data on MA admissions. 
SOURCE:  Adapted from the National Institute on Drug Abuse, 1998, page 14. 
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Uses of the Data:  Examples of How Treatment Data are 
Analyzed and Reported 
 
Treatment data can be analyzed in many ways, as illustrated in the examples 
below. When trend data are used and there are substantial changes in the 
numbers and types of clients over time, network members may need to check 
with treatment providers and the State funding agency. The changes may reflect 
new services to specific populations (e.g., drug courts, pregnant women) or the 
closing of one or more programs. 
Detecting Emerging Drugs in Ohio  
As noted earlier, treatment data can be an indicator of emerging drug problems.  
Wright State University researchers, who manage the Ohio Substance Abuse 
Monitoring (OSAM) surveillance network for the Ohio Department of Alcohol 
and Drug Addiction Services, reported the following example in their January 
2005 OSAM-O-GRAM:   In the year 2000, information about methamphetamine 
abuse in the State was beginning to filter down from law enforcement officials 
and drug abusers.  In 2002, treatment programs in Akron reported increases in 
methamphetamine treatment admissions.  Dayton treatment providers reported 
increases in methamphetamine treatment admissions in 2004.  Although meth-
amphetamine abusers still only represented a small proportion of the 2004 
treatment admissions in the State, treatment and other indicator data were being 
closely monitored by area and State officials. 
A Metropolitan Area:  Baltimore 
Leigh Henderson, Ph.D., the CEWG representative for Baltimore, accesses 
substance abuse treatment admissions data from the Maryland Drug Abuse 
Administration (State authority).  She accesses data for the Baltimore Primary 
Metropolitan Statistical Area (PMSA) and two different segments of the 
PMSA: Baltimore City and the PMSA areas excluding Baltimore City.  
Recently, Dr. Henderson requested multiyear data (2000 to 2004), by drug 
category, and the characteristics (gender, age and race/ethnicity) of first time 
treatment admissions.  Exhibit 2 displays data for the drug category Narcotic 
Painkillers, by year and geographic area (PMSA, city, and non-city).  Similar 
tables were constructed for the following drug categories: powder cocaine, 
smoked cocaine, intranasal heroin, injected heroin, and marijuana (see 
Henderson and Walker 2006).  From each table, one can determine the 
demographic characteristics by area and year, and these variables can be 
compared with the similar variables in tables displaying the same type of data 
for other drugs. Several different variables are shown in exhibit 2 (e.g., daily 
use, first treatment episode, median duration of use, and criminal justice 
referral), and these can be compared by type of area and drug.  As findings in 
exhibit 2 illustrate, the numbers of primary Narcotic Painkiller admissions to 
treatment increased each year (2000 to 2004) in all three Baltimore areas. 
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A Network of Areas Within a State:  Louisiana 
A drug abuse surveillance network has been operational in Louisiana since 
1997.  Established by the Louisiana State Office for Addictive Disorders, the 
State drug abuse authority, the network has been using treatment data as one 
of its primary sources for assessing drug abuse patterns and trends in parishes 
located throughout the State.  Representatives of the parishes assume 
responsibility for analyzing the treatment data along with other local data 
sources and reporting findings at annual meetings.  Exhibit 3 is an example of 
treatment admissions data reported by parish, making it possible to assess 
similarities and differences in the types of 2004 treatment admissions (in 
Thorton-Collins 2006). Crack cocaine (smoked cocaine) has been one of the 
most serious drug problems throughout the State for many years. Almost one-
half (45.5 percent) of the 2004 admissions in Baton Rouge reported smoked 
cocaine as their primary drug of abuse.  The percentages of heroin admissions 
were low in all parishes, with the exception of Orleans Parish, where 11 
percent of the 2004 admissions reported heroin as the primary drug. The 
percentages of methamphetamine admissions were also relatively low, but two 
parishes (Rapides and Bossier) reported higher percentages of primary 
methamphetamine admissions in 2004 than in prior years.   
 
Exhibit 3. Treatment Admissions for Selected Drugs in Nine Parishes of Louisiana, by Primary Drug and  
 Percent:  2004 
 
Parish 
Drug 
Orleans Bossier Calcasieu
East 
Baton 
Rouge 
Lafayette Ouachita Rapides St. Tammany
Terre-
bonne 
Cocaine 31.6 26.7 15.8 45.5 32.3 24.8 26.5 28.4 17.3 
Heroin 11.1 0.0 0.3 0.8 0.9 0.3 0.7 3.3 0.3 
Other Opiates 3.6 8.9 11.4 5.0 11.5 4.7 11.4 21.1 7.5 
Marijuana 32.1 15.4 30.0 13.2 13.3 26.6 17.5 17.3 37.3 
Methamphetamine 0.2 6.2 4.2 2.1 1.0 3.8 6.7 1.6 1.0 
Alcohol 18.7 40.8 30.7 32.6 37.8 36.1 32.9 24.7 34.2 
Other Drugs 2.5 2.0 7.6 0.8 3.2 3.7 4.3 3.6 2.4 
Total (N=)1 (2,306) (292) (983) (3,432) (885) (914) (1,295) (1,026) (986) 
 
1Excludes admissions for whom a primary drug was not reported. 
SOURCE:  Louisiana State Office of Alcohol and Drug Abuse 
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3. DRUG ABUSE-RELATED HOSPITAL DATA  
 
Hospital data on the effects of drug abuse can be a valuable indicator in 
assessing drug abuse patterns and trends within a community or State.  Hos-
pitals treat a broad range of substance abuse-related conditions and popula-
tions presenting with those problems. Hospitals are the only type of care 
available 24 hours a day, 365 days a year, to provide emergency care and re-
habilitative inpatient treatment. Hospitals are in a position to test patients for 
alcohol and drug use and to provide treatment or refer patients to appropriate 
treatment.  Detoxification and medical rehabilitation are among the primary 
services provided to substance abusers in a hospital setting.  
Often serious complications from abuse of drugs and alcohol occur at times 
when the hospital is the provider.  Cases involving accidents and illnesses 
may be complicated by drug or alcohol abuse. Some individuals are admitted 
to the hospital for a medical or psychiatric condition that is a consequence of 
drug-using behavior. Or, there may be a “co-morbid” condition, such as affec-
tive disorder coexisting with drug or alcohol dependence. 
Many drug abusers, especially those who do not have medical insurance, use 
the hospital emergency department (ED) as their primary source of care.  
Some chronic drug abusers relapse from time to time and seek care at various 
hospitals.  
Generally, alcohol and drug abuse patients receive care in three basic types of 
hospitals:  acute general, private psychiatric, and State psychiatric hospitals.   
Accessing Hospital Data 
Hospital data may be difficult to access for a new network. SAMHSA’s Drug 
Abuse Warning Network (DAWN) ED data, described below, are the easiest 
to review and access, if a network’s area is included in DAWN.  Automated 
hospital discharge data that have already been analyzed are also useful and 
can provide some insight into the effects of drugs in an area.  Local ED data 
are more difficult to obtain and analyze, but they can provide critical insights 
into the health impacts of drug use.  Local hospital data will generally provide 
smaller numbers than comparable DAWN ED data, and they may provide less 
insight into serious acute consequences of drug use.  
For network members interested in accessing data directly from local hospi-
tals, ties may need to be established with State and local health agencies to 
obtain the data.  For hospitals that do not have public online data, permission 
must be obtained to collect the data directly from medical records.  Hospital 
confidentiality procedures are stringent.  Strategies will need to be devised to 
convince those with data to share it with the network in ways that will be 
useful to the work group. Assurances must be explicitly stated regarding 
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maintaining confidentiality of records. The purpose of collecting the data 
needs to be made clear to hospital staff.  It should also be made clear that the 
network will provide the hospitals with a report of its findings.   
To facilitate accessing information, contact should be made with the hospital’s 
Executive Director, the official in charge of planning or marketing, or the 
hospital’s epidemiology department.  If the hospital is relatively small, it 
should be fairly easy to identify the appropriate hospital representative. 
 Whether the data are accessed electronically or manually by searching 
medical or toxicology records, the purposes for collecting the data should 
be explained to the hospital staff and it should be stated that the findings 
will be shared with the hospital.  
 Collecting and sharing the data will allow community-based providers to 
work more closely together to provide better case management and after-
care services. 
In cases where network members must collect the data directly from medical 
records, the data may be categorized by codes.  The diagnostic codes may be 
the Diagnostic Related Groups (DRGs), which are used to set limits on Medi-
care reimbursement, as established by the enactment of the Tax Equity and 
Fiscal Responsibility Act of 1982.  Or the data may be classified according to 
the International Classification of Diseases, Ninth Revision, Clinical Modifi-
cation (ICD-9-CM).1  Addendum A: Guidelines on Using Diagnostic Codes, 
presented at the conclusion of this chapter, lists the addiction-related codes, 
with a section on matching DRGs and ICD-9-CM codes.   
Admittedly, hospital-based drug use data are difficult to collect, aggregate, 
and analyze. While most hospitals collect and record drug-related data, there 
is a lack of uniformity among public, private, and not-for-profit hospital data-
bases that makes it challenging to report the extent of substance abuse in any 
jurisdiction, region, or on a statewide basis. Some of these challenges are en-
countered in the DAWN national coverage of emergency departments.  Ways 
in which “Reporters” are trained to systematically record drug-related data 
from patient records are described in Drug Abuse Warning Network:  
Development of a New Design (Methodology Report) (SAMHSA 2002), and 
may be useful to network members who need to explore different ways 
hospitals patient record data and the systematic way in which DAWN 
retrieves data. 
                                                 
1While ICD-9 has been the medical coding system in the United States for more than a quarter century, there is an effort under- 
way to adopt the World Health Organization’s ICD-10, which is better suited for new electronic health systems and is used in all  
other developed countries.  The American Health Information Management Association (AHIMA) calls for the adoption of ICD- 
10-CM for diagnostic coding and ICD-10-PSC for hospital inpatient services no later than 2008, and for support in the form of 
legislative authority and financial allocation.  The decision rests with the Secretary of Health and Human Services.  Additional 
information on ICD-10, including testing of the system, is available at <http://www.ahima.org/coding/index.asp> and 
<http//:www.cdc.gov/nchs/about/major/dvs/icd10des.htm>. 
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Given the difficulties in accessing hospital data directly from medical records, 
and the limited time and resources of a network, it is advisable to identify 
someone at the local level who has knowledge, skills, and time to do the nec-
essary work.  Unless there is a network member who has knowledge of and 
expertise in accessing and analyzing hospital data sets, via record search or 
electronically, a second step might be to identify a researcher who can assist 
the network in collecting and analyzing the data. This person may well be in-
terested in becoming a member of the network.  Ideally, this person would 
access, prepare, and report the data at the network meeting in a simple format 
so the data can be used with other indicator data to assess drug abuse patterns 
and trends. There should be a periodic independent investigation on a sam-
pling basis of the quality and accuracy of different hospital data systems.  
The remainder of this section focuses on accessing and using the following 
types of hospital data––emergency department drug-abuse data and drug-
related hospital admissions and discharge data. 
 
Emergency Department Data 
 
The American Hospital Association (1991) defines an emergency department 
as “an organized hospital facility for the provision of unscheduled outpatient 
services to patients whose conditions are considered to require immediate 
care.  An ED must be staffed 24 hours a day.”  
 
The Drug Abuse Warning Network (DAWN)  
Judy K. Ball, Ph.D., M.P.A. 
 
DAWN is administered by the Office of Applied Studies (OAS) at the 
Substance Abuse and Mental Health Services Administration (SAMHSA).  
DAWN has two components:  the emergency department (ED) component 
and the mortality component (which is described in Chapter 4). 
DAWN’s ED component provides information about drug-related ED visits 
for the Nation and for a selection of metropolitan areas.  ED estimates are 
published annually.  DAWN cannot be used to measure the prevalence of 
drug abuse (i.e., how many people abuse or misuse drugs); instead, it provides 
valuable information about the more severe health consequences of drug use, 
misuse, and abuse. 
DAWN was redesigned in 2003.  The current ED component is based on a 
statistical model that is more precise and a sample of hospitals that permits 
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generalizations for the entire Nation.  Other changes to DAWN include new 
case criteria, new case-finding methods, new data items, and improved quality 
assurance.  For these reasons, data published prior to 2003 are no longer 
comparable to those collected in the redesigned system (see SAMHSA 2002).  
DAWN relies on a stratified probability sample of short-term, general, non-
Federal hospitals that operate 24-hour emergency departments.  The sample of 
hospitals was designed to represent such hospitals nationally and also over-
samples such hospitals in selected metropolitan statistical areas (MSAs), 
including some of the MSAs that were in DAWN prior to 2003.  Network 
members interested in learning whether the DAWN ED component includes 
their MSA in any given year can access the information at the following 
World Wide Web site: <http://DAWNinfo.samhsa.gov>.  
 
Any emergency department visit related to recent drug use is reportable as a 
DAWN case.  This broad definition covers “drug use,” “drug misuse,” and 
“drug abuse.” All types of drugs are included:  illicit drugs, prescription and 
over-the-counter medications, dietary supplements, non-pharmaceutical 
inhalants, and alcohol.  Excluded are cases in adults when alcohol is the only 
drug involved, but alcohol in combination with other drugs is always 
reportable.  Alcohol only cases are included for persons younger than 21. 
Each case is assigned to one of eight case types, according to documentation 
in the medical chart (see exhibit 1 below).  Case types include suicide attempt, 
seeking detoxification, “underage drinking” (when alcohol is the only drug in 
a person under age 21), adverse reactions, overmedication, malicious 
poisoning, accidental ingestion, and “other.”  The final case type “other” 
includes all drug-related cases not assigned to any of the previous seven case 
types.  It is the category designed to capture most cases involving illicit drugs 
of abuse.  For analyses focusing on drug misuse and abuse, DAWN cases 
classified as overmedication, malicious poisoning, and case type “other” are 
combined.  Accidental ingestion and adverse reactions are never classified as 
“drug abuse.” Multiple drugs plus alcohol may be reported for any case.   
To be a DAWN case, a drug does not have to have been the direct cause of the 
visit; the drug only needs to be implicated in the ED visit.  Only recent drug use 
is included.  Case criteria are sufficiently broad to encompass all types of drug-
related events, including explicit drug abuse. It is recognized that medical 
records, the source of DAWN data, often lack explicit documentation of sub-
stance abuse, and distinctions between drug use, misuse, and abuse are often 
subjective (SAMHSA 2004b).  Therefore, explicit documentation of drug 
“abuse” is not used in making DAWN case determinations or in assigning case 
type. 
To find cases, DAWN Reporters review medical charts for all patients treated in 
participating EDs.  The Reporters submit data only for the ED visits that meet 
the DAWN case criteria.  Data are submitted electronically over a secure 
Internet connection, and the system alerts Reporters of inconsistent or invalid 
data. 
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Exhibit 1.  DAWN Decision Tree 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Office of Applied Studies, SAMHSA 
 
Is this a DAWN Case?  Based on documentation in the chart, 
was the ED visit for a condition induced by or related to drug use?
This is a DAWN Case.
Answer the following questions in order. Assign Type of Case to first Yes.
YES
1.  Does the chart indicate that the patient attempted suicide with a drug involved?
NO
•“Suicide ideation”
•No documentation of suicide attempt
•Psych evaluation
•Tried to harm self
2.  Does the chart indicate that the patient was seeking detox or entry into a drug 
treatment program?
NO •Withdrawal, but not seeking detox
3.  Is the patient under age 21 and alcohol is the only drug mentioned in the chart?
NO
•Other drug(s) and alcohol are involved
•Patient is age 21 or over
4.  Does the chart indicate that the patient had an “adverse reaction” to a 
prescription drug, over-the-counter medication, or dietary supplement taken as 
prescribed or recommended?
NO
•Unexpected reaction to illicit drugs
•Toxicity without documentation of “adverse reaction”
•Too little medication; took less than prescribed dose
•Took someone else’s drug or medication
5.  Did the patient exceed the prescribed dose of a prescription drug or the 
recommended dose of an over-the-counter medication or dietary supplement?
•Illicit drugs
•Malicious poisoning
•Took someone else’s drug or medication
•Accidentally took the wrong drug or medication
NO
6.  Does the chart indicate that the patient was deliberately poisoned or drugged 
by another person?
NO
7.  Does the chart indicate that the drug was used accidentally or unknowingly?
STOP
Not a DAWN Case
01  SUICIDE ATTEMPT
•“Suicide attempt
•Completed suicide
•Attempted to kill self
02  SEEKING DETOX
•Seeking detoxification
•Medical clearance for drug treatment   
admission
•Request for drug rehabilitation
03  ALCOHOL ONLY (AGE < 21)
•Patient under age 21 and alcohol is the 
only drug
04  ADVERSE REACTION
•Allergic reactions
•Drug interactions
•“Side effect” of drug
05  OVERMEDICATION
•Tried to make up a missed dose
•Forgot they had taken a dose
•Treated symptoms that did not subside 
with recommended dose
06  MALICIOUS POISONING
•Drug-facilitated assault
•Drug-facilitated rape
•Homicide with drug as the weapon
•Product tampering
07  ACCIDENTAL INGESTION
•Accidental child poisoning
•Took wrong drug or medication
08  OTHER
•Any DAWN Case not assigned above
•Most illicit drug use
•Toxicity due to drugs
•Withdrawal
•Psych evaluation with drugs detected
•Took someone else’s drug or medication
NO
NO
YES
YES
YES
YES
YES
YES
YES
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Primary users of the DAWN ED data are the participating hospitals, local 
public health officials, Federal agencies (SAMHSA, the Food and Drug 
Administration, the Office of National Drug Control Policy, and the Drug 
Enforcement Administration), and the Community Epidemiology Work 
Group.  DAWN data for MSAs can be accessed from SAMHSA publications 
or online. 
For additional information, contact Dr. Judy Ball, Acting Director, Division of 
Operations, OAS, SAMHSA; Phone: 240-276-1256; E-mail: 
<Judy.Ball@samhsa.hhs.gov>. 
 
Local ED Data 
The availability of local ED data (for hospitals not included in the DAWN 
sample) will vary from hospital to hospital and from community to 
community. Network members will need to obtain information about their 
local hospital emergency department before requesting access to the data.  
 
Where to Start: Accessing ED Data 
DAWN Data.  Communities located in metropolitan areas that are part of the 
DAWN ED system can access data on their MSAs from DAWN’s annual 
publications, available in hard copy from NCADI or online at 
<http://DAWNinfo.samhsa.gov>.  These data are released approximately 6 to 
12 months after the close of the data year.  There is a time lag between the end 
of the data year and the release of the data, because DAWN ED data must 
undergo a series of checks before they are weighted and analyzed.  SAMHSA 
ED publications now include confidence intervals (i.e., the margin of error) 
and relative standard errors (RSE), which provide information about the 
reliability and precision of the estimates.  
Network members whose communities are not covered in DAWN, or who 
wish to use data in addition to or other than DAWN, should check with the 
State hospital association, local health department, or other hospitals directly 
to determine whether any information on drug abuse-related ED patients can 
be accessed electronically.   
If data must be collected directly from hospital records, members need to 
check first as to what types of information the hospital maintains on drug-
abusing patients, and then determine whether the data will be useful to the 
network.  If the information appears useful and network members request and 
obtain permission to access information directly from medical records, and 
perhaps also toxicology laboratory reports, it will be most useful to prepare a 
data form(s) before requesting the data.  
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Local Data.  CEWG representative James Hall, together with colleagues in 
South Florida, gathered data on drug-related emergency department cases 
semiannually from a hospital in Broward County (Fort Lauderdale) before it 
became part of the DAWN sample. These data were derived from medical 
records, reported at the semiannual CEWG meetings, and published in CEWG 
Volume II Proceedings reports.  
In addition to extracting data from medical records, the Florida researchers 
found it useful to generate a daily printout of all toxicology laboratory work 
done by the lab from the previous day and to focus on those cases with a 
positive toxicology report.  The lab data helped in identifying specific drug-
related cases that may be missed or difficult to find by chart review alone. 
These researchers also educated ED staff in identifying drug-related cases and 
provided them assistance on how to document the cases.  
 
What to Request   
For networks that will rely on DAWN published reports, there will be ample 
data from which to select, including the types of information listed below.2  
Similar information may be available from local EDs that are not part of 
DAWN or other databases. 
 The total number of drug-related ED visits in a metropolitan area, and the 
ED visits broken out by case type. 
 The number of drug misuse/abuse ED visits.  For analyses using DAWN 
drug misuse/abuse data, cases classified as overmedication, malicious 
poisoning, and the category “other” are combined; accidental ingestion 
and adverse reactions are never classified as “drug abuse.” 
 The total number of ED visits and the number of drug misuse/abuse ED 
visits that involved a particular drug or drug category. 
 Drug concomitance (whether the ED visit involved a single drug or 
multiple drugs). 
 Demographic information about patients in drug-related ED visits (e.g., 
gender, age group, race/ethnicity). 
 The disposition (i.e., outcome) of the drug-related ED visits:  treated and 
released, admitted to the hospital, and all other dispositions. 
 
                                                 
2 DAWN will publish metropolitan-level estimates beginning with the 2004 ED estimates; these will be available at 
<http://DAWNinfo.samhsa.gov/>. 
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If raw data are collected from a hospital, it is important to provide a context 
for the data.  This can be done by documenting the total number of ED visits 
in the hospital, and/or the number of ED visits reviewed, as a denominator for 
the data.  The denominator can be used to calculate percentages (i.e., X 
percent of ED visits were drug-related, or X percent of drug-related ED visits 
involved Y drug).  
 
Uses of ED Data:  Some Examples 
DAWN Data. Exhibit 2 is an example from the first publication from the 
redesigned DAWN.  This simple chart shows the rate of ED visits for four 
major illicit drugs, per 100,000 population, in the second half of 2003. 
 
Exhibit 2. Rates of Illicit Drugs per 100,000 Population in DAWN ED Visits in the Coterminous United States:   
 Third and Fourth Quarter 2003 
 
 
 
 
 
 
 
 
SOURCE:  Adapted from the Office of Applied Studies, SAMHSA, Drug Abuse Warning Network 2004b, p.37 
 
Local Data.   Exhibit 3 illustrates some findings from the Fort Lauderdale 
hospital; these involved ED mentions of gamma hydroxybutrate (GHB) from 
1996 through 2003.  As shown, GHB mentions peaked in 2000 but remained 
higher in 2003 than from 1996 to 1998. 
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Exhibit 3. Emergency Department GHB Mentions in Fort Lauderdale, Florida:  1996–2003 
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SOURCE: Broward General Medical Center 
 
 
Other analyses of the Fort Lauderdale ED data accessed from the local ED 
were also reported including, by drug, patient demographic characteristics 
(age, gender, race/ethnicity), reasons for visiting the ED (e.g., depression/sui-
cidal, dependence/seeking detoxification, trauma/accident), and combinations 
of drugs used by patients (see Hall and Camejo 2005). 
 
 
Drug-Related Hospital Admissions and Discharge Data 
 
Hospital drug-related admissions and discharge data can be a valuable 
indicator of drug abuse and associated health consequences.  Many drug 
abusers require hospitalization and may be admitted to the hospital for a 
medical or psychiatric illness that is the consequence of a drug-using 
behavior. These data may be among the most difficult for network members to 
access and analyze. The data may be available from a local or State hospital 
association or a State health department.  Two examples are presented below. 
The first was prepared by James Cunningham, Ph.D., University of Arizona, 
and illustrates how drug-related hospital admissions data can be accessed and 
analyzed to provide information about the epidemiology of drug problems and 
the impacts of drug policies on hospital admissions. The second, prepared by 
former CEWG representative Bruce Mendelson, illustrates how hospital 
discharge data are used in Colorado. 
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Hospital Admissions Data: Access and Uses in Drug Analysis 
 
James K. Cunningham, Ph.D. 
 
Drug-involved hospital admissions data can provide important information 
about the epidemiology of drug problems and the impacts of drug policies.  
This paper describes procedures and sources for accessing these data and 
examples of their use in epidemiologic and drug policy analysis. 
 
 
Where to Start: Accessing the Data 
 
Data for the study of hospital admissions comes from what is known as 
hospital discharge data systems.  These systems consist of patient-level 
records that include date of admission as well as date of discharge.  The 
systems, however, are called discharge data systems because hospitals submit 
their data to the systems based on the date of patient discharge.  Researchers 
extract records from the systems and conduct analyses as needed.  Drug 
researchers typically extract the records for analyses that involve the date of 
admission.  Later in this paper, for example, data from a hospital discharge 
data system is used to examine trends in methamphetamine, cocaine, and 
heroin/opioid-related hospital admissions.  The term “discharge data” is used 
here in reference to the systems that provide the data.  The term “admissions 
data” is used in reference to data that have been extracted from these systems 
and analyzed according to date of admission. 
 
There are two main sources of data from hospital discharge systems in the 
United States—State-based agencies and the Healthcare Cost and Utilization 
Project. 
 
Most States now have agencies—governmental, educational, or private—that 
have been entrusted with the supervision, storage, analysis, and dissemination 
of statewide hospital discharge data.  Many of these agencies belong to the 
National Association of Health Data Organizations (NAHDO), which lists 
contact information for each of its member organizations (see 
<www.nahdo.org>).  To illustrate how discharge data are accessed from State-
based agencies, procedures for obtaining data in Arizona, California, and 
Nevada follow.   
 
In Arizona, the Department of Health Services, Bureau of Public Health 
Statistics, makes two types of limited (public use) discharge data sets 
available for the purposes of supporting research, public health, and health 
care operations.  One set consists of discharge data from acute care hospitals, 
the other includes discharge data from emergency room departments.  Each 
data set includes principal and secondary diagnoses (ICD-9-CM), as well as 
demographic (e.g., race/ethnicity, age, and gender), geographic (e.g., county), 
and service (e.g., principal and secondary procedures) variables.  Each data set 
requires an approved application form and fee.  In addition to providing 
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discharge data, the Bureau of Public Health Statistics also responds to requests 
for customized data reports. 
 
In contrast to State-based agencies, the Healthcare Cost and Utilization 
Project (H-CUP) is a Federal-State-Industry partnership sponsored by the 
Agency for Healthcare Research and Quality.  H-CUP operates the State 
Inpatient Databases (SID), which consist of records of all inpatient discharges 
from each of 36 different States, representing about 90 percent of all 
community hospital discharges in the Nation.  Of the 36 States that participate 
in SID, 20 provide their discharge data for direct access through H-CUP.  
These States are Arizona, California, Colorado, Florida, Iowa, Kentucky, 
Maine, Maryland, Massachusetts, Michigan, Nebraska, New Jersey, New 
York, North Carolina, Oregon, South Carolina, Utah, Washington, West 
Virginia, and Wisconsin.  H-CUP provides information on how to obtain SID 
files directly from the remaining 16 states: Connecticut, Georgia, Hawaii, 
Illinois, Kansas, Minnesota, Missouri, Nevada, Ohio, Pennsylvania, Rhode 
Island, South Dakota, Tennessee, Texas, Virginia, and Vermont. 
 
While there are differences across States in the availability of variables, each 
State’s SID data set generally includes at a minimum principal/secondary 
diagnoses as well as basic demographic, geographic, and service variables.  
Moreover, where possible, standardized formatting and coding are used to 
increase uniformity across the data sets.  Approved applications are required 
before a SID data set is released.  The fees charged generally differ from one 
State data set to another.  SID files are provided on CD in ASCII format for 
use with statistical packages such as SAS or SPSS.   
 
When interpreting local drug-related hospital discharge trends, it can be 
helpful to contrast them with national trends.  To this end, researchers may 
wish to consider H-CUP’s National Inpatient Sample (NIS), which contains 
discharge data from a national sample of approximately 1,000 hospitals.  As 
with SID, NIS includes principal/secondary diagnoses as well as 
demographic, geographic, and service variables; requires approval and a fee; 
and provides data on CD in ASCII format. 
 
 
Uses of Hospital Data  
 
Data derived from hospital discharge data sets may be unique in that they can 
provide information on drug problems both statewide and regionally, as well 
as information on the impact of specific drug policies.  An example of each is 
presented here using Arizona hospital admissions related to methampheta-
mine, cocaine, and heroin/opioids. 
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Methods Used in Analyzing Arizona Hospital Data 
 
Data for the Arizona Hospital Discharge Data System (AHDDS) are 
abstracted from hospital patient charts by coders employed by hospitals or 
hospital subcontractors to maintain medical records.  The coders review charts 
of all patients and abstract information such as race/ethnicity, sex, age, source 
of admission, and patient disposition.  They also assign ICD-9-CM codes to 
describe what occasioned the admission of a patient, what contributed to the 
patient’s length of stay and financial charges, and the Diagnostic Related 
Group appropriate to the patient.  The abstracted information and diagnostic 
codes are forwarded to the Arizona Department of Health Services, which 
until 1994, used up to five fields for diagnostic codes.  (Note that the ICD-9 E 
codes were entered in the diagnostic fields through 1994.)  Starting in 1995, 
the AHDDS began using nine fields for diagnostic codes that are not E codes 
(i.e., not external cause of injury or poisoning codes) and up to two E-code 
fields.  Starting in 2004, the system included four E-code fields.   All available 
diagnostic code and E-code fields were used in the analyses for this paper.  
The increase in diagnostic fields beginning in 1995 may have lead to more 
accurate reporting, and thus slightly larger drug admission counts for the years 
1995–2004 versus 1990–1994.   The changes in E-code fields may have had 
similar effects.   (Note, however, that a record that includes a drug-related E 
code usually includes other diagnostic codes related to the same drug.) 
 
The ICD-9-CM codes used to identify whether a hospital admission was 
amphetamine-related are 304.4 (amphetamine and other psychostimulant 
dependence), 305.7 (amphetamine or related acting sympathomimetic abuse), 
1969.7 (psychostimulant poisoning), and E854.2 (accidental psychostimulant 
poisoning).  These diagnostic codes are for the general category of 
amphetamines/psychostimulants; thus, analyses in this paper do not 
distinguish among types of amphetamines.  Notwithstanding this, most of the 
chemicals offered on the street as amphetamine or the other terms listed above 
include d-methamphetamine.  For this reason, the admissions examined here 
are referred to as methamphetamine admissions. 
 
The codes used to identify whether an admission was cocaine-related are 
304.2 (cocaine dependence), 305.6 (nondependent abuse of cocaine), 968.5 
(poisoning by surface and infiltration anesthetics including cocaine), and 
E855.2 (unintentional poisoning by local anesthetics including cocaine).  A 
case having any one of these codes was considered a cocaine admission. 
 
The codes used to identify whether an admission was heroin/opioid-related are 
304.0 (opioid type dependence), 304.7 (dependence involving combinations 
of opioid type drug with any other), 305.5 (opioid use), 965.0 (poisoning by 
opiates and related narcotics), E850.0 (accidental poisoning by heroin), 
E850.1 (accidental poisoning by methadone), and E850.2 (accidental 
poisoning by other opiates and related narcotics).  A case having any one of 
these diagnoses was considered a heroin/opioid-related admission.  (Codes for 
opioids causing adverse effects in therapeutic use—E950, E951, E952—were 
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not used to identify admissions because such use is generally not indicative of 
morbidity caused by heroin/opioid abuse.)  Historically, heroin has been the 
single most common opioid associated with hospital admissions.  In light of 
this, the term heroin/opioids, rather than opioids, is used here. 
 
Population data from the U.S. Census and the Arizona Department of Health 
Services were used in the construction of hospital admission population rates. 
 
Statewide Trends in Arizona 
 
In Arizona, methamphetamine hospital admissions rose and fell sporadically 
during the 1990s, then surged 229 percent during 2000–2004, from 1,649 
admissions to 5,424.  The increase in the rate of admissions per 100,000 
population during 2000–2004 was 194 percent (exhibit 1).  At the end of the 
study period (2004), there were 94 methamphetamine admissions per 100,000 
population, more than twice the highest rate of the 1990s (41 per 100,000 in 
1995).  During 1990–2004, the population rate for methamphetamine 
admissions increased 1,075 percent. 
 
 
Exhibit 1. Methamphetamine, Cocaine, Heroin/Opioid Hospital Admissions per 100,000 Population in  
 Arizona: 1990–2004  
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SOURCE:  The University of Arizona 
 
 
Cocaine admissions climbed steadily throughout the 15-year study period and 
increased 47 percent during 2000–2004, from 3,554 to 5,227—a 32-precent 
rise in the rate per 100,000 population.  During 1990–2004, the population 
rate for cocaine admissions increased 194 percent. 
 
Heroin/opioid admissions also climbed steadily throughout the study period 
and increased 52 percent during 2000–2004, from 3,658 to 5,568—a 37-
percent rise in the population rate.  During the 15-year study period, the 
population rate increased 194 percent. 
Rate
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Annual methamphetamine, cocaine, and heroin/opioid admissions for Arizona 
were comparable in number in 2004, related in part to the surge of 
methamphetamine admissions during the last 5 years of the study period. 
 
Regional Trends 
 
Trends in admissions for three Arizona regions are shown in exhibit 2.  One 
region is Maricopa County, which includes the city of Phoenix; another is 
Pima County, which includes the city of Tucson; and the third consists of the 
remaining counties in Arizona, which are predominantly rural and referred to 
here as the “Rural Counties.”  Rates in all three regions rose substantially 
during the last 5 years of the study period.   
 
Maricopa County had the highest rates throughout the study period.  This 
notwithstanding, and largely because of a particularly sharp rise in 2003–
2004, the rate in Pima County approached that of Maricopa County in 2004. 
 
The Rural Counties had the lowest rates.  This finding should be interpreted 
with caution, however, because it is possible that people from these counties 
often go to hospitals in Maricopa and Pima Counties (Arizona’s major 
population centers), which would artificially lower rates in rural areas, while 
raising rates in metropolitan areas. 
 
 
Exhibit 2. Methamphetamine Hospital Admissions per 100,000 Population in Maricopa, Pima, and Rural  
 Counties in Arizona:  1990–2004  
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SOURCE:  The University of Arizona 
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Cocaine admission rates in Maricopa County and the Rural Counties increased 
slightly, while rates in Pima County surged during the last 10 years of the 
study period (exhibit 3).  Early in the study period, rates in Maricopa and 
Pima Counties were fairly similar.  During the last study year, Pima County’s 
cocaine rate was more than three times that of Maricopa County and also 
substantially higher than that of the Rural Counties. 
 
 
Exhibit 3. Cocaine Hospital Admissions per 100,000 Population in Maricopa, Pima, and Rural Counties in  
 Arizona:  1990–2004   
 
             Rate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  The University of Arizona 
 
 
As with cocaine, heroin/opioid admission rates in Maricopa County and the 
Rural Counties increased slightly during the study period (exhibit 4).  In 
contrast, heroin/opioid rates in Pima County increased sharply during 1996–
1998, and again during 2003–2004.  During the first 5 years of the study period, 
rates in Maricopa and Pima Counties were fairly similar.  During the last year 
of the study period, Pima County’s heroin/opioid rate was more than twice that 
of Maricopa County.  It was also substantially higher than that of the Rural 
Counties, which consistently had the lowest rates of the three regions. 
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Exhibit 4. Heroin/Opioid Hospital Admissions per 100,000 Population in Maricopa, Pima, and Rural Counties in  
 Arizona:  1990–2004  
 
           Rate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  The University of Arizona 
 
 
In 2004, cocaine and heroin/opioid admission rates in Pima County far 
surpassed the rates for any of the drugs in Maricopa County and the Rural 
Counties (exhibit 5).  Maricopa and Pima Counties had similar metham-
phetamine rates, even though methamphetamine was the top drug associated 
with admissions in Maricopa County and the bottom drug associated with 
admissions in Pima County.  Within the Rural Counties, the three types of drug 
admissions ranked in the same order as those in Maricopa County. 
 
 
Exhibit 5. Methamphetamine, Cocaine, and Heroin/Opioid Hospital Admissions per 100,000 Population in  
 Maricopa, Pima, and Rural Counties in Arizona:  2004  
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SOURCE:  The University of Arizona 
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Relevant Findings: Admissions Data and Drug Policy Impacts 
 
One of the more useful approaches for evaluating large-scale drug-policy 
impacts is the time-series intervention design (also known as the interrupted 
time-series design).  This design involves assessing baseline data (i.e., data 
patterns prior to a policy change) and then determining whether the data 
changed beginning with the implementation of the policy.  Critical to the 
design is the availability of data with fine-grained time units.  Annual or 
biannual time periods are typically not appropriate for time series intervention 
designs, as the periods are too gross to facilitate a reasonable analysis.  
Fortunately, hospital data can often be analyzed using finer-grained time 
periods such as months or even weeks.  As such, they are particularly useful 
for policy analysis. 
 
To illustrate, monthly methamphetamine admissions data in Arizona and the 
points in time when the Federal Government implemented methamphetamine 
precursor regulations to reduce methamphetamine problems are shown in 
exhibit 6.  The first regulation noted in exhibit 6 targeted ephedrine pills in 
single ingredient form (ephedrine is a common chemical precursor used in the 
illicit production of methamphetamine).  Methamphetamine admissions fell 
sharply when the regulation was implemented.  Products that contained 
ephedrine in combination with other medicinal ingredients were implemented 
in 1996.  This regulation appears to have had little effect on admissions.  
Products containing pseudoephedrine (another common precursor chemical) 
were regulated in 1997, and hospital admissions began dropping once again. 
 
 
Exhibit 6. Trends in Methamphetamine Hospital Admissions in Arizona Following Different Precursor Chemical 
 Regulations:  1991–2000  
SOURCE:  Public Statistics Institute 
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Compare the monthly data in exhibit 6 to the annual methamphetamine data in 
exhibit 1.  While the associations between the regulations and hospital 
admissions data are easily seen in exhibit 6, the annual data in exhibit 1 
(which are very useful for epidemiologic purposes) would be too gross to 
facilitate a quality policy impact analysis.   
 
Note:  When conducting time-series impact analyses, impacts should be 
examined not only visually, but statistically as well using procedures such as 
ARIMA analysis.  More information on hospital discharge data, precursor 
regulations, and ARIMA analysis can be found in Cunningham and Lon-Mu 
(2003). 
 
 
Using Drug-Related Hospital Discharge Data in Colorado 
Bruce Mendelson, M.A. 
In this example, the author explains how drug-related hospital discharge data 
are accessed in Colorado and provides examples of how the data are analyzed. 
Findings from this database continue to be reported regularly in CEWG 
reports and to State planners (e.g., Brace 2006). 
 
Where to Start:  Accessing Hospital Discharge Data  
In Colorado, all hospital discharge data are initially collected and coded by the 
Colorado Hospital Association (CHA). Codes are based on the International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM). CHA annually provides a tape of all such discharge data to the Colorado 
Department of Public Health and Environment (CDPHE), which in turn 
provides the Colorado Alcohol and Drug Abuse Division (ADAD) with an 
Excel file of requested hospital discharge information.  The file includes the 
drug-related codes listed in exhibit 1. (ADAD also requests alcohol codes.) In 
requesting data, network members need to be familiar with these codes. 
ADAD can request a file from CDPHE with statewide data only (i.e., 
aggregated) by the specific ICD-9-CM codes; a file with a number of 
disaggregated cross tabulations by ICD-9-CM codes including age, gender, 
and county; or any combinations of these (e.g., a three-way cross tab of ICD-
9-CM code by gender by age).  In the data request, ADAD must clearly 
specify whether the needed data set is to be limited to only Colorado residents, 
or to both residents and out-of-state individuals (i.e., an “occurrence” vs. a 
“resident” analysis).  
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Exhibit 1. ICD-9-CM Drug-Related Codes Used in Colorado Department of Public Health and Environment  
 Discharge Data  
 
 
Drug Dependence (304.0-304.9): 
 Drug Dependence – Opioid Type 304.0 
 Drug Dependence – Barbiturate Type 304.1 
 Drug Dependence – Cocaine 304.2 
 Drug Dependence – Cannabis 304.3 
 Drug Dependence – Amphetamine Type and Other Psychostimulants 304.4 
 Drug Dependence – Hallucinogens 304.5 
 Drug Dependence – Other 304.6 
 Drug Dependence – Combination of Morphine Type With Other 304.7 
 Drug Dependence – Combination Excluding Morphine Type 304.8 
 Drug Dependence – Unspecified 304.9 
Drug Abuse, Not Alcohol or Tobacco (305.2-305.9): 
 Nondependent Abuse of Drugs – Cannabis 305.2 
 Nondependent Abuse of Drugs – Hallucinogens 305.3 
 Nondependent Abuse of Drugs – Barbiturates and Tranquilizers 305.4 
 Nondependent Abuse of Drugs – Morphine Type 305.5 
 Nondependent Abuse of Drugs – Cocaine Type 305.6 
 Nondependent Abuse of Drugs – Amphetamine Type 305.7 
 Nondependent Abuse of Drugs – Antidepressants 305.8 
 Nondependent Abuse of Drugs – Other, Mixed, or Unspecified 305.9 
Drug Poisoning (E850.0-E858.9): 
 Accidental Poisoning By Analgesics, Antipyretics, etc. E850 
 Accidental Poisoning by Barbiturates E851 
 Accidental Poisoning by Other Sedatives and Hypnotics E852 
 Accidental Poisoning By Tranquilizers E853 
 Accidental Poisoning By Other Psychotropic Agents E854 
 Accidental Poisoning By Other Drugs Acting on Nervous System E855 
 Accidental Poisoning By Other Drugs E858 
Opiates and Related Narcotics N965.0 
Barbiturates N967.0 
Surface and Infiltration Anesthetics N968.5 
Antidepressants N969.0 
Phenothiazine-Based Tranquilizers N969.1 
Other Antipsychotics, Neuroleptics and Major Tranquilizers N969.3 
Benzodiazepine-Based Tranquilizers N969.4 
Other Tranquilizers N969.5 
Psychodysleptics (Hallucinogens) N969.6 
Psychostimulants N969.7 
 
 
SOURCE:  International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), World Health Organization 
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Uses of Hospital Discharge Data: Colorado Highlights 
ADAD uses the hospital discharge data in a variety of analyses, including the 
following: 
 Statewide single-year or trend analysis of aggregate alcohol and/or drug 
hospital discharge numbers and/or rates; the analysis may also be done by 
demographic characteristics   
 Statewide single-year or trend analysis of specific alcohol and/or drug 
ICD-9-CM codes.  For drugs, this analysis usually focuses on drug types 
(e.g., cocaine or cannabis) 
 Substate planning area (typically counties) single-year or trend analysis of 
aggregate alcohol and/or drug hospital discharge numbers and/or rates  
The types of analyses described above represent only a fraction of those that 
can be done with this versatile data set.  However, there may be data issues, 
such as “small cell sizes,” that can present a misleading picture if not dealt 
with appropriately (e.g., when calculating rates for substate planning areas 
with small populations).  It may be necessary to suppress data for small 
geographic areas or specific subgroups, report averages for multiple years, or 
aggregate data by several geographic areas to increase case size.    
The examples that follow show how drug-related hospital discharge data have 
been used at the county and State level, with some illustrations of how the 
hospital discharge data have been triangulated with other drug abuse indicator 
data. 
Using Hospital Discharge Data for Local Planning in Colorado 
Exhibit 2, based on data from Adams County, illustrates how hospital 
discharge and treatment data can be used for local substance abuse services 
planning. In this populous county, east of the city and county of Denver, drug-
related hospital discharges increased dramatically (87 percent) during the 8-
year time period shown. The overall rate increase (23 percent) in drug-related 
treatment admissions from 1993 to 1999 indicated the county was attempting 
to respond appropriately with increased treatment services funding.  The 
decline in the treatment admission rate between 1999 and 2000 needed to be 
explored indepth by local planners to determine whether the drop reflected 
data system/reporting problems or an actual decline in the treatment effort that 
warranted a review of drug treatment funding policies.   
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Exhibit 2. Adams County Rates per 100,000 Population of Drug-Related Hospital Discharges and Treatment  
 Admissions:  1993–2000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Colorado Alcohol and Drug Division (analysis by Bruce Mendelson) 
 
 
Statewide Trend Analysis of Drug-Related Hospital Discharge Data 
Exhibit 3 shows Colorado statewide aggregate (i.e., all ICD-9-CM codes) 
drug-related hospital discharges by age group from 1995 through 1999.  
Overall, the discharges increased by 15.1 percent during the 5-year period, 
with those for those patients age 20 and younger increasing by nearly 36 
percent.  Like any other indicator, it is important to put hospital discharge 
data into perspective in comparison to population growth.  The last line of 
exhibit 3 does this by showing the annual rate of drug-related hospital 
discharges per 100,000 population.  The results clearly demonstrate that 
drug-related hospital discharges were increasing at a faster rate than the 
population size. Such rate calculations can also be made by age group.  
 
Exhibit 3. Colorado Drug-Related Hospital Discharges by Age:  1995–1999 
 
Age Group 1995 1996 1997 1998 1999 
20 and younger (n) 1,310 1,935 2,210 2,069 1,779 
21 and older (n) 9,556 9,194 10,096 10,531 10,729 
 Total 10,866 11,129 12,306 12,600 12,508 
20 and younger (%) 12.1% 17.4% 18.0% 16.4% 14.2% 
21 and older (%) 87.9% 82.6% 82.0% 83.6% 85.8% 
State Population (N)  3,764,585  3,819,789   3,892,996  3,966,198  4,039,402 
Hospital Discharge Rate per 100,000 
Population 288.6 291.4 316.1 317.7 309.6 
 
SOURCE:  Colorado Alcohol and Drug Division (analysis by Bruce Mendelson) 
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Analysts can go beyond examining aggregate drug-related hospital discharge 
data and document trends in specific types of drugs, as illustrated in exhibit 4.  
Statewide Colorado hospital discharge rates for the three drugs in the graph 
showed different trends from 1993 through 2001.  Cocaine rates increased 
from 1993 to 1998 but then stabilized; marijuana discharge rates climbed 
rather steadily; and amphetamine hospital rates fluctuated considerably, but 
still more than doubled over the 9-year period. 
 
Exhibit 4. Colorado Drug-Related Hospital Discharge Rates per 100,000 Population for Selected Drugs:   
 1993–2001  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Colorado Alcohol and Drug Division (analysis by Bruce Mendelson) 
 
 
Another way to look at single drug-type hospital discharge rates is to compare 
them with trends in other indicators for the same drug, as in exhibit 5. While 
the indicators shown are not based on comparable samples or data collection 
methods, showing trends for each data source is a parsimonious way of 
looking at the findings.  As illustrated in exhibit 5, cocaine-related hospital 
discharge rates increased through 1993–2001, while other indicators showed a 
mixed pattern.  ED mentions fluctuated dramatically, peaking in 1999; 
cocaine-related death rates rose fairly steadily up to 1999 and then declined; 
the percentages of primary cocaine treatment admissions declined 
dramatically; and there was a slight decline in the proportion of cocaine 
admissions among new users (i.e., those who entered treatment within the first 
3 years of their cocaine use).  
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Exhibit 5. Colorado Cocaine Trends—Selected Indicators:  1993–2001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Based on the DAWN system prior to its redesign in 2003. 
SOURCE:  Colorado Alcohol and Drug Division (analysis by Bruce Mendelson) 
 
The mixed picture in this assessment of multiple cocaine indicators suggests 
that a more detailed examination might be useful. For example, one might 
look at age group proportions across indicators. The increasing percentage of 
older users among the various indicator populations represented in exhibit 5 
suggested an aging cocaine-using population that was experiencing 
consequences of long-term drug use, rather than a new cocaine epidemic.   
 
Psychiatric Hospital Data 
 
Both State and private psychiatric hospitals sometimes have units dedicated to 
the dually diagnosed patient or units dedicated to the addicted population.  For 
State psychiatric hospital data, one should contact the State mental health 
authority and become familiar with its data system and the people who 
maintain it.  If the private psychiatric hospital data are not in a State database, 
this information will be harder to access; one will need to visit each private  
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psychiatric hospital to determine the extent to which these hospitals serve 
drug-abusing populations.  Network members might want to see if there is a 
separate association of private psychiatric providers in the area who would be 
interested in the network’s data collection and reporting efforts.    
An Internet site that identifies psychiatric hospitals in communities is 
<http://www.hospitallink.com>®.  
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ADDENDUM A: Guidelines on Using Diagnostic 
 Codes 
 
As noted earlier, it may be necessary to collect hospital data by diagnostic 
code (as shown in the examples in Arizona and Colorado drug-related hospital 
admissions and discharge data).  This addendum provides an overview of 
widely used diagnostic classification systems and focuses primarily on ICD-9-
CM and Diagnostic Related Groups (DRGs). 
The International Classification of Diseases (ICD) led the way for the current 
text in international use today in the United States, the International 
Classification of Diseases, 9th Revision, Clinical Modification, referred to as 
ICD-9-CM.  This version precisely delineates the clinical picture of each 
patient, providing exact information beyond that needed for statistical 
groupings and analysis of health care trends.3  
Another classification system is the fourth edition of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV) published by the American 
Psychiatric Association (1994).  In DSM-IV, psychoactive substance use 
means “the persistence of psychoactive substance use for at least 1 month or 
repeatedly over a long period of continuing use despite the recurrence or 
persistence of one or more known adverse consequences or taking of recurrent 
physical risks such as driving while intoxicated.”  Nearly all six DSM-IV 
classifications are identical to ICD-9-CM codes. 
Another classification system is the DRGs.  Since 1982, DRGs have been 
used to set limits on Medicare reimbursement.   
Since it requires considerable knowledge and expertise to work with these 
data, networks should identify a researcher who knows how to access and 
analyze the information.  This might be someone who is associated with a 
hospital, health department, or university. 
 
Drug-Related IDC-9-CM Diagnoses and Diagnostic Related Groups 
Computer systems can usually use either the ICD-9-CM or DRG classification 
system.   
The ICD-9-CM classification system provides principal, secondary, and 
tertiary diagnostic codes.  It will be useful to look at secondary (and perhaps  
                                                 
3ICD-9-CM, Official Guidelines for Coding and Reporting can be obtained from:  Superintendent of Documents, P.O. 
Box 37194, Pittsburg, PA 15250-7954; fax (202) 512-2250. 
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tertiary) codes.  There may be as many drug cases that fall into the secondary 
diagnostic codes as fall into the principal diagnostic codes.  The majority of 
cases where the drug code is not the principal code may have a mental health 
code (e.g., affective disorder, adjustment reaction) as the principal code.  
Other conditions that may have a secondary code related to drug or alcohol 
dependence, psychosis, or nondependent abuse are pregnancy, accidental 
poisoning, and fractures. 
Below are the addiction-related DRG codes matched to ICD-9-CM codes. 
DRG 433: Alcohol/Drug Abuse or Dependence, Left Against Medical Advice 
  
DRG 434: Alcohol/Drug Abuse Dependence, Detoxification or Other Symptomatic Treatment with 
Complication Condition 
  
Principal ICD-9-CM Codes: 
291 Psychosis, alcoholic 
292 Psychosis, drug 
303.0 Intoxication, acute alcoholic, or alcoholism 
303.9 Other and unspecified alcohol dependence 
304 Dependence, drug 
304.9 Other and unspecified drug dependence 
305.0 Abuse, alcohol; nondependent 
305.2 Abuse, cannabis; nondependent 
305.3 Abuse, hallucinogen; nondependent 
305.4 Abuse, barbiturate, similarly acting sedative or hypnotic; nondependent 
305.5 Abuse, opioid-mixed; nondependent 
305.6 Abuse, cocaine; nondependent 
305.7 Abuse, amphetamine; nondependent 
305.8 Abuse, antidepressant; nondependent 
305.9 Abuse, unspecified drug; nondependent 
790.3 Excessive levels of blood alcohol 
  
DRG 435: Alcohol/Drug Abuse or Dependence, Detoxification or Other Symptomatic Treatment Without 
Complicating Condition 
  
DRG 436: Alcohol/Drug Dependence with Rehabilitation Therapy 
  
Principal or secondary ICD-9-CM codes: 
291.0 Delirium, alcohol withdrawal 
291.1 Syndrome, amnestic, alcohol 
291.2 Dementia, alcoholic, other 
291.3 Hallucinosis, alcohol withdrawal 
291.8 Psychosis, alcoholic, specified 
291.9 Psychosis, alcohol, unspecified 
292 Drug withdrawal syndrome 
303.0 Intoxication, acute alcoholic, alcoholism 
  
Secondary IDC-9-CM codes:  Non-operating room procedures 
94.61 Rehabilitation, alcohol 
94.64 Rehabilitation, drug 
94.67 Rehabilitation, combination alcohol and drug 
  
DRG 437: Alcohol/Drug Dependence with Combined Rehabilitation and Detoxification Therapy 
Secondary IDC-9-CM codes:  Non-operating room procedures 
94.63 Rehabilitation/detoxification, alcohol 
94.66 Rehabilitation/detoxification, drug 
94.69 Rehabilitation/detoxification, alcohol and drug 
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In addition to these DRG codes and the 29 ICD-9-CM codes corresponding to 
them, there are drug-related ICD-9-CM codes that are not matched to DRG 
codes, including the following: 
 
265.2 Pellagra (alcoholic) 
357.5 Alcoholic polyneuropathy 
357.6 Polyneuropathy due to other toxic agents (specific illicit drugs can be found in E codes 850-
854) 
425.5 Alcoholic cardiomyopathy 
535.3 Alcoholic gastritis 
571.0 Alcoholic fatty liver 
571.1 Acute alcoholic hepatitis 
571.2 Alcoholic cirrhosis of liver 
571.3 Alcoholic liver damage, unspecified 
572.3 Portal hypertension 
573.3 Hepatitis (unspecified toxic) 
648.3 Complications of pregnancy due to drug dependence 
648.4 Complications of pregnancy due to alcohol and drugs 
655.4 Suspected damage to fetus from alcohol 
655.5 Suspected damage to fetus from drugs 
760.71 Fetus affected by alcohol (fetal alcohol syndrome) 
760.72 Fetus affected by narcotics 
760.73 Fetus affected by hallucinogenic agents  
760.75 Fetus affected by cocaine 
965.00 Poisoning by opium 
965.01 Poisoning by heroin 
965.09 Poisoning by other drugs 
967.0 Poisoning by barbiturates 
967.4 Poisoning by methaqualone compounds 
967.8 Poisoning by other sedatives and hypnotics 
968.5 Poisoning  by topical and infiltration anesthetics (e.g., cocaine) 
970.0 Poisoning by central nervous system stimulants analeptics 
970.1 Poisoning by central nervous system-opiate antagonists 
980.0 Toxic effect of alcohol 
 
 
Limitations of Using Hospital Data 
 
Limitations of the ICD-9-CM handicap efforts to assess the true nature and 
magnitude of drug-related health consequences.  For example, there is no 
code-specific category for acute alcoholic pancreatitis or drug-related HIV 
transmission.  Therefore, it is impossible to separate drugs or alcohol from 
other causes of illness; when presenting the information, one can say the 
utilization data being prepared present a conservative estimate, since the data 
do not include all drug-related conditions (Dufour and Caces 1993).  Many 
State health statistics units are working on these issues and should be 
consulted by network members. 
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4.  DRUG-RELATED MORTALITY DATA   
 
 
Medical examiners and coroners (ME/Cs) provide vital information about 
drug-related mortality patterns and trends in the United States, and they are an 
excellent source of data for epidemiology networks.  Often, ME/Cs or 
members of their staff will be interested and active participants in a network 
because they need to know what drugs are on the street, as well as information 
on changes in purity or drug combinations that could be causing a series of 
overdose deaths. 
 
Causes of death are listed on death certificates, which are completed by local 
doctors, coroners, and justices of the peace, among others.  The death 
certificate is submitted by the local official to the section of the State health 
department that is responsible for handling birth and death data. The names, 
addresses, and telephone numbers for State officials in charge of mortality 
data can be accessed through CDC’s Medical Examiner and Coroner 
Information Sharing Project (MECISP) at <http://www.cdc.gov/epo/dphsi/ 
mecisp>.  Go to “About MECISP” and to the link on Death Investigation 
System Description for U.S. States; this will lead to a place where one can 
click on a State name to find information.   
 
Many State databases on drug-involved mortality aggregate all drug-involved 
deaths into a “single” drug category and present the data alongside alcohol-
involved deaths. To obtain information on specific drugs, it may be necessary 
to contact local ME/Cs or the toxicology laboratory to which the local 
jurisdictions send samples for testing. 
 
Network members whose local jurisdictions participate in SAMHSA’s Drug 
Abuse Warning Network (see below) may find these data the easiest to use if 
they are reported for their area, since these data are already collected and 
analyzed.  ME/C annual reports often have drug-specific data and are also 
easy to use.  Secondary analyses of ME/C or toxicology data can provide far 
more detail than DAWN or ME/C annual reports; they allow an analyst to 
examine drug-specific combinations and demographic data.  However, 
secondary analyses can be quite complicated and time intensive.  Other death 
data may be available from State or county health or law enforcement 
agencies, either in preformatted or raw format form.   
 
There are limitations in drug-related morality data.  As noted in MECISP, 
only about 20 percent of the deaths in the United States are investigated by 
ME/Cs, although the percentage varies by State.  The guidelines for which 
deaths are to be investigated also vary widely by jurisdiction (whether State, 
county, district, or city).  The most notable difference is that some 
jurisdictions use the medical examiner system while others use the coroner 
system.  The type of system used may be uniform throughout the State or may 
vary from county to county within a State.  Medical examiners may have 
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State, district, or county jurisdiction.  Usually the MEs are appointed and must 
be licensed physicians; some are expert forensic pathologists.  In comparison, 
coroners or justices of the peace may have district or county jurisdiction, are 
usually elected, and need not be physicians.  Many are only required to be of a 
minimum age (often 18) and a resident of the county or district.  
 
Within local jurisdictions, there is also variation in the percentage of deaths 
that are investigated. In addition, the guidelines for which deaths are to be 
investigated vary widely by jurisdiction, but most require the following types 
of deaths to be investigated: 
 Deaths caused by homicide, suicide, or accidental causes such as motor 
vehicle crashes, falls, burns, or the ingestion of drugs or other chemical 
agents 
 Sudden or suspicious deaths or unattended deaths 
 Deaths caused by an agent or disease constituting a public health threat 
 Deaths that occurred while the decedent was at work 
 Deaths of people in custody or confinement and those institutionalized for 
reasons other than organic diseases 
 Deaths of persons to be cremated 
 
The thoroughness of death investigations (and, consequently, the 
completeness of death investigation records) also varies from case to case.  
Sometimes a postmortem examination may consist of only an external 
examination of the body.  A record of a complete examination includes the 
following items: 
 The initial report of the death made to the ME/C office (e.g., by a family 
member, police officer, or attending physician) 
 A determination of the circumstances surrounding the death 
 Findings of a scene investigation 
 Findings of a postmortem examination or autopsy 
 Results of laboratory tests conducted to determine the presence of drugs, 
toxins, or infectious agents 
 Certification of the cause and manner of death 
 
As noted above, there are variations across States and local jurisdictions in 
who completes the death certificate, e.g., trained personnel such as 
pathologists or medical examiners versus persons with no formal training. 
Discrepancies and nonreporting can occur for several reasons. For example, 
staff of the ME’s office may not be consistent in their reports; one may 
specify the exact drugs involved while another may record only “drug abuse,” 
even when toxicological reports are available.  Or, to spare the feelings of the 
family, a coroner may not mention drugs on the certificate.  In areas where 
suicide has a negative religious connotation, suicide may not be mentioned as 
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the motive on the certificate. There is no way of determining how widespread 
such underreporting is. 
 
The death certificate may be submitted to the responsible State health 
department immediately, or there may be a significant time lag with the cause 
of death shown as “pending.” In the latter case, an amended certificate will be 
issued later, following receipt of the toxicology or pathology report.  It could 
take 6–10 months to get complete data. 
 
One standardized system for collecting information on deaths related to drug 
abuse is the Drug Abuse Warning Network’s system described below.    
 
 
Drug Abuse Warning Network  
Elizabeth Crane, Ph.D., M.P.H. 
 
Medical examiner/coroner data on drug abuse cases is one component of the 
OAS, SAMHSA, DAWN surveillance system (the emergency department 
[ED] component was described in Chapter 3).  
 
The DAWN mortality component provides information about drug-related 
deaths that were investigated by medical examiners/coroners in participating 
jurisdictions.  Data are currently collected from 8 States and 35 metropolitan 
areas.  Profiles of the States and metropolitan areas are published annually.  
DAWN does not produce national estimates of drug-related deaths.   
 
When DAWN was redesigned in 2003, the case definition and types of 
information collected changed.  The metropolitan area boundaries were 
updated to be consistent with the ED component; the new DAWN also seeks 
to cover 100 percent of death investigation jurisdictions in each of the selected 
metropolitan areas.  DAWN now collects data on all drug-related deaths, 
which are then categorized by manner of death.  Data collected by the 
redesigned system are not comparable to data collected in 2002 or before. 
 
The new DAWN mortality component includes all deaths related to recent 
drug use, both intentional and accidental, for all ages.  In addition to deaths 
that were the direct result of drug use (such as an overdose or an allergic 
reaction), DAWN includes deaths where drugs contributed, but did not 
directly cause, the death (such as motor vehicle crash where the driver was the 
under the influence of drugs).  DAWN data are abstracted from death 
certificates and the ME/C’s death investigation records by a trained DAWN 
Reporter.  After determining that the death was a DAWN case (i.e., drug-
related), the Reporter completes an electronic case report form.  Detailed 
information about the manner and cause(s) of death is recorded, together with 
information about all drugs that were involved in the death.  All types of drugs 
are included:  illicit drugs, prescription drugs, over-the counter medications, 
dietary supplements, nonpharmaceutical inhalants, and alcohol. 
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From 2003 to 2005, DAWN Reporters assigned each death to one of seven case 
types, as shown in the “Decision Tree” diagram (exhibit 1).  For analytic 
purposes, deaths in the following case types—homicide by drugs, overmedica-
tion, all other accidental, and could not be determined—were combined to 
create a new analytic category, drug misuse deaths.   
 
Exhibit 1. DAWN ME/C Decision Tree1   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Discontinued in 2006. In order to align the DAWN case types with the categories with the death certificate and improve data consistency, 
DAWN replaced its case types with the Manner of Death categories from the standard death certificate, effective January 1, 2006.  
Because the Manner of Death is obtained directly from the death certificate, a Decision Tree is no longer needed. 
SOURCE:  Diagram adapted from DAWN, OAS, SAMHSA, 2005, page 10 
Is this a DAWN Case?  Based on available documentation, 
was the death induced by or related to the decedent’s ingestion
or use of a drug?
Relationship of drug use to the death was confirmed or presumed.
Drug use includes appropriate or inappropriate use of legal or illegal drugs or substances.
Alcohol alone (with no other drug) is a DAWN case for decedents under age 21.
This is a DAWN Case.
Answer the following questions in order. Assign DAWN Manner of Death
to first Yes.
YES
1.  Does the documentation indicate that the death was ruled a Suicide?
NO
2.  Does the documentation indicate that the death was ruled a Homicide and the 
method of homicide was poisoning by a drug?
NO Homicide not poisoning
Homicide related to drug trafficking
3.  Does the documentation indicate the death was ruled Natural or Accidental and
the death resulted from an adverse reaction to a prescription drug, over-the-
counter medication, or dietary supplement?
NO
Unexpected reaction to illegal drugs
Took too little medication
Combination of legal and illegal drugs
4.  Does the documentation indicate the death was ruled Natural or Accidental and
the death resulted from exceeding the recommended dose of a prescription drug, 
over-the-counter medication, or dietary supplement?
NO
Illegal drugs
Combination of legal and illegal drugs
Accidental ingestion
5.  Did the documentation indicate the death was ruled Natural or Accidental and
the death resulted from the decedent accidentally or unknowingly ingesting a 
drug?
NO
6.  Does the documentation indicate the death was ruled Natural or Accidental and
the death could not be assigned to another category above?
NO
7.  Does the documentation indicate the manner of death was “Could not be 
determined” or “Undetermined” when the case was closed?
STOP
Not a DAWN Case
01  SUICIDE 
Legal or illegal drugs
02  HOMICIDE BY DRUGS
Legal or illegal drugs
Drug was weapon
Product tampering
Malicious poisoning
03  ADVERSE REACTION TO 
MEDICATION
Legal drugs only
Drug interaction
Allergic reaction or side effect
04  OVERMEDICATION
Legal drugs only
Took more than prescribed or 
recommended dose
05  ACCIDENTAL INGESTION
Legal or illegal drugs
Accidental child poisoning
Took wrong medication by accident
06  ALL OTHER ACCIDENTAL
Legal or illegal drugs
Combination of legal and illegal drugs
07  COULD NOT BE DETERMINED
Legal or illegal drugs
Combination of legal and illegal drugs
NO
YES
YES
YES
YES
YES
YES
YES
Manner of Death on 
Death Certificate
SUICIDE
HOMICIDE
NATURAL
or
ACCIDENTAL
COULD NOT BE 
DETERMINED or 
UNDETERMINED
NATURAL
or
ACCIDENTAL
NATURAL
or
ACCIDENTAL
NATURAL
or
ACCIDENTAL
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The 2003 Area Profiles of Drug-Related Mortality focuses on deaths from 
drug misuse and drug-related suicides.  Profiles of illicit drugs also include all 
case types and manners of death.  The drug categories included in the 2003 
mortality publication are illustrated in exhibit 2 for the Boston-Cambridge-
Quincy metropolitan area (see below); rates per 100,000 population are 
illustrated for each participating jurisdiction in the metropolitan area for drug 
misuse and suicide cases (exhibit 3).  Alcohol is reported if at least one other 
drug is involved in the death.  Deaths involving alcohol alone are only 
reported to DAWN for persons under age 21.  For drug misuse and suicide 
cases, the number of single-drug deaths (those involving only one drug) are 
published. 
There are a number of things to keep in mind when using DAWN mortality 
data... 
 Participation in DAWN is voluntary, and the number of participating 
jurisdictions is likely to vary from year to year.  It is therefore important 
for DAWN users to note which jurisdictions did and did not participate in 
DAWN in any given year.   
 The jurisdictions in DAWN do not represent a statistical sample; 
therefore, the counts do not represent the Nation as a whole.   
 The mortality data for a metropolitan area are only representative if all of 
the jurisdictions in the metropolitan area participated. 
 Because different areas have different population sizes, they should only 
be compared using rates, which take population size into account. 
 Because DAWN data are collected directly from death investigation 
records, they reflect any differences in the way deaths are investigated and 
documented by ME/Cs in different jurisdictions.  For example, some 
jurisdictions may report cases as drug-related based on circumstantial 
evidence, while others may only consider a death as drug-related if it is 
confirmed by toxicology.  The types of toxicology tests used may also 
differ; for example, some jurisdictions do not test for marijuana. 
 Death investigations are often complex, and reporters may have to wait for 
the results of autopsies and laboratory tests to determine whether a death 
involved drug abuse.  This can affect data completeness. 
 The case types used by DAWN in 2003 (exhibit 1) differed from the case 
types on death certificates, which was confusing for DAWN Reporters and 
data users.  Therefore in 2006, DAWN adopted the categories from the 
“manner of death” on the standard death certificate:  Natural; Accident; 
Suicide; Homicide; Could not be determined; and Other.  The new DAWN 
categories now align with the death certificate and will improve data 
consistency.  DAWN will still report drug misuse deaths, and it will still 
be possible to examine trends from 2003 on because data from the old 
case types will be mapped to the new case types. 
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Where to Start:  Accessing DAWN ME/C Data 
 
The first publication from the new DAWN ME/C component provides 
mortality data from 2003 for 122 jurisdictions in 35 metropolitan areas for 
2003 (SAMHSA 2005).  Based on participating jurisdictions, the overall 
population coverage for the metropolitan areas was 64 percent, with coverage 
exceeding 90 percent in 13 metropolitan areas.  Data are also presented for six 
States.  Information about the States and metropolitan areas that participated 
in DAWN in 2003 can be found at <http//:dawninfo.samhsa.gov>.  Network 
members should periodically check the DAWN Web site to determine 
whether data are available for their area in any given year.  Mortality 
publications can be accessed at <http//:dawninfo.samhsa.gov/pubs/mepubs/>. 
 
 
What to Access from DAWN ME/C 
 
The following information in the DAWN system would be useful to an 
epidemiology network: 
 Number of death cases by category and by drug or drug category 
 For each drug, the number of single-drug deaths (i.e., deaths that involved 
only that drug) 
 Demographic characteristics (gender, age, race/ethnicity) of the decedents 
 Cause of death (e.g., drug abuse, body systems [includes infections], 
accident and/or injury) 
 Alcohol involvement in drug-related deaths and, for decedents younger 
than age 21, deaths in which alcohol was the only substance involved 
 
As the redesigned system matures, the mortality publications will add data 
from multiple years, which will enable networks to monitor the trends in drug-
related deaths, the involvement of particular drugs, and other factors in their 
areas. 
 
 
Uses of DAWN ME/C Data  
 
Exhibit 2 shows the number of drug-related deaths by drug category for the 
DAWN area that includes the Boston, Massachusetts, metropolitan area in 
2003. This is one of the areas where the entire population is covered by the 
DAWN mortality system.  As shown, opiates/opioids, heroin, and cocaine 
were the most frequently recorded drugs of misuse, while cocaine and 
opiates/opioids accounted for the largest numbers in the suicide category. 
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Exhibit 2. Drug-Related Deaths by Drug Category in the Boston-Cambridge-Quincy, MA-NH Area:  2003  
 
Illicit Drugs 
(All Case Types) Drug Misuse Suicide Drug Category 
Deaths Single-drug Deaths Deaths 
Single-drug 
Deaths Deaths 
Single-drug 
Deaths 
All Drugs 334 135 486 206 63 31 
Alcohol1   114 –2 15 0 
Cocaine 237 80 216 72 21 8 
Marijuana 18 – 18 – 0 0 
Stimulants – 0 – 0 0 0 
Club Drugs3 – 0 – 0 0 0 
Hallucinogens4 0 0 0 0 0 0 
Inhalants 6 4 5 – – – 
Antidepressants   32 6 11 – 
Antipsychotics   10 – 5 – 
Benzodiazepines   88 16 7 – 
Misc. Anxiolytics, Sedatives, and 
Hypnotics   5 – 5 – 
Opiates/Opioids   316 99 23 7 
Heroin (specified) 111 50 109 50 – 0 
Methadone   35 8 – 0 
All other opiates/opioids   118 41 20 7 
Nonsteroidal anti-inflammatory 
agents   0 0 0 0 
Salicylates/Combinations   – 0 – – 
Misc. Analgesics/Combinations   4 – – – 
Anticonvulsants   – – 0 0 
Muscle Relaxants   – 0 0 0 
 
1Includes alcohol in combination with other drugs (all ages) and alcohol alone in decedents under age 21. 
2Dashes indicate a number less than 4 has been suppressed. 
3Includes MDMA (ecstasy), GHB, flunitrazepam (Rohypnol), and ketamine. 
4Includes PCP, LSD, and miscellaneous hallucinogens. 
SOURCE:  Adapted from DAWN, OAS, SAMHSA, 2005, page 53 
 
 
DAWN also provides mortality rates for drug misuse and suicide cases in each 
reporting jurisdiction in a metropolitan area.  Exhibit 3 illustrates these data 
for the Boston-Cambridge-Quincy, Massachusetts, and New Hampshire 
DAWN metropolitan area. 
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Exhibit 3. Boston-Cambridge-Quincy, MA-NH Area Overview:  Deaths and Population by County:  2003 
 
 
 
     Deaths reported to DAWN 
      Drug Misuse 486 
      Suicide    63 
 
     Metro area population, 2003 
      4,439,971 
  
     Population covered by DAWN 
      4,439,971 
 
     Percent of population covered by DAWN 
      100% 
 
 
Metro Area Overview:  Deaths and Population by County, 2003 
 
Drug Misuse Suicide 
Metro Area Component 
Deaths Rate1 Deaths Rate1 
Total Population 
Total Participating (7) 486 109.5 63 14.2 4,439,971 
1. Essex County, MA 93 126.0 13 17.6 737,848 
2. Middlesex County, MA 108 73.4 14 19.5 1,471,724 
3. Norfolk County, MA 56 85.6 11 16.8 654,331 
4. Plymouth County, MA 51 104.6 4 8.2 487,521 
5. Suffolk County, MA 132 193.9 14 20.6 680,705 
6. Rockingham County, NH 31 106.9 6 20.7 290,102 
7. Strafford County, NH 15 127.4 1 8.5 117,740 
 
1Deaths per 100,000 population. 
SOURCE:  Adapted from DAWN, OAS, SAMHSA, 2005, page 52 
 
 
Local Mortality Data 
 
 
 
Another way to obtain mortality data related to drug abuse is to access the 
information directly from local medical examiners or coroners, as is done by 
some CEWG representatives.  Medical examiners in these jurisdictions vary 
somewhat in their classification of death cases in which drugs are detected, as 
will be illustrated by information from two CEWG representatives––Caleb 
Banta-Green, Seattle, and Samuel Cutler, Philadelphia.  Additional 
information on accessing mortality data was provided by the St. Louis 
representative, Heidi Israel, Ph.D. 
 
Because there are no standardized ways of classifying death cases, and 
because the data are complex, it is important that network members establish a 
continuing and fruitful working relationship with the ME’s office.  The 
following strategies have proven useful to one or more of the CEWG 
representatives mentioned above, resulting in longstanding collaboration 
between the representatives and their local MEs: 
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 Begin by sending a letter of introduction to the chief ME. The letter might 
include… 
¾ A statement that a new work group is being formed, with a brief 
description of its mission and goals, how it will function, and the types 
of agencies/organizations involved in the group 
¾ An emphasis on the importance of mortality data in the array of 
indicators that will be analyzed and used by the group to portray drug 
abuse patterns and trends in the area 
¾ An invitation to the ME to attend the next meeting of the group, or to 
send an assigned staff member to the meeting 
¾ A request for the ME to assign a representative to be a permanent 
member of the group 
¾ An inquiry as to the most appropriate person to contact about 
obtaining information on deaths in which there is a presence of illicit 
drugs and probable abuse of licit drugs, with a mention that the 
network will follow all ME regulations related to confidentiality  
¾ Inform the ME that his/her office will receive network reports and that 
they may review summaries of their data prior to release if they 
request  
 
 Once an initial contact has been identified, set up a meeting to define the 
network’s needs and to obtain relevant information, such as…  
¾ Reports by the ME’s office.  There will probably be a “Glossary” that 
defines terms.  Familiarizing yourself with these terms is a good way 
to learn about and understand the language used by the ME’s office.  
Study the data (e.g., abbreviations that appear in case reports, such as 
“6-MAM, heroin” and “PND,” presumed natural death). 
¾ A clear understanding of how the ME’s office defines “drug 
mortality.” In Philadelphia, the case definition is “deaths with the 
presence of drugs,” and alcohol is not counted.  To meet this 
definition, a decedent must have at least one drug that is not alcohol in 
his/her system.  In other areas, the data may be subsumed under “drug-
related” or “drug-induced,” as noted earlier in the DAWN ME/C 
database. As Samuel Cutler notes, there are difficulties in assigning a 
case using definitions such as drug-related and drug-induced (e.g., a 
pedestrian stricken and killed by a vehicle may be found to have 
heroin, cocaine, and alcohol in his/her system, but whether use of the 
drugs was “related” or “involved” in the death is probably unknown).  
The definitions used by the Philadelphia ME to classify “deaths with 
the presence of drugs” are summarized at the conclusion of this 
chapter in Addendum A. 
¾ A clear understanding of the confidentiality “laws” followed by the 
ME’s office.  Generally the death certificate data are public, while the 
case file data are not.  Find out which data are considered “sensitive” 
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and which are actually “confidential.”  Make it clear that the network 
will never report data that could identify an individual (e.g., by 
reporting date of death, an individual’s demographic characteristics). 
 
 Find out whether the ME data are automated. If not, work with staff to 
develop a system. As Caleb Banta-Green notes “This might take some of 
your time, but then you are ‘giving’ them something in return and you will 
be getting the data in the format you require.  Someone with a moderate 
level of analytic skill can easily create a useful database in a relatively 
short amount of time.” 
 
Note that between network meetings, it is useful to call the ME representative 
from time to time to share information. For example, the Philadelphia CEWG 
representative shares with the ME representative information obtained from 
conversations with drug users and outreach workers about a new drug or 
combination of drugs being used in the area, and any information obtained on 
new drug-using groups.  This may alert the ME to conduct tests on new drugs. 
An inquiry is also made with the ME representative as to whether the ME staff 
is witnessing any new drug trends. 
 
 
Accessing Local Mortality Data 
 
If ME data are not available electronically, it will be necessary to pull the 
charts on a regular basis (e.g., the Philadelphia CEWG representative did this 
every 6 months for many years before the system was automated).  This will 
be time consuming because not all deaths will be drug-related, and it will 
involve a “learning curve” on the network’s part. In either case, the task will 
be facilitated by knowing which data and case types to request and having a 
system for recording the data.  
 
At a minimum, network members will want to request the following, as is the 
case in Seattle: 
 The case number (this will be useful if there are any questions about a 
case) 
 Date of the death 
 Demographic characteristics of the decedent (e.g., age, gender, 
race/ethnicity) 
 Manner of death (e.g., accident, suicide, undetermined, or “other”) 
 “BAC” for alcohol (this may be inconsistently coded)  
 Primary, secondary, tertiary, and quaternary causes of death 
 Other conditions 
 Zip Code (last known residence of the decedent) 
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(Similar data are retrieved in Philadelphia, following the definitions shown in 
Addendum A.)   
 
In Seattle, Caleb Banta-Green receives data in Excel format and has created 
an SPSS program to recategorize drugs identified under causes of deaths into 
drug types, e.g., prescription opiates and sedatives/depressants. Use of 
statistical software allows for additional analyses, including the total number 
of drugs, counts for multiple drugs of the same type, and counts of specific 
combinations of drugs. An example of the recategorized data that are ready 
for analysis is illustrated in exhibit 4.  Note that this table is a simplified form 
of the necessary data. One would want to collect information on at least six 
drugs; data on additional drug categories such as muscle relaxants and 
hallucinogens would need to be included, and Zip Code should be gathered if 
available. 
 
 
Exhibit 4. Example of Method for Documenting Drug Deaths in King County, Washington 
 
Case Descriptors Original Data Disaggregated Manually 
Data Recategorized  
Automatically with Statistical Software 
DOD Age Sex Race Manner Drug 1 Drug 2 Drug 3 Cocaine Heroin/ Opiate 
Other 
Opiate 
Amphet-
amine 
Depres- 
sant 
1/1/09 22 F Nat. Amer. Accident Opiate Cocaine  1 1 0 0 0 
1/2/09 33 F White Suicide Mepro- bamate   0 0 0 0 1 
1/3/09 44 F White Undeter- mined Clozapine   0 0 0 0 0 
1/4/09 55 M Black Accident Metham- phetamine 
Metha- 
done 
Oxyco- 
done 0 0 2 1 0 
1/5/09 66 M White Accident Opiate Cocaine  1 1 0 0 0 
1/6/09 77 M Asian Accident Metha- done 
Oxyco- 
done 
Prometha-
zine 0 0 2 0 1 
 
SOURCE: Caleb Banta-Green; information provided for this publication 
 
 
Uses of Local Mortality Data:  King County, Washington, Example 
 
Both the Philadelphia and the Seattle CEWG representatives have developed 
methods for analyzing drug death data received from the local MEs.  Both use 
descriptive statistics (e.g., frequencies, percentages, averages) in reporting 
data, and both report trends over time.  The Seattle representative notes that 
when the data are received from the ME, drug names are often collapsed 
within one cell and need to be disaggregated manually. For example, Primary 
Cause may read as “combined effects of methamphetamine, oxycodone, 
citalopram, and dextromethorphan." In this case, four new variables are 
created:  drug 1=methamphetamine, drug 2=oxycodone, and so on.  
Occasionally, data are received for deaths involving only drugs that cannot be 
abused (e.g., acetaminophen, aspirin), and such cases are excluded. 
 
Exhibit 5 illustrates one of the ways the data are reported for King County 
over an 8-year period (see Banta-Green et al. 2006).  As can be seen, deaths 
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involving heroin and cocaine have tended to account for more deaths than the 
other drugs in most years; however, the increases in deaths involving 
depressants and prescription (Rx) opiates are substantial when 1997 data are 
compared with 2004 data for these two drug types.  
 
 
Exhibit 5. Deaths in King County, Washington, Related to Illicit and Prescription (Rx) Drugs:  1997–2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Medical Examiners Office, Public Health Seattle – King County 
 
 
Heroin and Prescription Opiates—Categorization Issues 
 
As Caleb Banta-Green notes, heroin is identified in a large proportion of drug-
involved deaths in many areas. Recent data indicate that deaths involving 
prescription opiates have surpassed those involving heroin in some cities 
across the Nation. It is therefore vital to disaggregate heroin-involved deaths 
from opiate prescription drug-involved deaths whenever possible. Recent data 
indicate important similarities and differences for heroin- and prescription 
opiate-involved deaths that would be undetectable if these two substances 
were aggregated into a single category.  While it is impossible to perfectly 
disaggregate these two types of opiates, it is possible to separate them in the 
Number of Times Drug I entified
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majority of cases if sophisticated equipment is used.  Many toxicology labs, 
including the labs in Washington State, use the type of equipment that will 
detect most prescription-type opiates in the blood or other bodily fluids of a 
decedent. Urine screens alone do not detect all prescription-type drugs.  
Heroin can be definitively identified by the presence of a heroin-specific 
metabolite (monoacetylmorphine); however, this metabolite degrades quickly 
and is often not detected by toxicological analysis. Often, other evidence 
obtained by the ME/Cs or the death investigator points to use of heroin. 
Heroin may be noted in the death record even if only more general opiate 
metabolites are detected by toxicology. The ME in King County, Washington, 
recently added a “flag” to its database so that any ME entering “opiate” into 
the death record must indicate whether the death was heroin-related.  
Frequently, opiate or morphine is noted in the toxicology report. Some ME/Cs 
will aggregate heroin, morphine, and opiate into a “presumed heroin” 
category. This probably slightly overestimates heroin-involved deaths.  
It is most appropriate to create a “presumed heroin” case type if there are 
detailed data on which prescription opiates are present, and it is possible to 
create a very specific prescription opiates category.  Most prescription opiates 
are readily detectable and identifiable via toxicological analysis, including 
oxycodone, methadone, hydrocodone, hydromorphone, meperidine, and 
propoxyphene. Fentanyl is difficult to detect for some toxicologists. Codeine 
may be pharmaceutical or it may be secondary to heroin. However, as noted 
earlier, the range of prescription-type opioids are easily detected only by the 
highly specific screens, not by the “run of the mill” urine screens.      
These are general rules that can be followed in identifying and categorizing 
heroin/morphine/opiate versus prescription opiates, and these should be 
verified with local experts. 
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ADDENDUM A. Classification of Mortality Cases in  
 Philadelphia 
 
Samuel Cutler 
 
 
Deaths with the presence of drugs, based on the cause of death determined at 
the Philadelphia ME’s Office, are placed into the following five groups for 
CEWG reporting. 
 
1.  Adverse Effect of Drugs (AED) or Adverse Reaction to Drugs 
 
AED cases are deaths attributable to the ingestion of drugs. These cases may 
have just one drug present; however, they often involve positive toxicology 
reports for more than one drug, although not necessarily in excessive 
quantities. It is the action of one or more drugs, or the interaction of the drugs 
with each other or on the body, that cause the adverse (and unexpected) 
reaction. 
 
The Philadelphia ME records the levels of drugs detected by the toxicology 
screen and uses this information to attempt to distinguish the intent of the 
decedent. AED is the most common cause of death with drugs in the system in 
Philadelphia. 
 
2.  Overdose 
 
The most rare cause of death with drugs in the system is overdose. In 
overdose cases, there is a toxic level of a drug or drugs detected by the 
toxicology screen. Sometimes there is even a suicide note. Other factors may 
help distinguish adverse reaction cases from overdose cases, especially if 
there are notes in the record that came from the scene of the death.  
 
The CEWG representative from Philadelphia has always taken pains to use 
the precise expression to convey what we mean by “overdose.”  Overdose 
usually implies intent to die, and definitely includes findings of abnormally 
high levels of a drug or drugs. Conversely, “adverse reactions” are absent of 
the intent to die and such cases generally have lower levels of drugs than 
“overdose” cases.  Overdose, in fact, is a relatively uncommon event, so it is 
important to define and provide information about AED and the other causes. 
 
3.  Violence—Other   and   4. Violence—Self 
 
Violence is often the attributed cause of death with drugs in the system. In 
Philadelphia, it is broken down by “violence inflicted by another person” 
(called “Violence–Other”) or “violence to oneself” (called “Violence–Self”).  
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The most common forms of violence encountered are gunshot wound, 
stabbing, and hanging; however, there are other, less common ways, such as 
being pushed or jumping from a roof or bridge, jumping in front of a moving 
train or other vehicle, and bleeding to death from cutting. Generally speaking, 
homicides are “Violence–Other” cases, but not all homicide victims have 
positive toxicology reports. 
 
5.  Other Causes 
 
There are other ways to die with drugs in the system (or not), and these are 
lumped into the catchall "Other" category in dealing with Philadelphia ME 
data. These include vehicular deaths (driver, passenger, or pedestrian), a 
variety of accidents (such as falling off the roof while working as a roofer), 
other accidents (such as falling in the home and hitting the head in such a way 
that death results), and people who die from illnesses or natural causes (e.g., 
liver failure).  For the CEWG reports and other purposes, such information 
(e.g., falling from the roof) is recorded. 
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5. OTHER DRUG-RELATED HEALTH DATA 
 
This chapter focuses on other sources of drug-related health data that may be 
useful to epidemiology work groups: 
 Poison Control Center Data. In areas where a poison control center 
operates, network members can access drug-specific data on illegal, 
prescription, and over-the counter drugs. These data can be analyzed and 
are often summarized in reports.   
 Telephone Hotline Data.  These data represent both the level of drug use 
and the level of concern about drugs; some hotline calls represent 
informational calls. 
 HIV/AIDS and Hepatitis B and C Data.  These data are important 
population-level indicators of specific risk factors associated with 
transmission of these blood-borne diseases, including drug use in some 
proportion of the population. 
 
Poison Control Center Data 
 
Jane C. Maxwell, Ph.D., and William A. Watson, Pharm.D. 
 
Poison Control Centers (PCCs) are a potential source of current information 
on trends and patterns of the abuse of illicit and licit drugs.  The primary 
purpose of PCCs is to provide information and management guidelines to 
callers from designated geographical areas.  Trained professionals are 
available by telephone to respond to concerns and emergency situations 
related to exposures to a chemical, environmental, or drug product. The 
specialists in poison information offer telephone advice, treatment 
recommendations, and referral sources. Profiles, problems, and procedures are 
recorded by PCC staff to ensure appropriate practices and procedures are 
followed. 
With regard to misuse and abuse of illicit and licit drugs, a particularly 
important value of PCC data relates to emerging drug trends (e.g., as in the 
use of dextromethorphan illustrated later in this paper).  The system can 
provide data on new patterns of abuse that have only been heard anecdotally 
elsewhere. PCCs can report leading data, incidents that can occur early in the 
abuse cycle of a substance, rather than lagging data, such as after the users 
have become dependent and are reported in treatment data years later. 
Information is uploaded to the database in real time, so data are available for 
analysis almost immediately. 
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Where to Start:  Accessing PCC Data 
There are currently 76 PCCs in the United States. They provide services to all 
50 States, the District of Columbia, and Puerto Rico.  More detailed informa-
tion about PCCs and the American Association of Poison Control Centers is 
provided in Appendix B.  All PCCs in the United States can be contacted using 
a single toll-free telephone number, 800-222-1222, which routes the call to the 
center providing service for the caller area.  The administrative telephone 
numbers of each poison control center can be found on the AAPCC Web site 
in the Poison Center Lists section <http://www.aapcc.org/director2.htm>. 
 
What to Request 
To track patterns of drug use, a request can be made for PCC data.  The Toxic 
Exposure Surveillance System (TESS) is a database of all human exposures; 
more recently added to the database are requests for information that are 
received by poison control centers when no exposure has occurred.  All PCCs 
use the same dictionary of terminology and case coding. 
For substance abuse, confirmed human exposures, as well as the age, age 
group, and gender of each case, together with the county from which the call 
was made, are documented for each case when the data are available.  In 
addition, the substance(s) involved in the exposure is coded both as the 
specific substance (including slang terms) and also into larger categories, such 
as “hallucinatory amphetamines.” Information about the route of drug 
administration, and whether it is acute, acute or chronic, or chronic is also 
documented. Also of interest is information collected on the exposure site, 
where the patient was taken for health care, treatments provided, medical 
outcome, clinical effects, and duration of clinical effects. These latter 
variables can be used for special studies. 
Before requesting data, the Annual Report of the American Association of 
Poison Control Centers Toxic Exposure Surveillance System should be 
reviewed to understand the various data fields that are collected.  The Annual 
Reports are also available on the AAPCC Web site. 
There are five major categories of reasons for exposure: unintentional, 
intentional, adverse reaction, other, and unknown…  
 Unintentional reasons for exposure include subcategories of general, 
therapeutic error, bite/sting, misuse, environmental, food poisoning, 
occupational, and unknown. Unintentional exposures are unplanned or 
unforeseen events.  Unintentional misuse involves the improper or 
incorrect use of a nonpharmaceutical substance. 
 Intentional reasons for exposure include suspected suicides, abuse, 
misuse, and unknown. Intentional misuse is defined as an exposure 
resulting from the improper or incorrect use of a substance for reasons 
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other than the pursuit of a psychotropic or euphoric effect. Intentional 
abuse is an exposure resulting from the improper or incorrect use of a 
substance, where the likely intent of the victim was to achieve a euphoric 
or psychotropic effect. All recreational uses of substances for any effect 
are included in this category. Intentional unknown is an exposure 
determined to be intentional but the specific motive is unknown. 
 Adverse reaction is an adverse event occurring with normal, prescribed, 
labeled, or recommended use of a product. This includes cases caused by 
allergic reactions to a drug or food. 
 Other includes “contamination or tampering” that occurs when the 
patient is an unintentional victim of exposure to a substance that has been 
adulterated either maliciously or unintentionally; “malicious” is used to 
capture data on patients who are victims of another person’s intent to harm 
them. “Withdrawal” is a recently added code. 
 Unknown includes those exposures for which the reason for exposure is 
unknown. 
 
Uses of PCC Data: Texas Highlights 
In the remainder of this paper, several examples of ways PCC data can be 
used are provided from the Texas PCC data.  Persons need to confirm the 
accessibility of data with the PCCs in their locale. 
Exhibit 1 on the following page shows categories of drugs that can be 
requested.  For illicit drugs listed in the A column (e.g., cocaine, heroin, 
marijuana, and ecstasy), it is important to gather data on all calls that involved 
direct human contact with the drug, regardless of reason for exposure (or 
“intent codes”). Illicit drugs are not normally available except in drug-using 
situations, so all cases are of interest.  Using census data, the number of 
human poison exposure cases reported per 1,000 individuals per year in the 
population served can be determined, and using the penetrance rate, 
comparisons of a single substance, or various substances, can be made over 
time.   
For prescription drugs or substances that have common household use (but 
can also be abused), the intent codes are needed to separate cases in which 
there was an adverse reaction or unintentional use, as compared with 
intentional misuse or abuse for euphoric effects. These drugs are listed in 
column B in exhibit 1. Because some users may not admit to having used the 
substance specifically for euphoric or psychotropic effects, researchers should 
use both the intentional misuse and abuse categories listed in the footnote in 
exhibit 1.   
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Exhibit 1. Suggested Categories of Substances and Exposure Reasons1 
 
A.  Drugs—All Reasons/Codes B.  Drugs—Separate Intent Codes 
Cocaine 
Heroin 
Marijuana 
Ecstasy 
Rohypnol/Flunitrazepam 
Gamma Hydroxybutyrate 
Phencyclidine/AMP/Fry 
Lysergic Acid Diethylamide 
Hydrocodone 
Oxycodone 
Methadone 
Amphetamine/Methamphetamine 
Ketamine 
Formaldehyde/Formalin 
Dextromethorphan 
Coricidin HBP 
Mushrooms 
Ritalin 
Alprazolam/Xanax 
Diazepam/Valium 
Clonazepam/Clonopin 
Fentanyl 
Hydromorphone 
Codeine 
Meperidine 
Inhalants 
 
1Exposure/Intent Codes  
    a Intentional – Misuse 
    b Intentional – Abuse 
    c Intentional – Unknown 
    d Contamination/tampering 
    e Other – Malicious 
    f Withdrawal 
SOURCE:  Texas Poison Control Center Network, Texas Department of Public Health 
 
 
The PCC data can also be triangulated with other drug indicators to provide a 
clearer picture of trends.  Exhibit 2 presents data on four phencyclidine (PCP) 
abuse indicators in Texas from 1998 to 2003. PCC calls involving PCP 
increased each year. PCP treatment admissions followed a similar trend, as 
did the number of PCP exhibits identified in the Department of Public Safety 
labs. Overdose deaths involving PCP increased from 1999 to 2002, but 
declined in 2003.  
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Exhibit 2. PCP Indicators in Texas:  1998–2003 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCES:  Texas Poison Control Center Network, Department of Health; Texas Commission on Alcohol and Drug 
Abuse; Texas Department of Public Safety; and Bureau of Vital Statistics, Texas Department of State Health Services 
 
 
One advantage of PCC data is that they may provide information about 
substance abuse that is usually not available from other data sources. Inhalant 
abuse, for example, appears to be one of the most hidden substance abuse 
problems. Death data are often underreported, the proportion of treatment 
admissions is often low (less than 1 percent in Texas), and users are not seen 
in large numbers in surveys of older youth and adults. Yet, the Texas PCC 
data for 1998–2003 show that inhalant abuse occurs not only among young 
teenagers, but also among persons in their twenties. This phenomenon is 
illustrated in exhibit 3, which shows the number of misuse and abuse cases 
involving the inhalation of various substances during that time period.  
Persons who misused or abused typewriter correction fluid were young, with 
an average age of 12.9 years. Persons who used amyl or butyl nitrite 
(“poppers”) were age 27.6, on average. Those who misused paint and other 
products used in painting were in their early twenties. 
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For a study of inhalants, request all substances (not just those listed in exhibit 
1) by inhalation as route of administration and then delete those that are not 
substances of interest. Also, delete all that were not intentional abuse or 
misuse cases, since many products can be misused unintentionally in an 
accident. 
Exhibit 3. Exposures Involving Misuse or Abuse of Inhalants Reported to the Texas PCC, by Year and Average  
 Age:  1998–2003 
 
Year Total Average Age Product 
1998 1999 2000 2001 2002 2003 1998–2003 1998–2003 
Air Freshener: Aerosol 4 3 9 3 10 4 33 14.6 
Amyl/Butyl Nitrite 1 2 1 1 – 8 13 27.6 
Automotive Product: Hydrocarbon 
(Transmission Fluid, Power Steering Fluid) 6 7 10 16 16 23 78 20.2 
Automotive Product: Methanol (Dry Gas, 
Windshield Washing Solution) 5 5 9 14 18 23 74 25.3 
Freon/Other Propellant 23 24 21 20 23 15 126 17.6 
Gasoline 24 19 16 18 18 6 101 14.8 
Mineral Spirits/Varsol/Stoddard Solvent  3 6 5 6 4 2 26 23.5 
Nitrous Oxide 4 4 2 5 4 2 21 23.4 
Paint: Oil-Base  30 22 17 18 20 7 114 23.6 
Propane and Other Simple Asphyxiant 18 14 10 4 10 7 63 15.5 
Toluene/Xylene (Excluding Adhesives) 10 19 14 10 10 4 67 24.3 
Typewriter Correction Fluid 2 4 3 1 3 2 15 12.9 
Unknown Paint, Varnish or Lacquer  16 7 14 8 10 7 62 23.8 
Varnish and Lacquer  – 6 2 – 1 1 10 20.2 
 
SOURCE:  Texas Poison Control Center Network, Texas Department of Public Health 
 
Exhibit 4 provides another example of an emerging drug, but one that seldom 
appears with any frequency in other indicators––dextromethorphan (DXM). 
The over-the-counter DXM-containing products most commonly abused 
include Robitussin-DM, Tussin, and Coricidin Cough and Cold Tablets HBP. 
The drug has also been linked to deaths among those who obtained it in pure 
bulk form via the Internet. Exhibit 4 shows that not only have the number of 
abuse and misuse cases of human exposure to DXM increased in Texas, but 
also that this increase has occurred even when the increase in population is 
considered, which is shown in the penetrance rate per 1,000 persons. 
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1Rate per 1,000 population. 
SOURCE:  Texas Poison Control Center Network, Texas Department of Public Health 
 
 
For additional information, see Watson, W.A. et al.  2003 Annual Report of 
the American Association of Poison Control Centers Toxic Exposure 
Surveillance System, American Journal of Emergency Medicine 22(5): 335-
404, 2004. 
For additional information on accessing a relevant Web site, see Appendix B. 
 
Telephone Helpline Data 
 
Drug helplines provide confidential telephone-based treatment referral and 
assistance. Typically, helplines operate on a 24-hour basis, and are organized 
to provide education and counseling services to individuals concerned about 
or experiencing problems after using drugs. Caller data are recorded and can 
be a useful source of information about drugs and drug abusers.   
By quantifying information collected by helplines in a systematic way, it is 
possible to detect potential changes in the use of particular drugs and the 
emergence of new drugs of abuse.  However, one should keep in mind that 
helpline information cannot be used to determine the actual prevalence of use 
of specific drugs in the population. Furthermore, the caller may not inquire 
about his or her own drug use but because he or she is concerned about  
1
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someone else’s drug use. The data may be considered an indicator of drug use 
in a community and also an indicator of community concern about use of a 
particular drug or drugs in an area, sometimes in response to community 
education forums. 
These data are particularly subject to historical context, both on the part of 
callers and of staff. For example, a call that might have been recorded as a 
“pain pill” in 1999 might be recorded in 2004 as OxyContin if the staff person 
probed the caller about the specific name of the pill they took. 
Generally, helpline counselors fill out forms to record information about each 
telephone contact, including the types of problems of concern to the caller, 
drugs involved, services needed, and assistance/information provided to the 
caller.  The information is often recorded on a standardized form by trained 
staff so it can be aggregated and analyzed systematically and efficiently. 
 
Where to Start:  Accessing Helpline Data 
Network members need to identify the helpline agency. For example, in 
Washington State the agency is the Alcohol/Drug Help Line. This confidential 
24-hour helpline has a computerized database that maintains and quantifies 
information from callers throughout the State.  CEWG representative Caleb 
Banta-Green utilizes this database semiannually to analyze data for various 
counties, particularly for King County (in which Seattle is located); the 
information is documented regularly in his CEWG paper. In Massachusetts, 
CEWG representative Daniel Dooley accesses such data semiannually from 
the Massachusetts Substance Abuse Information and Education Hotline for 
the Boston region (comprising the cities of Boston, Brookline, Chelsea, 
Revere, and Winthrop) and reports findings in the Boston CEWG paper.  
 
What to Request    
Before you request helpline data, first become familiar with the helpline’s 
database so you can be specific about the types of information that will be 
most useful to the network.  The number of mentions for each drug will 
exceed the number of calls, because some callers inquire about more than one 
substance.  Besides requesting numeric data (number of calls for each drug 
within a specific time period), network members may wish to talk with 
helpline counselors.  Counselors can provide valuable explanations and 
insights into what appear to be new drug abuse trends and “fads.” 
It may be possible to obtain the helpline datafile electronically in an Excel 
format, which will clearly show any small numbers for a particular drug (or 
area). The Seattle CEWG representative, Caleb Banta-Green, is sent the data 
in an Excel format; the “threshhold” set for noting a change for a particular 
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drug is a substantial change from the previous reporting period (e.g., if 
cocaine were to increase from 30 to 40 percent of the calls, but 
benzodiazepines were to increase from only 5 to 8 percent, only the cocaine 
data are reported for that time period). 
Uses of Helpline Data: Boston Example 
Exhibit 1, developed by CEWG representative Daniel Dooley (in publication), 
exemplifies the type of information that can be accessed and analyzed from 
helplines.  Like other Boston drug abuse indicators, these helpline data 
substantiate alcohol, heroin, and cocaine/crack abuse in the city.  The 6-year 
trend data also substantiate findings from other indicator data that point to the 
increased abuse of narcotic analgesics (especially oxycodone) the Boston area.  
As shown in exhibit 1, the proportion of calls involving narcotic analgesics 
rose from 6 percent of the calls in FY 2000 to 19 percent in FY 2005.  
 
Exhibit 1. Helpline Calls in Greater Boston,1 by Drug and Percent:  FYs 2000–2005 
 
FY 2000 FY 2001 FY 2002 FY 2003 FY 2004 FY 2005 
Drug2 
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Alcohol-only 2,034 (37) 2,206 (39) 1,965 (34) 1,627 (31) 1,597 (28) 1,730 (35)
Cocaine/ 
Crack 1,118 (20) 1,1068 (19) 1,072 (18) 1,041 (20) 1,017 (18) 949 (19)
Heroin 1,832 (33) 1,862 (33) 2,038 (35) 1,895 (36) 2,230 (40) 1,562 (31)
Narcotic Analgesics 344 (6) 508 (9) 785 (14) 832 (16) 1,025 (18) 931 (19)
Marijuana/ 
Hashish 309 (6) 291 (5) 339 (6) 261 (5) 253 (5) 226 (5)
Benzodiazepines 151 (3) 154 (3) 204 (4) 187 (4) 175 (3) 168 (3)
Methamphetamine 2 (<1) 7 (<1) 11 (<1) 10 (<1) 14 (<1) 16 (<1)
MDMA 43 (1) 40 (1) 45 (1) 32 (1) 24 (<1) 17 (<1)
Hallucinogens 17 (<1) 24 (<1) 8 (<1) 14 (<1) 8 (<1) 6 (<1)
Inhalants 100 (2) 55 (1) 40 (1) 15 (<1) 25 (<1) 12 (<1)
Total Number of Calls 5,478 5,695 5,814 5,221 5,627 4,977 
 
1Greater Boston includes Boston, Brookline, Chelsea, Revere, and Winthrop  (CHNA 19).  
2Narcotic Analgesics include codeine, methadone, morphine, oxycodone (incl. OxyContin), Percocet, Roxicet, Vicodin and other opiates. 
Benzodiazepines include Ativan, Halcion, Klonopin, Librium, Rohypnol, Valium, and Xanax.  Hallucinogens include LSD, PCP, psilocybin, 
and mescaline.  Inhalants include acetone, aerosols, glue, markers, paint, and other inhalants. 
SOURCE: Massachusetts Substance Abuse Information and Education Helpline; data analysis by the Boston Public Health Commission 
Research Office 
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HIV/AIDS and Hepatitis B and C Data  
 
HIV/AIDS, hepatitis B (HBV), and hepatitis C (HCV) may be transmitted 
through the use of contaminated needles and other paraphernalia by injection 
drug users (IDUs) and from having unprotected sex with an IDU.  
For more than two decades, studies of HIV seroprevalence among IDUs have 
shown that spread of this infection can occur rapidly among IDUs and their 
sexual partners, especially among men who have sex with men (MSM) and 
are also IDUs.  Studies have also shown considerable variation in HIV 
seroprevalence by geographic area and by demographic characteristics such as 
age, gender, and race/ethnicity. 
 
Where to Start: Accessing HIV, HBV, and HCV Data 
The Centers for Disease Control and Prevention’s Divisions of HIV/AIDS 
Prevention Web site offers easily accessible information on HIV/AIDS by 
region and for the Nation overall <www.cdc.gov/hiv/dhap.htm> (click on 
Statistics & Surveillance, then Reports).  Another CDC Web site offers links 
for State and local HIV/AIDS surveillance reports: <http://www.cdc.gov/hiv/ 
stats/hasr1402/website.htm>. The link will lead to the Web site by State (e.g., 
Alabama) <http://www.adph.org/aids>. After you click on the URL for the 
State, click on Annual Report for several options to access the data by region 
of the State (counties are combined in regions) or HIV/AIDS Cases 
Countywide and Statewide.  States vary in how this information is presented.   
Other sources of HIV/AIDS data include State health departments, local 
health departments, local AIDS programs, universities, and outreach 
programs. The Chicago CEWG representative and colleagues, for example, 
use CDC data in reporting HIV/AIDS patterns and trends, but also use 
information from State and city health departments and data from studies 
conducted by the University of Illinois at Chicago (see, e.g., Broz et al. 2005). 
Some local health departments, as in the State of Washington, have 
increasingly maintained trend data on HIV exposure categories.  Network 
members may wish to contact their local health department and inquire 
whether such data are available for their area. 
The CDC also collects information on hepatitis, including HBV and HCV.  
These data are reported weekly to CDC by State and territory health 
departments. The data are prepared in reports by CDC that are available at 
<www.cdc.gov/hepatitis> (see also below). Most local health departments 
have infectious diseases epidemiologists who track HBV and HVC.   
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State epidemiologists are listed on the Council of State and Territorial 
Epidemiologists Web site at <http://www.cste.org/members/state 
_and_territorial_epi.asp>. 
 
Hepatitis Surveillance Report No. 60, September 2005, as an example, 
includes data from 1975 through 2003.  Figure 12 of the report shows the Rate 
Per 100,000 Population of Incidence of Acute Hepatitis by Region of the 
Nation; Figure 13 shows the same data by county (see http://www.cdc.gov/ 
ncidod/diseases/hepatitis/resource/index.htm; click on Hepatitis Surveillance 
Report). Network members may find State and local health departments, 
outreach programs, and universities useful sources of data on HVB and HVC.  
Sources of information on HBV and HCV found useful by CEWG 
representatives are shown later in exhibit 2. 
 
What to Request 
For diagnosed AIDS cases, request the following types of information by year 
(e.g., 1999 through 2005) and for “cumulative” cases (e.g., 1981–2005): 
 Gender (male, female) 
 Race/ethnicity (e.g.,White, Black, Hispanic, Asian/Pacific Islander, 
Unknown) 
 Age group (e.g., 0–12, 13–19, 20–29, 30–39, 40–49, 50–59, 60 and older) 
 Mode of exposure 
¾ MSM  
¾ IDU/MSM 
¾ IDU 
¾ Heterosexual contact 
¾ Mother with HIV 
¾ Others that may be of interest (e.g., hemophilia, transfusion/transplant, 
other) 
 Deaths during each year 
Similar data can be requested for HIV cases and, if available, for HBV and 
HCV cases. 
For these data, be sure to inquire about case coding protocols. For example, in 
some areas heterosexual contact will only be recorded for women if they have 
never injected drugs or had sex with an MSM.  This rules out many prostitutes 
who may have contracted HIV through sex with a man. 
 
Uses of the Data on AIDS and Hepatitis B and C 
CEWG representatives regularly report data on HIV/AIDS.  An example is 
provided in exhibit 1, as reported by CEWG representative Heidi Israel, 
Ph.D., and James Topolski, Ph.D. (2006). These data show, for example, that 
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the majority of persons living with HIV in St. Louis are male, White or 
African-American, and between the ages of 30 and 49. Injection drug use and 
combined male-to-male sex and injection drug use accounted for 10 percent of 
the positive cases through June 2004. 
 
Exhibit 1. Persons Living with HIV Disease in St. Louis Metropolitan Area by Exposure Category, Gender, 
 Race/Ethnicity, and Age: Year-to-Date and Cumulative Totals:  1995–June 2004 
 
HIV-Positive Test Results 
January 2004–June 2004 Cumulative from 1995 through June 2004 Category 
Number Percent Number Percent 
Exposure Category     
MSM 61 50.0 4,583 70.0 
IDU 6 5.0 301 5.0 
IDU/MSM 3 2.0 319 5.0 
Hemophilia 0 0.0 58 1.0 
Heterosexual 12 10.0 920 14.0 
Blood transfusion 0 0.0 34 0.2 
Perinatal 0 0.0 41 1.0 
Unknown 41 33.0 416 6.0 
Total 123  6,672  
Gender and Race/Ethnicity     
Male     
 White 40 33.0 2,914 45.0 
 African-American 62 51.0 2,582 40.0 
 Hispanic 1 0.0 79 1.0 
 Other 1 0.0 19 0.0 
 Unknown 0 0 208 3.0 
Female     
 White 4 3.0 170 2.0 
 African-American 14 12.0 671 10.0 
 Hispanic 2 0.0 15 0.0 
 Other 0 0.0 13 0.0 
Age     
12 and younger 0 0.0 53 1.0 
13−19 5 4.0 160 2.4 
20−29 39 32.0 1,644 25.2 
30−39 30 24.0 2,799 43.0 
40−49 41 33.0 1332 20.4 
50 and older 8 7.0 522 8.0 
Unknown 0 0 162 2.0 
Total 123  6,672  
 
SOURCE: St. Louis Metropolitan AIDS Program 
 
Some CEWG representatives also reported available information on hepatitis 
B and C at the June 2004 CEWG meeting. Their findings are summarily 
presented in exhibit 2, together with information on the data sources, methods, 
and population covered by the data source.  As can be deduced, reports and 
estimates of HBV and HCV infection among the populations studied are 
alarmingly high.  New networks need to monitor these diseases as data 
become increasingly available. 
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Exhibit 2. Data on HBV and HCV Reported by CEWG Representatives1 from 7 Areas 
 
Site/Data Source/Year Method/Population Major Findings 
Hawaii: State Department of 
Health, Hawaii, 2003 
Testing  
113–114 Syringe Exchange 
Program participants 
 
69.3 percent tested HBV positive; 54.0 
percent tested HCV positive 
Maryland: Department of Health 
and Mental Hygiene, 2002 
Survey and testing  
Persons entering Baltimore   
detention centers 
 
30 percent tested HBV positive; 9 percent 
tested HCV positive 
Michigan: Department of 
Community Health, Immunization 
and Communicable Disease 
Division, 2003 
Estimates  
General population 
 
 
Prison inmates (48,000)   
 
 
179,000 in the general population are HCV 
infected 
 
18,000 inmates are HCV infected 
Minnesota: Department of 
Health, 2003 
Estimates  
Methadone maintenance patients  
 
Up to 90 percent HCV infected 
San Francisco: Urban Health 
Study, 2003 
 
 
 
 
 
University of California at San 
Francisco, 2003 
Self-reports  
IDUs 
 
Estimates based on earlier 
testing     
IDUs 
 
Research study   
Homeless and marginally housed 
HIV-infected persons 
 
67 percent said they were infected with 
HCV 
 
 
90–95 percent are HCV positive 
 
 
73 percent were HCV and HIV “co-infected” 
Seattle: Public Health-Seattle & 
King County, HIV-AIDS 
Epidemiology Program, 1994–
2003 
 
 
 
 
Local researchers 
 
Estimates  
King County IDU population 
(based on a sample of more than 
4,000 since 1994) 
 
 
 
Local incidence studies 
IDUs who were not HCV infected 
 
IDUs who were not HBV infected 
 
85 percent may be infected with HCV; 70 
percent show markers of prior HBV infection 
 
 
 
 
 
21 percent acquire HCV each year 
 
10 percent acquire HBV each year 
Texas:  Department of Health, 
2003 
 
Research study (NIDA Grant R21 
DA014744, Maxwell and Spence 
2004) 
Testing   
8,798 persons 
 
Self-report  
Heroin addicts 
 
18 percent were HCV positive (41 percent 
of positives were IDUs) 
 
48 percent said they were HCV infected 
 
1Data were extracted from papers by D. William Wood, Ph.D. (Hawaii), Leigh Henderson, Ph.D. (Maryland), Phil Chvojka (Michigan), 
Carol Falkowski (Minnesota), John Newmeyer, Ph.D. (San Francisco), Caleb Banta-Green (Seattle), and Jane Maxwell, Ph.D. (Texas).  
SOURCE:  NIDA 2005 (Volume II CEWG reports) 
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6. LAW ENFORCEMENT/CRIMINAL JUSTICE  
SYSTEM DATA  
 
There are many sources of law enforcement data that can provide useful 
information to network members.  They are subsumed in this chapter under 
the following broad headings: 
 Drug-Related Arrest Data.  Arrest and/or criminal file data can provide 
interesting information; however, data quality and availability vary by 
area. 
 Crime Laboratory Drug Data. These data are available in most States; 
they provide considerable detail about specific drugs and require no 
analyses. 
 Drug Trafficking Data.  These data, if available, are in an easily usable 
format and provide an essential context to other drug indicator data. 
 
Major contributions to portions of this chapter were provided by CEWG 
representative Erin Artigiani and her colleague Eric Wish, Ph.D., Center for 
Substance Abuse Research (CESAR), University of Maryland, who regularly 
monitor such data for the State of Maryland. Other contributions were made 
by Dr. Jane Maxwell and Caleb Banta-Green in their review of the material, 
and some data are extracted from recent papers of other CEWG 
representatives.  
Erin Artigiani and Dr. Eric Wish offer the following tips to persons requesting 
law enforcement data: 
 Know the agency contact 
 Identify existing data sets and review existing reports to ensure that the 
right person is approached at the right time 
 Follow agency procedures for making data requests 
 Ask for everything at once 
 Be detailed and specific 
 Be patient 
 Build a rapport and express gratitude for the information 
There are many 
sources of law 
enforcement data 
that can provide 
useful information 
to network 
members. 
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Drug-Related Arrest Data 
Local police and sheriffs’ departments can often provide information on the 
number of arrests for different drugs, as well as data on the characteristics of 
arrestees.  
Another source of information on arrestees is the Uniform Crime Report 
(UCR), maintained by the Federal Bureau of Investigation (FBI). The UCR 
provides information on drug-related arrests for several broad drug categories.  
UCR data, by State, can be found at <http://www.fbi.gov/ucr/ucr.htm>; local 
officials will need to be contacted for county-level data. In some areas, there 
are agencies that conduct urinalysis; such data provide especially valid infor-
mation on the particular drugs used by arrestees and information on their 
demographic characteristics. Another data source on drug-abusing arrestees is 
the Treatment Accountability for Safer Communities (TASC) programs; a 
description of TASC can be found at <www.nationaltasc.org>.  Still another 
potential data source is the drug courts (see <http://www.nadcp.org>).  These 
and other data sources are covered in this section. 
 
Police Department and Sheriff’s Office Data 
Police departments generally assign someone the primary responsibility for 
the task of collecting, managing, and reporting arrest data. If a police 
department is relatively large, this responsibility is likely to be delegated to a 
particular division (e.g., narcotics unit). 
While a particular police department may use a standard format to collect data 
on arrestees, the format is likely to vary across different towns and cities. 
Some departments may have only one category for drug-related offenses, and 
the types of drugs may not be specified. Others will have detailed information. 
Also, police departments differ with regard to how drug arrests are classified 
and recorded. For example, the Boston Police Department, Office of Planning 
and Research, categorizes drug arrests by class (see exhibit 2 below). Or, in 
some areas, if a person is arrested while driving under the influence (DUI) and 
drugs are found, the arrest report may include only the DUI (the greater of the 
two offenses). Some police departments may not consider an arrest for 
injection equipment as a major arrest and would not record it in the database. 
Some departments may test arrestees for drug use (e.g., by urinalysis). While 
testing is not a common practice, such data are particularly useful, since they 
provide a valid estimate of recent use of specific drugs. 
Some police departments may make use of several types of law enforcement 
data/information to assess local drug abuse patterns and trends. A case in 
point is the Phoenix Police Department. Indicators used by the Phoenix Police 
Department include data on drug seizures, arrests, and bookings. For example, 
the Department’s Drug Enforcement Bureau (DEB) made 1,384 drug-related 
…source of 
information on 
drug-related 
arrests… 
…police depart-
ments differ with 
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arrests in 2005 (see exhibit 1 below). From 2003 to 2005, there was a 69-
percent increase (from 241 to 362) in methamphetamine-related arrests. 
Methamphetamine seizures increased from 42 in 2004 to 68 in 2005, despite 
the fact that the number of small clandestine methamphetamine labs decreased 
during this time period. According to the DEB, increasing amounts of 
methamphetamine were being transported into Phoenix from Mexico, and the 
purity of the Mexican methamphetamine was much higher than the 
methamphetamine that was produced in local labs (Vermeer in publication). 
Network members should inquire about the different types of drug-related 
information/data available from a police department or Sheriff’s Office. 
Where to Start:  Accessing Police/Sheriff’s Office Arrest Data 
One very useful source of information is USACOPS. Through the USACOPS 
Web site, it is possible to access the names, addresses, and phone numbers for 
local law enforcement agencies. Relevant information on how to access data 
from the USACOPS Web site, and a minimal list of questions network 
members should ask of police informants, are shown in the box below. (See 
also Appendix B.) 
 
Accessing USACOPS Web Site and Questions to Ask 
 
 
A. Access online at <http://www.usacops.com> 
 
First: On the map, click on the State you want (e.g., Minnesota) 
Second: On the State map, click on the county you want (e.g., Hennepin County) 
Third: Click on the county site of interest (e.g., Minneapolis SO) 
 
Summary: (1) Minnesota (2) Hennepin County (3) Minneapolis SO 
 
 
B. Accessing Data from the Law Enforcement Agency (e.g., Sheriff’s 
Office, Police Department) 
 
By phone or in person: 
1. Find the best “informant” (e.g., the officer who has information on drug arrests or 
the person in charge of data entry). 
2. Ask the informant specific questions for a specific time period (e.g., year) on the 
number of arrests (cases) for each drug of interest; if data are available, request the 
number of cases for manufacture/sales versus possession for each drug of interest. 
 
Inquire also and obtain any information available on seizures and trafficking of drugs of 
interest, and any other insights the informant may have on drug use in your community. 
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Network members should first check on how the local sheriff’s office or 
police department maintains data on drug arrests, how arrests are recorded, 
and what types of changes (if any) have been made in how the data were 
recorded over, say, the past 5 years. If there have been major changes in how 
arrests are recorded, it would be advisable to collect the data only for the most 
recent years in which uniform data have been collected so that trend data will 
be comparable over time. If the information must be accessed from existing 
records (rather than online), it would be useful to develop a form for 
requesting or accessing the data before the task begins. It is also useful to find 
out whether there have been any changes in a policy, formal or informal, that 
have led to a changing focus on any specific populations, neighborhoods, or 
specific drugs. 
 
What to Request 
The types of information to be requested depend, of course, on the types of 
data the police department collects. If the data are available, focus on the 
following types of information: 
 The total number of arrests for a specific time period 
 The number of arrests for each type of drug (and for DUI, if the network 
chooses to include DUI data) 
 The demographic characteristics of arrestees by type of drug and by type 
of arrest (e.g., possession, sales) 
 Any testing data (e.g., urinalysis, hair testing, or testing of evidence)  
Uses of Police/Arrest Data:  Examples from the CEWG 
The Phoenix Police Department, Drug Enforcement Bureau, maintains 
information on arrests for various illicit drugs. Data show a sharp rise in 
cocaine arrests from 2003 to 2004, followed by a sharp decline in 2005. 
Arrests for methamphetamine show an opposite trend, that is, an increase in 
2005 from 2003 and 2004 (Vermeer in publication). 
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Exhibit 1. Number of Drug Arrests Made by the Drug Enforcement Bureau,1 Phoenix Police Department:   
 2003–2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1These numbers do not include arrests made by patrol precincts or other bureaus. 
SOURCE:  Phoenix Police Department 
 
In Boston, drug arrests are categorized by “class.” These data are reported 
regularly in tabular form by CEWG representative Daniel Dooley (2006).  
Exhibit 2 shows the number of arrests and the percentage of the total for each 
class of drug from 1998 to 2004 (drugs included in each class are shown in 
footnotes). The predominance of Class B arrests reflects the high level of 
cocaine abuse in the Boston area.  
Exhibit 2. Boston Police Department Arrests for Possession, Distribution, Manufacturing, and Trafficking  
 of Drugs, by Class of Drug and Percent:  1998–2004 
 
Drug Class 1998 1999 2000 2001 2002 2003 2004 
A1 22.5 24.0 27.1 26.4 22.5 22.5 20.7 
B2 47.1 45.1 40.6 41.7 41.9 41.6 43.3 
D3 25.6 27.7 29.0 28.7 32.7 32.7 32.8 
Other 4.8 3.3 3.3 3.2 3.0 3.2 3.2 
Total Drug Arrests (N) (4,723) (4,097) (3,770) (3,426) (4,209) (4,174) (3,807) 
Total Arrests (N) (25,481) (23,592) (22,216) (20,470) (21,025) (20,686) (19,577) 
Drug Percentage of Total 18.5 17.4 17.0 16.7 20.0 20.2 19.4 
 
1Heroin, morphine, gamma hydroxybutyrate, ketamine, and other opiate derivatives. 
2Cocaine, “other opiates,” MDMA, lysergic acid diethylamide, phencyclidine, methadone, fentanyl, amphetamines,  
 methamphetamine, methaqualone, and others. 
3Marijuana, barbital, butyl nitrite, and others. 
SOURCE: Boston Police Department, Office of Planning and Research 
 
283
319
289
380
538
298
241
238
363
14
47
34
2003
2004
2005
2003                                 Marijuana 
Cocaine 
Methamphetamine 
Heroin 
2004                                 Marijuana 
Cocaine 
Methamphetamine 
Heroin 
2005                                 Marijuana 
Cocaine 
Methamphetamine 
Heroin 
6.   Law Enforcement/Criminal Justice System Data 
 
 
A Guide for Community Epidemiology Surveillance Networks on Drug Abuse 95
  Uniform Crime Report Data 
UCR programs in States collect, evaluate, and process uniform statistical 
arrest data, and, in turn, report the data to the FBI; 17,000 jurisdictions report 
UCR data to the FBI in a given year. Because of computer problems, changes 
in record management systems, personnel shortages, or a number of other 
reasons, some agencies cannot provide data for publication in a given time 
period.   
UCR data are collected regularly and consistently and provide State, county, 
and local measures of crime. State, county, and municipal law enforcement 
agencies are required by law to submit monthly Uniform Crime Reports on 
the number of offenses known to have occurred in their locality and the 
number of arrests made. Data are provided in a format that has remained 
unchanged since 1994. Annual statistical publications, such as the 
comprehensive Crime in the United States, are available. 
There are a number of limitations in the UCR data. The UCR does not 
measure the prevalence of crime. Drug categories are not drug specific and are 
limited to four: (1) opium, cocaine, and derivatives; (2) marijuana; (3) 
synthetic narcotics; and (4) dangerous non-narcotics. Arrests for two major 
drugs, such as heroin and cocaine, cannot be separated for analysis. Rules on 
how methamphetamine should be coded are not specified. Only the most 
serious charge is recorded.  The UCR is not a measure of drug use, since 
many persons committing other types of crime or not getting arrested at all 
use drugs. Nor does the UCR measure the number of different individuals 
arrested. The data reflect the level of law enforcement concentrated on the 
problem, not the magnitude of the crimes committed.  Dr. Jane Maxwell, 
CEWG representative, has found that local UCR data may contain duplicates, 
because each assigned department is required to complete the UCR.  For this 
reason, it may be preferable to obtain UCR data from the State agency and to 
request relevant data on specific drugs for the network’s local area. 
Where to Start: Accessing UCR Data 
Statewide data are available through national reports prepared by the FBI and 
may be found at: <http://www.fbi.gov/ucr/ucr.htm>. (See also Appendix B.)  
Network members may also wish to confer with local law enforcement 
personnel to see whether recent data are available either online or in hard 
copy. 
What to Request 
Ideally, network members will request data for the most recent year and for 3–
5 prior years, depending on the time span selected for trend analyses of 
different indicator data. 
…17,000 jurisdic-
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Requests can be made for Total Arrests and for (1) Possession and (2) Sales 
and Manufacturing of (a) Opium Cocaine/Derivatives, (b) Marijuana, (c) 
Synthetic Narcotics, and (d) Other Dangerous Non-Narcotics. 
Members might also be interested in the demographic characteristics of 
persons arrested for particular drug charges. Data are available by gender, 
race/ethnicity, and age group.  
Uses of UCR Data:  Baltimore City/Maryland Example 
Exhibit 3 shows the 2003 Maryland UCR data at one substate level––
Baltimore City. As depicted in the exhibit, Baltimore City accounted for 53 
percent of all drug possession arrests in the State and 69 percent of all sales 
and manufacturing arrests in 2003.  Opium or cocaine and their derivatives 
accounted for 80 percent of the combined possession and sales/manufacturing 
violations for that drug category in Maryland in 2003. 
 
Exhibit 3. Number of UCR Drug-Related Arrests in Baltimore City, by Type of Violation and Drug, and  
 Percentage of All Drug Arrests in Maryland:  2003 
 
Violation Opium or Cocaine/ Derivatives Marijuana Other
1 Total 
Baltimore City     
Possession 15,544 4,710 38 20,292 
Sales and Manufacturing 10,858 348 31 11,237 
Subtotal 26,402 5,058 69 31,529 
Percentage of All Maryland Drug Violations    
Possession 79 26 0.5 53 
Sales and Manufacturing 81 <2 0.4 69 
All Drug Violations 80 25 0.4 58 
 
1Other includes “Synthetic Narcotics” and “Other Dangerous Non-Narcotics.” 
SOURCE:  Crime in Maryland:  2003 Uniform Crime Report, Maryland State Police (2004) 
 
Network members may wish to convert UCR drug arrests into rates per 
100,000 population for juveniles (persons under age 18) and adults (18 and 
older), based on the most recent census data, as has been done by the CESAR 
research team.  
 
Other Sources of Arrest Data 
TASC. The Treatment Accountability for Safer Communities (formerly called 
Treatment Alternatives to Street Crime) has operated in many States since the 
early 1970s. Currently, the Bureau of Justice Assistance provides grants to the 
National TASC organization, which advocates to improve and expand 
services for offenders. There are 203 TASC offices located in 29 States and 
Puerto Rico.  TASC is heavily represented in States such as Arizona, 
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Colorado, Florida, Illinois, North Carolina, New York, Ohio, and 
Pennsylvania.  Funding is provided by a variety of sources, including State 
legislatures and State legislative initiatives, local earmarked funds, criminal 
justice system agencies, private organizations, and client fees. A more detailed 
description of this program can be found at <http://www.nationaltasc.org>. 
Network members may find TASC data useful if there is a TASC program in 
their locality. However, programs may be quite complex in a given locality, 
operate under an organizational name other than TASC, and have ties to 
various service organizations. If a TASC-type program cannot be easily 
identified through the telephone directory, members could contact local law 
enforcement personnel or the county superior court to inquire whether a 
program exists in their community. 
TASC staff work with arrestees and other criminal offenders to conduct 
assessments, place the arrestees into treatment, and monitor the progress of 
their clients. Some programs serve juveniles as well as adults. Some conduct 
urine toxicology screens to assess drug use among offenders. TASC also 
reports back to the referring criminal justice agency. TASC programs vary 
widely in terms of the services they provide, the characteristics of their target 
groups, and their niche in the criminal justice system. 
If a TASC program is operating in your community, inquire as to the type of 
information that can be obtained on drug use among offenders and whether 
the information is available for both adults and juveniles. Urinalysis data 
would be especially useful. 
The TASC program in Arizona, called Treatment Assessment Screening 
Center, provides a variety of services to criminal justice agencies and courts in 
Arizona, including intake management, evaluation/diagnosis, psychological 
evaluations, counseling, psychotropic medications, and education.  TASC data 
are regularly reported by the Phoenix CEWG representative Ilene Dode, Ph.D. 
(see Dode 2006). TASC toxicology laboratories processed more than 4 
million urinalysis tests of individuals in the criminal justice system in 2005. 
Data from the testing are used to assess the drug abuse patterns and trends of 
the criminal justice populations by geographic area and type of drug. For 
example, of the 34,408 positive drug screens reported for adults (e.g., in 
Deferred Prosecution, pretrial, drug courts, probation and the Department of 
Corrections) in Maricopa County, Arizona, in 2005, 51 percent were for 
methamphetamine/amphetamine. As shown in exhibit 4, the Arizona TASC 
data can be used to make comparisons by area and type of drug (Zugor in 
publication). 
 
…inquire as to the 
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Exhibit 4. Percentage of Positive Drug Tests for Adults in Criminal Justice Programs in Maricopa County, Pima  
 County, and Arizona Rural Areas, by Percent:  2005 
 
Area Number of Positive Tests 
Amphetamines/ 
Methamphetamine 
THC 
(Marijuana) Cocaine Opiates Other
1 
Maricopa 34,408 41 33 16 7 3 
Pima 7,672 20 34 36 8 2 
Rural 2,753 51 31 3 10 5 
 
1Includes mostly alcohol but also benzodiazepines, barbiturates, lysergic acid diethylamide (LSD), phencyclidine (PCP), and 
methylenedioxymethamphetamine (MDMA). 
SOURCE:  Treatment Assessment Screening Center, Arizona 
 
Pretrial Services. Most jurisdictions have an agency that provides pretrial 
services to persons charged with crimes. The Washington, DC, Pretrial Services 
Agency (PSA) is a “premiere example of this type of agency” (Artigiani, Hsu, 
and Wish 2006). PSA has conducted drug testing of adult and juvenile arrestees 
in the District of Columbia since 1984, operating as an independent entity 
within the Court Services and Offender Supervision Agency. More than 2,000 
arrestees are tested each month. Network members can check in their area to see 
whether a similar service is provided. Exhibit 5 exemplifies the types of 
information provided by the PSA. As shown, around 45 percent of the adult 
arrestees in 2004 tested positive for a drug. Throughout the 21-year time period, 
cocaine dominated among the three drugs shown.  
 
Exhibit 5. Percentages of Adult Arrestees in Washington, DC, Testing Positive for Any Drug, Cocaine,  
 PCP, and Opiates:  1984–2004  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Adapted by CESAR from data from the District of Columbia Pretrial Services Agency 
 
Drug Courts.  As of April 2006, there were 1,557 drug courts in the United 
States, and an additional 394 in the planning phases. Fifty States plus the 
District of Columbia, North Mariana Islands, Puerto Rico, Guam, and 136 
tribal programs have drug courts in operation or planned. A few are some 
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combination of adult/juvenile/family/DUI courts (<http://www.whitehouse 
drugpolicy.gov/enforce/drugcourt.html>). 
Title V of the Violent Crime Control and Law Enforcement Act of 1994 (P.L. 
1-3-322) authorizes the U.S. Attorney General to make grants to States and 
local governments to establish drug courts. Drug courts started out as 
diversionary programs that dealt with less-serious offenders, typically those 
charged with simple drug possession or under the influence charges. As courts 
were proven effective in controlling both drug use and criminality among 
drug-using offenders (see, e.g., Belenko 1998), communities have 
successfully expanded drug courts to probationers, including drug-using 
offenders charged with non-drug offenses.  
Drug courts are given responsibility to handle cases involving substance-
abusing offenders through comprehensive supervision, drug testing, treatment 
services, and immediate sanctions and incentives. More information on drug 
courts can be found at the National Association of Drug Court Professionals 
Web site <http://www.nadcp.org/>.  
Given the variation in drug courts, it can only be suggested here that network 
members inquire as to whether a court is operating in their community, and, if 
so, what type of population the court serves. For example, there is a special 
drug court in St. Louis that serves female drug abusers and dually diagnosed 
non-violent arrestees. In an analysis of a random sample of 50 of these 
women, it was possible to obtain information on their sociodemographic 
characteristics and their drug of choice (Sullivan 2004). A majority were 
African-American (64 percent), had less than a high school education (60 
percent), were single (80 percent), and had children (80 percent). Crack 
cocaine was clearly the drug of choice among these women, either singly (24 
percent) or as a first, second, or third drug of choice (70 percent). Network 
members whose community is served by a drug court should request these 
types of data, if they are available. 
Criminal Filings.  Data on criminal filings are often available for local 
jurisdictions. These are cases for which there is sufficient evidence to warrant 
the local prosecutor to bring charges against a person.  There will be fewer 
cases than arrests; however, the data on the drugs actually involved will be 
more valid than arrest data.  Many of the limitations of arrest data also apply 
to criminal filings data.  Some States track superior court filings for all 
jurisdictions. Many prosecutors compile annual reports from which data can 
be readily extracted. 
 
…data on drugs 
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Crime Laboratory Drug Data 
 
Crime laboratories analyze drug items seized by law enforcement to 
chemically verify which drug or drugs are in the seized evidence.  There are 
many forensic laboratories in the Nation, making it likely that a network will 
be able to identify a laboratory in its community or State.  As with all law 
enforcement data, forensic laboratory information is subject to law 
enforcement procedures and priorities that may change over time, as well as 
available resources. These factors may result in some inconsistencies in the 
laboratory data from different time periods.  Also, laboratory procedures may 
differ from community to community. Whether an item is analyzed by a lab 
may depend on the drug schedule category (e.g., some labs may have the time 
and resources to analyze only the highest schedule drugs).  Networks that plan 
to compare their community data to forensic laboratory data from another 
community should first determine whether the data are truly comparable. 
Two crime lab systems are described in this section:  the National Forensic 
Laboratory Information System (NFLIS) and the Automation of Reports and 
Consolidated Orders System (ARCOS-2). Both are maintained by the Drug 
Enforcement Administration. 
 
NFLIS Data 
Network members should determine whether forensic laboratories in their 
area report to the National Forensic Laboratory Information System. The first 
NFLIS annual report was published by DEA in 2000. As of November 2005, 
258 of the Nation’s approximately 300–315 State and local labs participated 
in NFLIS; these represent 41 State systems, 88 local or municipal laboratories, 
and 1 territorial laboratory. Plans are underway to enroll all local, State, and 
Federal labs in the NFLIS.  
The NFLIS systematically collects results from solid dosage drug analyses 
conducted by participating laboratories.  The NFLIS database consists of case- 
and item/exhibit-level information.  Data are reported by laboratories in a 
convenient format. An Interactive Data Site (IDS), a secure Web site, permits 
all NFLIS laboratories to run queries of their own data sets and calculate 
regional and national results.  NFLIS findings are published in annual, 
semiannual, and special topic reports. 
Within-State comparisons may be possible.  For example, in Washington, data 
are available for the entire State, the Seattle-area lab, and for the State 
excluding Seattle (see exhibit 7 below). 
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The limitations of NFLIS are acknowledged.  They include differing policies 
and procedures among laboratories, the fact that Federal laboratories are not 
yet in the system, and variations within and across areas that can result in 
differences in drug seizures and analyses (e.g., police priorities, types of 
arrests from which specimens are taken, and other criminal justice 
procedures).  Local data are not adjusted for population size, and, thus, are not 
comparable across NFLIS sites. Additional information on NFLIS can be 
accessed at <http://www.deadiversion/usdoj.gov/nflis/index.html>. (See 
Appendix B.) 
Where to Start: Accessing Forensic Laboratory Data 
As noted above, one potential source of forensic laboratory data is the NFLIS. 
Check the DEA Web site or obtain an NFLIS Quarterly Report or Annual 
Report to determine whether such data are available for your community.  If 
not, check with local law enforcement agencies and inquire about forensic 
laboratory analyses that may be conducted in the network’s locale.  It may be 
necessary to inquire with a State agency; for example, in Texas, it is the 
Department of Public Safety that takes responsibility for forensic laboratory 
analyses in various areas of the State. It is important also to record the type of 
forensic labs that can provide data (e.g., police department, Sheriff’s Office, 
State Police). 
What to Request 
It will be important to access the following for each laboratory included in a 
network’s data collection effort: 
 The total number of items reported to the laboratory 
 The total number analyzed 
 The total number of items by substance (e.g., cocaine, heroin, marijuana) 
 The percentage that each substance represents of the total items analyzed  
If the network is interested in changes in the types of items analyzed over a 
multiyear period, determine whether the data are comparable, and, if so, 
request data for each year of interest.  It will be useful also to find out if, and 
why, any particular drug (e.g., marijuana) is not analyzed by the laboratory.  
Uses of Forensic Laboratory Data:  Some Examples  
The Drug Enforcement Administration uses NFLIS and similar data to 
monitor and assess drug abuse trafficking across the Nation, including the 
diversion of legally manufactured drugs into illegal markets.  For example, in 
Atlanta in 2003 and 2004, major drug abuse indicators, such as treatment 
admissions, toxicology screening of adult male arrestees, and hospital 
emergency department data pointed to cocaine and marijuana (cannabis) as 
the major drugs of abuse in the area, and to the increasing abuse of 
methamphetamine.  The Atlanta NFLIS data, as shown in exhibit 6, supported 
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the patterns found in the other drug abuse indicators, e.g., the increase in 
methamphetamine abuse in the city.  
 
Exhibit 6. Percentages of Drug Items Analyzed by Forensic Laboratory in Atlanta, Georgia:  2003–2004 
 
Substance 2003 2004 
Cocaine 39.72 44.20 
Methamphetamine 22.97 30.30 
Cannabis 28.03 14.40 
Alprazolam 1.63 2.12 
3,4-Methylenedioxymethamphetamine 1.51 2.00 
Hydrocodone 1.24 1.76 
Heroin 0.99 1.08 
Oxycodone 0.94 0.89 
Methadone 0.31 0.46 
Carisoprodol 0.38 0.37 
Amphetamine 0.37 0.37 
3,4-Methylenedioxyamphetamine 0.16 0.37 
Diazepam 0.43 0.36 
Clonazepam 0.14 0.24 
Psilocin 0.13 0.22 
Codeine 0.11 0.13 
Morphine 0.13 0.11 
Ketamine 0.12 0.09 
Non-controlled Non-narcotic drug 0.11 0.09 
Methylphenidate 0.13 0.06 
Lorazepam 0.06 0.05 
Lysergic Acid Diethylamide 0.04 0.04 
Benzocaine 0.07 0.03 
Meperidine 0.07 0.02 
Other Drugs1 0.06 1.50 
Total Analyzed 19,632 16,555 
Total Items Reported 19,663 16,583 
 
1In 2004, included gamma hydroxybutyrate (GHB), hydromorphone, secobarbital, phentermine, benzphetamine, phencyclidine, and a few 
other drug items; in 2003, included propoxyphene. 
SOURCE:  National Forensic Laboratory Information System, Drug Enforcement Administration 
 
Exhibit 7 illustrates how crime lab data from a major metropolitan area differ 
from that for the State overall (Banta-Green et al. 2005). The data clearly 
indicate the differences in cocaine and methamphetamine analyses, with the 
former being high in Seattle and the latter drug being high in the rest of the 
State (excluding Seattle). 
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Exhibit 7. Test Results for Law Enforcement Seizures of 4 Drugs1 in Seattle and the Rest of Washington  
 State, by Percent:  2004 
 
 
 
 
 
 
 
 
1N=3,495 items in Seattle and 12,002 for the rest of the State.  Another 8 drug items not shown above each accounted for small 
percentages of the reports, with no clear differences between Seattle and the rest of the State.                                     
SOURCE:  National Forensic Laboratory Information System 
 
ARCOS Data 
The Automation of Reports and Consolidated Orders System monitors the 
flow of DEA controlled substances from the point of manufacture through 
commercial distribution channels to the point of sale or distribution at the 
dispensing/retail levels. DEA uses the data, together with another DEA 
database, to identify the diversion of controlled substances into illicit channels 
of distribution.  ARCOS data are reported, by State, in PDF format and can be 
accessed at <http://www.deadiversion.usdoj.gov/arcos/retail_drug_summary>.  
(See also Appendix B.) A Site Map site can be used to access Field Office 
information, including the names of staff and phone numbers (go to 
<http://www.deadiversion.usdoj.gov/site.htm> and click on Offices and 
Directories, then Field Office Locations).   
Network members may find ARCOS data useful if there is an interest in the 
dispensing of controlled substances to the dispensary/retail level (e.g., 
pharmacies, hospitals, and practitioners) in their area or State. The data are 
available for several reporting periods, beginning with 1997.  The controlled 
substances reported in ARCOS include codeine, fentanyl, hydrocodone, 
methadone, morphine, oxycodone, and propoxphene.  
Exhibit 8 shows ARCOS data on selected narcotic analgesics purchased by 
“registrant” pharmacies in Missouri in 2004.  The data were accessed through 
the DEA Web site (see above) from “Report 5:  Statistical Summary for Retail 
Drug Purchases”––State: Missouri. Data by drug are also available by Zip 
Code for each State, see “Report 1.” 
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Exhibit 8. Retail Distribution of Narcotic Analgesic Drugs to Pharmacies in Missouri, Grams:  2004  
 
Registrant Pharmacies (Ps) 
Drug 
Number Ps Sold To Total Grams Sold to Ps1 
Oxycodone 1,147 1,114,260 
Hydrocodone 1,158 432,435 
Morphine 1,110 373,287 
Codeine 1,152 326,392 
Methadone 943 49,990 
Meperidine (Pethidine) 947 45,605 
Hydromorphone 755 7,692 
Fentanyl Base 1,106 7,279 
 
1Figures rounded. 
SOURCE:  Drug Enforcement Administration, ARCOS-2 
 
 
Drug Trafficking and Related Data 
 
Price and Purity Data—Illicit Drugs 
Information on the price and purity of different illicit drugs can provide 
insights into changes in patterns of drug abuse and consequences, such as drug 
overdose. As a drug becomes increasingly expensive, users may switch to 
other drugs. Or, conversely, as a drug becomes inexpensive, especially if it is 
popular in the drug scene, use may escalate. Also, when heroin, for example, 
becomes purer and replaces low purity heroin, users may experience an 
overdose, which sometimes proves fatal. In summary, price and purity data 
may help the work group explain a particular drug pattern or trend. 
Network members may find three sources of information on price of illicit 
drugs useful if they cover the network’s community.  One is DEA’s Domestic 
Monitor Program (DMP), which provides information on the price and purity 
of different forms of heroin. Another is DEA Reports that may be available 
from local DEA field offices or field divisions; as shown later below, these 
reports may provide price data on several types of illicit drugs. Still another is 
the reports by the National Drug Intelligence Center (NDIC), Department of 
Justice, which covers the wholesale, midlevel, and retail price of major illicit 
drugs. If these systems do not cover your community, ask whether such 
information is available from local law enforcement personnel (e.g., an officer 
in the narcotics unit of the local police department). 
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Domestic Monitor Program (DMP) 
The DMP, under the auspices of the Intelligence Division of the Drug 
Enforcement Administration, reports on the origin, types, cost, and purity of 
retail-level heroin available in the open-air drug markets in major 
metropolitan areas of the United States as well as San Juan, Puerto Rico.  
Typically, there is a 1-year lag in reporting, although preliminary data for a 
particular period may be available. In 2005, DMP reported 2004 price and 
purity data for 25 metropolitan areas, including most CEWG metropolitan 
areas (with 4 being in Texas). Network members may wish to contact their 
local DEA field office to determine whether DMP data are available for their 
area, and, if so, how they can be accessed. 
DMP data are based on actual undercover heroin purchases made by the DEA 
on the streets of the metropolitan areas.  The heroin buys provide information 
on the type of heroin (Southeast Asian, Southwest Asian, Mexican, South 
American, or underdetermined) and the types of diluents and adulterants 
present in the drug.  The reports indicate where the buy was made, the brand 
name (if any), the purity level, and the price per milligram pure.  Price and 
purity for particular types of heroin can vary across the years, especially if the 
number of buys made in a particular area was small. 
Exhibit 9 shows price and purity data across CEWG areas, as reported by 
DEA’s DMP in late 2005. 
Exhibit 9. Domestic Monitor Program—Average Heroin Purity and Price Per Milligram Pure in CEWG Areas:   
 20041 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Not included here are some types, e.g., Southeast and Southwest Asian heroin. 
SOURCE:  DMP, DEA 
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Information on heroin purity is of special interest to the researchers in 
Chicago, since heroin abuse indicators continue at high levels in the area 
(Broz et al. 2005).   
DMP annual price and purity data can be compared over time to determine 
whether there are any changes.  An example from the most recent Chicago 
CEWG report is depicted below (Broz et al. in publication). As shown, the 
purity of heroin at the retail or street level in Chicago trended down from 
23.80 percent in 2000 to 13.80 percent in 2004. During this time span, the 
price of heroin per milligram pure fluctuated. It is likely that the reduction in 
purity has had an impact on drug abuse patterns in Chicago among heroin 
addicts. 
 
Exhibit 10.  Trends in South American Heroin Purity and Price Per Milligram Pure in Chicago:  2000–2004 
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SOURCE:  Domestic Monitor Program, Drug Enforcement Administration 
 
 
DEA Reports 
Intelligence reports published by the Drug Enforcement Administration are 
another useful source of drug price data.  For example, the DEA field office in 
New Mexico provided drug price and purity data for several illicit drugs at the 
New Mexico State Epidemiology Work Group (SEWG) meeting held in 
September 2004 (Selander and Monnette 2004).  It was reported that… 
 The price for an ounce of methamphetamine in New Mexico in 2004 
ranged from around $500 to $800, while an “8 Ball” (1/8 of an ounce) cost 
$100.  The purity of the drug from local manufacturers was 70 to 91 
percent pure. 
 Cocaine sold for approximately $800 to $1,400 per ounce, $100 per gram, 
and $150 for an “8 Ball.” Crack sold for $500 to $1,000 an ounce. 
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 Black tar heroin cost about $1,200 to $2,900 an ounce and $120 to $180 
per gram. Most of the heroin on the streets was 50 to 70 percent pure. 
Network members may find it useful to contact their local DEA office or field 
division.  Local DEA personnel are often a valuable resource for CEWG 
representatives. 
NDIC Data on Drug Prices 
The NDIC Intelligence Bulletin National Illicit Drug Prices––December 2005 
compiles prices for the 6 most commonly available and abused illicit drugs in 
126 cities and Puerto Rico. The cities, listed by State, constitute major drug 
markets that are situated along major transportation corridors, serve as 
regional economic centers, or have high population levels relative to their 
surrounding geographic areas.  The cities were not selected randomly, nor can 
statistical comparisons be made between cities or to previously reported drug 
prices for a given city.  The drug price data have other limitations.  For 
example, while NDIC derives drug prices from undercover purchases, some 
reported prices are derived from informants who may have criminal histories 
and may not provide totally accurate information; the units of weights 
reported may not be exact; and the undercover purchases probably constitute 
only a small percentage of drug transactions within a city.  An example of the 
information available in the bulletin referenced above is shown in exhibit 11 
for one city, Detroit. 
 
Exhibit 11. Prices for 6 Illicit Drugs in Detroit:  2005 
 
Price in Dollars Drug Wholesale Midlevel Retail 
Powder Cocaine $18,500–$24,000/kg1 $700–$1,500/oz1 $50–$100/g1 
Crack Cocaine – $750–$1,300/oz $10–$20/rock 
Heroin2 
$45,000/kg MBT 
$55,000–$80,000/kg SA, SWA 
 
$2,500/oz MBT 
$5,000/oz SA, SWA 
$150/oz CG 
$10/bag MBT 
$15/bag SA, SWA 
$20/g CG 
Marijuana 
$1,600–$5,000/lb1 BC 
$1,100–$3,000/lb SN 
$900$1,300/lb CG 
– – 
Methamphetamine4 $16,000/lb PM $1,200/oz $125/g 
MDMA $3–$15/du1 – $15$28/du 
 
1du=dosage unit; kg=kilogram; oz=ounce; g=gram; lb=pound. 
2MBT=Mexican Black Tar; SA=South American; SWA=Southwest Asian. 
3BC=BC Bud (Canada); SN=sinsemilla; CG=commercial grade. 
4PM=Powder methamphetamine. 
SOURCE:  National Drug Intelligence Center, NDIC Intelligence Bulletin National Illicit Drug Prices—December 2005, 
U.S. Department of Justice 
 
NDIC publications are available on the Web at <http://www.usdoj.gov/ndic>. 
 
NDIC’s Field Program Specialists (FPSs) regularly conduct interviews with 
Federal, State, and local law enforcement officials and summarize anecdotal 
reporting in Intelligence Information Reports (IIRs); these reports often detail 
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trends related to the availability and short-term disruptions in drug prices for a 
region. These reports are available at the following Web sites:  <ADNET:  
https://ndicosa/index.htm> and <http://www.iir.com/riss/default.htm>. 
 
 
 
Drug Seizure Data 
 
  High Intensity Drug Trafficking Area (HIDTA) Data 
Information on drug seizures at the local level may be available from law 
enforcement agencies. Network members may also extract useful information 
from the HIDTA data briefly described below. 
The National Drug Intelligence Center synthesizes Federal, State, and local 
counterdrug reporting into a single source of information related to drug 
trafficking and abuse trends. NDIC publishes, for example, a State Drug 
Threat Assessment Report that provides detailed assessments of drug trends in 
a particular State and areas within a State or region. 
The Threat Assessment is an annual compilation of drug-related threats in a 
High Intensity Drug Trafficking Area.  The purpose of the HIDTA is to 
disrupt the illegal drug market in the Nation by assisting Federal, State, and 
local law enforcement entities participating in the program to dismantle and 
disrupt drug trafficking organizations.  Twenty-eight HIDTAs have been 
established across the Nation.  A map and contact information for each is 
available through the Office of the National Drug Control Policy at 
<http://www.whitehousedrugpolicy.gov/hidta/index.html>.  (See Appendix B.)  
Network members can also access National Threat Assessment reports and 
strategic (Drug Threat) assessments through the NDIC Web site <http://www. 
usdoj.gov/ndic/topics/ndtas.htm>.   
The HIDTA information that follows was provided by Erin Artigiani and Eric 
Wish, Ph.D., CESAR, for this guide, and represents 2003 data from the 2004 
Threat Assessment for the Washington/Baltimore area. 
The Washington/Baltimore HIDTA region covers two distinct population 
centers, Washington, DC, and Baltimore City, and includes 13 separate city 
and county jurisdictions in Maryland and Virginia.  HIDTA data show that the 
three jurisdictions plagued with the most serious drug abuse, drug trafficking, 
and drug-related crime problems in the region are Baltimore City and Prince 
George’s County, both in Maryland, and the District of Columbia. The 2004 
Threat Assessment identified marijuana, heroin, powder cocaine, crack 
cocaine, and ecstasy as major threats. Low cost heroin was reportedly 
available primarily in Baltimore City.  Methamphetamine was beginning to be 
encountered in the region. 
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The report also indicated that more than 150 drug trafficking organizations 
(DTOs) were active in the region in 2003.  A majority were in Baltimore City 
(60) and Southern Maryland (47), with 26 being in Washington, DC, and 20 
being in Northern Virginia.   
The data also show that marijuana accounted for nearly two-thirds of the 
seizures in 2003 (exhibit 12). 
Exhibit 12.   Seizures of Drugs in the Washington/Baltimore Region, by Drug and Percent:  2003 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOURCE:  Artigiani and Wish, CESAR (based on NDIC’s 2004 Threat Assessment for Washington/Baltimore) 
 
 
  National Clandestine Laboratory Seizure Database (NCLSD) 
NCLSD was developed by the El Paso Intelligence Center (EPIC), 
Department of Justice, in an effort to stay abreast of changing drug trends.  
The EPIC database serves as a clearinghouse for HIDTA Intelligence Centers 
by gathering State and local law enforcement drug information and providing 
drug intelligence back to the HIDTA Intelligence Centers.  The database is 
often used by the HIDTAs to track the number of clandestine laboratories in 
their region.  EPIC data are often cited in the HIDTA reports.  The data are 
also available through DEA reports and State factsheets.  Additional 
information on drug seizures is available online at <http://www.dea.gov/ 
concern/map_lab_seizures.html>.  
Exhibit 13 depicts the number of methamphetamine laboratory, equipment, 
and dumpsite seizures in 47 reporting States, Guam, and the District of 
Columbia in 2004.  As shown, the largest numbers of methamphetamine 
seizures were in Missouri (2,788) and Iowa (1,335). 
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Exhibit 13. Number1 of Seizures of Methamphetamine Laboratories, Equipment, and Dumpsites2 in 47  
States, Guam, and the District of Columbia:  2004   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1N=17,170. Data are for 2004, as reported by DEA; updated August 18, 2005. 
2The States with the 10 highest numbers of statewide seizures are shown in dark gray. 
SOURCE:  DEA <http://www.dea.gov/concern/map_lab_seizures.html> 
 
Customs & Border Protection, U.S. Department of Homeland 
Security 
Customs & Border Protection, U.S. Department of Homeland Security, has 
the responsibility of preventing the entry of terrorists and terrorist weapons 
into the Nation, apprehending contraband smugglers, and protecting the 
Nation from disease and disease carrying creatures. The agency's Web site is 
<http://www.cbp.gov >. The Press Release button on the left hand side of the 
homepage provides information of drug seizures in different areas on specific 
dates.   
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7. QUALITATIVE RESEARCH STUDIES 
 
Networks may find qualitative research a valuable supplement to indicator and 
other quantitative data sources described in earlier chapters.  For example, in-
dicator data sources may not address an emerging problem of seemingly criti-
cal concern in the community, either because the problem was not covered by 
the data source(s) or because the data are not current (e.g., data from large-
scale surveys and databases such as TEDS may not be available for 1 to 2 
years after the time the data are collected).  Conversely, there may be one or 
more findings in the indicator data that pique the interest of network members 
because the findings seem particularly pertinent to the locale and suggest a 
need for more indepth information.  In summary, there may be many reasons 
why networks may want to incorporate qualitative data into their surveillance 
efforts to provide more current assessments of drug abuse patterns and trends 
in their areas.  Periodic contact with key informants, identification and use of 
existing local ethnographic studies, or the planning and implementation of 
small-scale focused qualitative studies can be used by networks to add an in-
depth understanding to indicator data or to examine specific drug trends in 
greater detail. 
 
 
Key Informants 
 
 
Key informants are individuals who frequent, work, or live in network areas 
and who are knowledgeable about… 
 The community, or specific neighborhoods in the area 
 Drugs of abuse and drug abusers 
 Different populations and their cultures 
 
Key informants can be valuable sources for helping to understand and inter-
pret indicator data and may offer important observations on drug use patterns 
or consequences in local communities. The following section discusses some 
of the challenges in interpreting indicator data and provides some examples of 
how key informants can contribute significantly to epidemiology networks. 
 
Key Informants: Interpreting Indicator Data 
 
In assessing drug abuse information from different sources, it is important to 
know what the different indicators represent. Why do the numbers change 
from one period to another? Which factors influence the numbers and types of 
people who are identified through these sources? 
 
The following examples demonstrate how interpretations are influenced by 
qualitative understanding of indicators.  Consider, for example, that… 
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 Police departments change their tactics from time to time in the types of 
drugs, drug problems, and geographic areas they target.  
 Lower income people are more likely than other populations to use emer-
gency rooms for general medical care, while higher income people tend to 
use private health care facilities.  
 The types of clients treated by drug abuse treatment programs vary by type 
of facility, and these patterns may change because of changes in health in-
surance regulations and government funding policies.  
 
It is therefore important to obtain background information on each of the 
sources of indicator data to understand the limitations of the data and gain a 
better understanding of the results. The first step is to ask those who represent 
the sources from which the indicator data are produced to explain how the in-
dicators reflect certain policies and populations. Ideally, a member of the net-
work will be in a position to explain what the numbers mean or who can pro-
vide an explanation. 
 
If members can not explain substantial changes in the data from one period to 
another, some members may be in a position to access information from key 
informants. For example, if the treatment data show that there was a signifi-
cant increase in primary marijuana users admitted into drug abuse treatment 
programs during the prior 6 months, it might be useful to contact treatment 
providers to get their views. If one or more network members volunteered to 
get this information, they could prepare a brief supplementary report and 
communicate the information to the other members.  
 
The question of why indicator data change over time may be partially an-
swered when additional information about the data sources is obtained. For 
example, an increase in heroin arrests may reflect special efforts made by the 
police department to “crack down” on heroin dealers during a particular time 
period. Future research is needed to explain the extent to which increased fo-
cus by the police or an increase in heroin use has resulted in more arrests. 
 
Surveillance networks generally do not have the time or resources to conduct 
studies to determine how and why patterns of drug use are changing. That 
does not mean that insights into plausible explanations cannot be obtained. 
Network members may already know or suspect some of the reasons for the 
changes, especially members who come into direct contact with drug abuse 
clients. Anecdotal information can be valuable in helping to guide interpreta-
tions and future research. 
 
Another method is to investigate the reason for changes by exploring the who, 
what, when, where, why, and how. One or more network members might as-
sume a lead role. If time and resources permit, members could go into the 
community and talk to people close to or directly involved with the drug 
scene. In gathering this type of information, it might be possible to identify 
some of the possible causes for the changes. 
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Key Informants: Monitoring Local Drug Trends 
 
Another reason for using key informants is to address the question: How can 
network members broaden their perspective and identify new drug abuse pat-
terns and trends before they emerge through indicator data? 
 
Network members can never be sure (especially when beginning a local 
group) who might be in a position to contribute new information. Therefore, it 
is useful for a network to establish a list of such people over time. The people 
on this list may be able to serve as key informants. 
 
To be helpful to a network, key informants should be… 
 Interested in assisting the network in assessing drug abuse problems 
 Invested in their community or neighborhood 
 Reliable (i.e., proven credible over time) 
 Reachable 
 Capable 
 
The following types of individuals may prove to be valuable key informants: 
 Current or ex-drug abusers 
 Non-drug-using peers or associates of drug abusers 
 School counselors 
 Representatives of different racial/ethnic populations 
 Community leaders 
 Outreach workers 
 Treatment personnel (e.g., program directors, clinicians) 
 Local police “on the beat” in selected neighborhoods 
 Police narcotics unit staff 
 Recreational workers (e.g., coaches) 
 Other community services workers (e.g., bartenders, beauticians) 
 
There can be several types of key informants who can be contacted in person, 
by telephone, by e-mail, or by other means… 
 Those contacted by one or more network members on a regular basis 
 Specific types of informants who have unique knowledge of or experience 
with a drug-abusing population 
 Informants selected only for a specific purpose at a specific time 
 
 
…establish a list of 
such people… 
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Key informants who prove credible and knowledgeable over time can be re-
quested and should feel free to alert the network directly at any time when 
something new or unique appears to be happening in the community or a par-
ticular neighborhood.  Different network members may elect to have working 
ties with specific types of key informants. What is most important is to con-
stantly tap the “pulse” of the community so the network can be alerted to new 
or escalating drug abuse problems in their area. 
 
Key informants may have biases and may not always be objective. When what 
appears to be important information is provided by one or more key infor-
mants, the network needs to seek confirmation of the information, e.g., by ex-
panding the informant sample to gather additional information or by seeking 
confirmation through existing record data or more indepth qualitative re-
search.  Ethnographic research provides one option for gathering more indepth 
qualitative data on a specific population or issue. 
 
 
Ethnographic Research 
 
 
At some point, a network might decide that more detailed information is 
needed about some pattern of drug use or what seems to be an emerging trend, 
something more systematic than current knowledge, telephone calls, or con-
versations with knowledgeable people can provide.  
 
Ethnographic methods can be used to learn more about particular drugs of 
abuse and the people who use these drugs. These methods can be used to…  
 Learn more about an emerging drug abuse problem when little is known 
about the use of a drug 
 Gain insight about user groups and populations 
 Answer questions that emerge from quantitative research studies 
 Help researchers plan quantitative studies 
Questions may focus on… 
 Why are particular drugs being used? 
 How are they being used? 
 What are the consequences of using the drug(s)? 
Ethnography goes beyond objective analytic description to include analysis of 
the knowledge and beliefs that underlie behavior.  Ethnographic methods in-
clude observation and formal and informal interviews.  Information is often 
gathered by talking with drug abusers in their natural settings, getting to know 
them and their language and culture, gaining their trust, and engaging them in 
…alert the network 
directly… 
Ethnographic meth-
ods can be used… 
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conversation.  Interviews are often taped with the prior consent of the inter-
viewees, so the researchers have a good record of the interview and can con-
duct content analysis of the transcripts. 
Ethnographers in their studies of drug abusers generally collect the following 
routine information: 
 Demographic information 
 Drugs used  
 Combinations of substances used  
 Frequency of use  
 Modes of administration  
 Social setting in which drugs are used  
 Ages and circumstances for initiation to drugs  
 Reasons for using drugs  
 Drug effects  
 Adverse reactions to drugs  
 Consequences of drug use over time 
 
Ethnographers can obtain data from a variety of sources and systematically 
assess the constant and variable patterns that range across the data collected.  
In addition to observation and interviews, archives, memoranda, newsletters, 
and other documents can be used for analysis. 
 
Network members should optimize existing data where possible, including 
findings from local ethnographic studies. Ethnographic research can provide 
contextual and behavioral data/information to guide members in interpreting 
findings from quantitative data and drug abuse indicators.  Network members 
should check with local colleges, universities, and other agencies and organi-
zations to determine whether ethnographic studies involving drugs or drug-
abusing populations have been or are being conducted, including quantitative 
studies that may have qualitative components. Network members might also 
check studies funded through grants by NIH to determine whether any studies 
are underway or have been recently completed in their area(s) (see the CRISP 
link <http://crisp.cit.nih.gov/> on the NIDA Web site). 
Network members may also find it beneficial to collaborate with local ethnog-
raphers in planning local studies. In selecting an ethnographer, it is important 
to review the person's training, type of degree, publications, professional or-
ganization, and affiliation. Also, obtain and review the individual's recently 
published ethnographic research, especially if it involves drug abuse. Ethnog-
raphers often work as faculty in university anthropology or sociology depart-
ments, two disciplines with strong traditions in cultural and behavioral pat-
terns in different populations and in qualitative research. 
…assess the con-
stant and variable 
patterns… 
…guide members  
in interpreting  
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Examples of how qualitative research methods can be used to monitor drug 
abuse trends and explore emerging problems are briefly described below. 
Los Angeles 
CEWG representative Beth Finnerty (2005b), together with colleagues, used 
key informants to verify and supplement information obtained from focus 
groups on the use and abuse of phencyclidine in the Los Angeles area.  This 
effort was initiated in 2003 in response to concern that indicator data pointed 
to a rise in PCP arrests and treatment admissions, suggesting an increasing 
problem of PCP abuse in the population.  In this small study, treatment data 
were used to identify geographic areas in Los Angeles where the majority of 
PCP treatment admissions were concentrated.  Key informants were drawn 
from a pool of existing professional colleagues and referrals and were selected 
to represent a range of perspectives, including law enforcement and treatment 
counselors.  Study findings helped to clarify patterns of use and effects of PCP 
and factors influencing manufacture and distribution. 
Colorado 
In an exploratory study of clonazepam abuse among treatment admissions in 
Colorado, Bruce Mendelson used treatment data to identify the geographic ar-
eas in the State where clonazepam clients were admitted to treatment. Thirteen 
clinicians served as key informants and provided information on the primary 
reasons clients were using clonazepam; the desired effects of the drug; how 
the drug is obtained; and the street cost of the drug (Mendelson 2005). 
New York City 
The Street Studies Unit (SSU), Division of the Ethnography and Trends 
Analysis Section of the Treatment Services Bureau, New York State Office of 
Alcoholism and Substance Abuse Services, has been using ethnographic 
methods for more than 20 years.  
The Field Researchers in the SSU are former substance abusers who have 
been trained in ethnographic techniques to observe and record information 
about drug dealing and abuse on the streets of New York City.  Information 
from the SSU studies is regularly reported to the CEWG by Rozeanne Marel, 
Ph.D., and appears in CEWG reports (see, e.g., Marel et al. 2005). 
 Ohio 
Ohio’s Substance Abuse Monitoring System (OSAM) Network uses archival 
data, ethnographic methods, and other qualitative methods (e.g., focus groups) 
to monitor drug abuse patterns and trends.  Informants are located throughout 
the State and provide information for the semiannual monitoring of substance 
abuse trends.  Findings are disseminated through reports and through the 1-
page OSAM-O-GRAM (see Addendum A for an example). 
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 Maryland 
Researchers at CESAR, University of Maryland, used ethnographic and other 
qualitative methods to obtain up-to-data information on how and why PCP 
was being used in Prince George’s County, Maryland, where PCP indicators 
had shown increases in abuse of the drug (see Addendum B). 
Connecticut 
Researchers at the Institute for Community Research (ICR), in partnership 
with the Hispanic Health Council, conducted a study of drug use among youth 
and young adults in 1999–2002 through a NIDA grant (RO1DA11421). In a 
second NIDA-funded grant (R01DA4863), ICR is focusing on use of club 
drugs. In both studies, the researchers have used a combination of ethno-
graphic field observations, key informant interviews, semistructured inter-
views, and survey methods. Data from the first study were presented at the 
CEWG PCP Panel in December 2003, providing insights into why and how 
PCP was being used and the consequences of its use (Schensul 2004). 
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Addendum A. Ohio Substance Abuse Monitoring (OSAM)  
   Network   
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Addendum B. The Center For Substance Abuse Research  
   (CESAR) 
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8. OTHER USEFUL DATA SOURCES 
 
 
Several other data sources can provide useful information for epidemiologic 
networks:  the U.S. Census Bureau, university researchers, and community-
level sources.  These are briefly covered in this chapter. 
 
Census Data 
 
Census data are collected and reported by the U.S. Census Bureau every 10 
years, and estimated changes in populations are projected between each 
decennial census. Census data can be useful to networks in a number of ways, 
including the following:  
 To describe the population living in the network’s geographic area, 
including the population’s… 
¾ Demographic characteristics (e.g., gender, age, race/ethnicity) 
¾ Socioeconomic status (e.g., median family income, percentage of 
families living below the poverty level) 
¾ Marital status 
¾ School enrollment and educational attainment 
¾ Housing (e.g., value of home or monthly rent paid, number of rooms 
and bedrooms, plumbing and kitchen facilities) 
 To learn more about populations in areas where particular types of drug 
use are prevalent or drug use and trafficking are high 
 To determine whether a particular population group is underrepresented or 
overrepresented in a specific drug-abuser group documented in indicator 
data1  
 As the basis for determining rates, e.g., per 100,000 population of a 
specific subpopulation (e.g., among female methamphetamine abusers in 
treatment)  
The Census Bureau data are available for many types of geographic areas.  
Detailed results of the Census 2000 are contained in a series of five files that 
can be accessed through the Internet and on CD-ROM or DVD. Profiles are
                                                 
1For example, treatment indicator data may show that White primary methamphetamine abusers represent 55 percent of 
the total treatment admissions in a given year, but that Whites represent 73 percent of the area population.  Conversely, 
African-American primary heroin admissions may represent 25 percent of all treatment admissions, but only 16 percent 
of the area population. In the former case, the White admissions group would be underrepresented in treatment, while in 
the latter case, the African-American admissions group would be overrepresented. 
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provided for most geographic areas; Quick Tables allow users to choose from 
approximately 50 table shells and then specify the geographic area and the 
universe or population subgroup (e.g., the African-American population).  
There are also approximately 30 Geographic Comparison Tables that allow 
users to compare key data items across geographic areas. A series of three 
reports are available in Portable Document Format (PDF) on the Internet.  For 
easy access to all Census 2000 information, click on American FactFinder™ 
on the Census Bureau’s Home Page <www.census.gov>. 
The Census Bureau has established “census tracts” as units for the study of 
small statistical subdivisions (averaging about 4,000 people) of counties, as 
well as “counties and equivalent areas” (the primary divisions of most States).  
These two types of census areas may be of most interest to networks that are 
not focused on “metropolitan areas” with large populations.   
In intervening years between the censuses, your State Census Data Center can 
provide information on updated census estimates by county.  In some 
instances, the State center makes the estimate, while in other instances, 
another State agency makes the official State and county population estimates 
for these years. 
 
University Researchers 
 
Often there are local university or college faculty, especially in health, social 
science, and science departments, who are interested in alcohol and drug 
abuse issues or have expertise in research methods that can be used by 
epidemiologic networks. The network and these faculty members, who may 
be conducting very relevant research, may be unaware of each other’s efforts. 
In addition to their research interests, faculty often have students who want to 
become engaged in projects. These students can be useful in collecting 
information and analyzing data, especially since they have access to 
computers and statistical software programs that can be used in data searches 
and data analysis.  
To find interested faculty, contact academic departments in public health, 
pharmacy, sociology, anthropology, social work, psychology, criminal justice, 
nursing, health sciences, and education. Research centers for special ethnic 
studies also may house researchers who are interested in substance abuse 
issues. 
…faculty members… 
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Community-Level Sources 
 
It is sometimes difficult to identify sources of information at the community 
level. Find out what types of information are available from these sources, and 
establish procedures to obtain relevant information initially, and perhaps on a 
regularly scheduled basis. It must be kept in mind that information about drug 
abuse is likely to be confidential. The people responsible for collecting and 
reporting information about drugs are usually very busy and are likely to have 
reservations about sharing information.  
If a network does not already have connections with community data sources 
through its members, there are two ways to start the process of identifying 
sources that can be done concurrently. The first way is to get local telephone 
numbers of criminal justice, health, and treatment agencies so that calls can be 
made to identify potential data sources. The mayor’s office, chamber of 
commerce, or a similar source may have a directory of human resource 
organizations. Community or local telephone books generally specify in the 
front pages telephone numbers of local police and sheriff departments. The 
regular telephone directories may list police and sheriff departments under 
Government Listings and hospital and treatment programs in yellow pages or 
the business section (by name). Support staff at network-backed agencies may 
be helpful in this task.  In many towns and cities, such information is likely to 
be found on the Internet. 
The second way to start to identify potential information sources at the 
community level is to start at the top and work down. In attempting to identify 
sources of treatment data, begin by calling individuals at your State Substance 
Abuse Agency who can identify and provide a list of the substance abuse 
treatment programs that are located within or serve particular communities. 
For arrest data, call the State Police Department and the UCR office to find 
out who their contacts are at the local level. In trying to identify individuals 
and departments within hospitals, contact representatives of the State health 
department to find out what and whom they know. 
 
…there are two 
ways to start the 
process of identi-
fying sources… 
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9. ESTABLISHING AND DEVELOPING 
RELATIONSHIPS WITH INFORMATION 
SOURCES  
 
 
Public Versus Private Information Sources 
 
In establishing a network and in accessing data, it should be kept in mind that 
most public organizations are obligated to release data/information. For 
example, arrest data collected by police departments fall under the category of 
public information as long as individuals cannot be identified. These data are 
generally reported to another level of authority, e.g., the city and county police 
departments report to regional Drug Enforcement Administration offices, the 
Federal Bureau of Investigation (Uniform Crime Report), and to their State 
Police Department. On the other hand, private hospitals are not obligated to 
give information to outside sources other than those to which they are 
accountable for documenting services provided and costs associated with 
providing services. That said, data may not be readily available, and potential 
data providers will be most responsive to polite inquiries rather than demands. 
They may give you the minimum dataset they have, which may be of no 
value, while a more politic approach may yield much richer data and vital 
context. 
Private facilities, while not obligated to provide data, may still be willing to 
share information. Given that there are often numerous private agencies, it is 
important to prioritize those that serve populations of particular interest. It 
may also prove useful to select those large agencies or those that are part of a 
multisite agency that maintains data from all affiliated sites. 
 
Preparation/Making Contact 
 
Prior to contacting representatives of agencies and departments about the 
availability of data/information, it is important to be well prepared by… 
 Specifying whom you represent, the reason for pursing the information, 
and how the information will be used and reported  
…data may not be 
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most responsive  
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 Specifying clearly that the network is involved in a public health project 
and that you do not want the names and identities of individuals who used 
drugs, but only data that have been aggregated and do not contain such 
personal identifiers 
 Inviting individuals who have access to data/information to attend or 
participate in a network meeting 
 Following up a telephone contact with a letter or e-mail reiterating whom 
you represent, confirming your understanding about the availability of 
data and how it might be obtained, and perhaps formally inviting the 
individual to the next network meeting 
 Sending each individual information about the network, and, if available, a 
copy of a network meeting report or summary, or an outline of a project 
being planned 
 
Developing Relationships 
 
It is important to maintain good relationships with representatives of 
community agencies, schools, and organizations that have access to current 
and potential data sources. As indicated earlier, it is difficult to identify 
sources of information at the community level; however, once relationships 
are established, continued two-way information sharing can lead to long-term 
data access. 
Several steps can be taken to develop working relationships with data sources, 
including the following: 
 Inviting representatives to network meetings 
 Meeting with representatives so they get to know you personally (e.g., 
invite them to your office or visit them) 
 Visiting a contact; this can provide unanticipated benefits by allowing 
network members to see the facility and the computer applications with 
which staff work, as well as meet other people at the agency who may be 
interested in the network 
 Sending them information, including any documents developed by the 
network. If they are willing to review reports prior to dissemination and 
make any corrections or provide important context, this will be of great 
benefit to the network. 
…continued two-
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10. REPORTING 
 
 
Networks will find it useful to have a standardized format for reporting 
findings.  This can be useful, as in the following ways: 
 As the network evolves over time and produces several reports, a 
standardized format will make it easier to review data from different 
reporting periods to develop and access trends across different time 
periods. 
 For networks that cover more than one geographic area, a standardized 
format will make it easier to summarize data across different areas, and 
also make it easier for readers to make their own comparisons across 
reporting areas. 
 For networks that plan to distribute reports to policymakers, practitioners, 
and other interested parties, it is advisable to have a standard format with a 
concise table of contents to guide readers and facilitate their review of the 
report; over time, readers will become accustomed to the format and find 
the reports easier to review. 
 
It is important to recognize that your network is not likely to have all the 
sources of data described in earlier chapters of this guide as it begins its 
surveillance work.  Yet, much can be learned in initial efforts. For example, 
when the Louisiana State Epidemiology Work Group (SEWG) began in 
September 1997, only seven parishes reported indicator data from their 
jurisdictions. A year later, 11 parishes reported the type of indicator data.  By 
2002, this work group was reporting data by administrative region, with data 
on some or all of the parishes included in the 10 regions.  These SEWG 
reports have been prepared in a standard format, with each regional or parish 
paper containing an Abstract of key findings and section on Drug Abuse 
Patterns and Trends by drug or data source. Tabular and graphic data appear 
at the conclusion of each paper. 
 
The Community Epidemiology Work Group has used a similar format over 
the years, always reporting patterns and trends by drug of abuse.  The CEWG 
area reports are published semiannually in a series entitled Epidemiologic 
Trends in Drug Abuse, Volume II, and can be viewed on the NIDA Web site 
<http://www.nida.nih.gov> (see Appendix B). 
 
Once a network has become established, members may opt to disseminate 
findings in a brief one-page fax or e-mail, such as the examples provided in 
the addenda to Chapter 7. 
 
 
…a standardized 
format will make it 
easier to review 
data… 
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APPENDIX A. CURRENT CEWG  
  REPRESENTATIVES,  
  BY LOCATION 
 
Atlanta 
Brian J. Dew, Ph.D., L.P.C. 
Assistant Professor 
Department of Counseling and Psychological 
  Services 
Georgia State University 
P.O. Box 3980 
Atlanta, GA  30308 
Phone: 404-808-5436 
Fax: 404-651-1160 
E-mail: bdew@gsu.edu 
Baltimore 
Leigh A. Henderson, Ph.D.  
Project Director 
Synectics for Management Decisions, Inc. 
3001 Guilford Avenue 
Baltimore, MD  21218-3926 
Phone: 410-235-3096 
Fax: 703-528-6421 
E-mail: leighh@smdi.com 
Boston 
Daniel P. Dooley  
Boston Public Health Commission 
1010 Massachusetts Avenue 
Boston, MA  02118 
Phone: 617-534-2360 
Fax: 617-534-2422 
E-mail: ddooley@bphc.org 
Chicago 
Larry Ouellet, Ph.D. 
Community Outreach and Intervention Projects 
2121 West Taylor Street, Room 552 
Chicago, IL 60612-7260 
Phone:  312-996-5523 
Fax:  312-996-1450 
E-mail:  ljo@uic.edu 
Denver 
Tamara Hoxworth 
Research Analyst 
Colorado Alcohol and Drug Abuse Division 
4055 S. Lowell Boulevard 
Denver, CO 80236 
Phone:  303-866-7497 
E-mail:  Tamara.hoxworth@state.co.us 
Detroit 
Cynthia L. Arfken, Ph.D. 
Associate Professor 
Psychiatry and Behavioral Neurosciences 
Wayne State University 
2761 East Jefferson 
Detroit, MI  48207 
Phone: 313-993-3490 
Fax: 313-993-1372 
E-mail: carfken@med.wayne.edu 
Honolulu 
D. William Wood, Ph.D.  
Department of Sociology 
University of Hawaii at Manoa 
265 North Kalaheo Avenue 
Honolulu, HI  96822 
Phone: 250-384-3748 
Fax: 808-9565-3707 
E-mail: dwwood@shaw.ca 
Los Angeles 
Beth A. Rutkowski, M.P.H.  
Associate Director of Training/Epidemiologist 
ATTC/NIDA Liaison 
Integrated Substance Abuse Programs 
University of California, Los Angeles 
Suite 200 
1640 South Sepulveda Boulevard 
Los Angeles, CA  90025 
Phone: 310-445-0874, ext. 376 
Fax: 310-312-0538 
E-mail: finnerty@ucla.edu 
Miami 
James N. Hall  
Director 
Center for the Study and Prevention of 
  Substance Abuse 
Up Front Drug Information Center 
Nova Southeastern University 
Suite 215 
12360 Southwest 132nd Court 
Miami, FL  33186 
Phone: 786-242-8222 
Fax: 786-242-8759 
E-mail: upfrontin@aol.com 
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Minneapolis 
Carol L. Falkowski  
Director 
Research Communications 
Hazelden Foundation 
Butler Center for Research 
15245 Pleasant Valley Road, Box 11 
Center City, MN  55012-0011 
Phone: 651-213-4566 
Fax: 651-213-4344 
E-mail: cfalkowski@hazelden.org 
New York City 
Rozanne Marel, Ph.D.  
Head, Epidemiology and Needs Assessment 
New York State Office of Alcoholism and 
  Substance Abuse Services  
501 7th Avenue, 9th Floor 
New York, NY  10018 
Phone: 646-728-4605 
Fax: 646-728-4685 
E-mail: rozannemarel@oasas.state.ny.us 
Newark 
Allison S. Gertel-Rosenberg, M.S. 
Program Manager 
Division of Addiction Services 
Office of Policy Development 
New Jersey Department of Human Services 
120 South Stockton Street, 3rd Floor  
P.O. Box 362 
Trenton, NJ  08625 
Phone: 609-984-4050 
Fax: 609-292-1045 
E-mail: allison.gertel@dhs.state.nj.us 
Philadelphia 
Samuel J. Cutler  
Program Manager 
Coordinating Office for Drug and Alcohol 
  Abuse Programs 
City of Philadelphia, Office of Behavioral Health 
Suite 800 
1101 Market Street 
Philadelphia, PA  19107-2908 
Phone: 215-685-5414 
Fax: 215-685-5427 
E-mail: sam.cutler@phila.gov  
Phoenix 
Ilene L. Dode, Ph.D.  
EMPACT-Suicide Prevention Center, Inc. 
2528 East Geneva Drive  
Tempe, AZ  85282 
Phone: 480-784-1514, ext. 1116 
Fax: 480-967-3528 
E-mail: idode@aol.com 
St. Louis 
Heidi Israel, Ph.D.  
Division of Infectious Diseases 
St. Louis University 
School of Medicine 
1200 South Grand Avenue 
St. Louis, MO  63104-1017 
Phone: 314-268-5448 
Fax: 314-268-5196 
E-mail: israelha@slu.edu 
San Diego 
Steffanie Strathdee, Ph.D. 
Professor and Harold Simon Chair 
Chief, Division of International Health and 
  Cross Cultural Medicine 
Department of Family and Preventive 
  Medicine 
Adjunct Professor 
Department of Epidemiology 
Johns Hopkins Bloomberg School of Public 
  Health 
University of California San Diego 
School of Medicine, 
9500 Gilman Drive, Mailstop 0622 
San Diego, CA  92093 
Phone: 858-822-1952 
Fax: 858-534-4642 
E-mail: sstrathdee@ucsd.edu 
San Francisco 
John A. Newmeyer, Ph.D.  
Epidemiologist 
Haight-Ashbury Free Clinics, Inc. 
612 Clayton Street, 2nd Floor 
San Francisco, CA  94117 
Phone: 415-931-5420 
Fax: 415-864-6162 
E-mail: jnewmeyer@aol.com 
Seattle 
Caleb Banta-Green, M.P.H., M.S.W. 
Research Scientist 
Alcohol and Drug Abuse Institute 
University of Washington 
Suite 120 
1107 N.E. 45th Street 
Seattle, WA  98105 
Phone: 206-685-3919 
Fax: 206-543-5473 
E-mail: calebbg@u.washington.edu 
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Texas 
Jane C. Maxwell, Ph.D.  
Research Professor 
Center for Social Work Research  
University of Texas at Austin 
Suite 335 
1717 West 6th Street 
Austin, TX  78703 
Phone: 512-232-0610 
Fax: 512-232-0616 
E-mail: jcmaxwell@sbcglobal.net 
Washington, DC 
Eric Wish, Ph.D. 
Director 
Center for Substance Abuse Research 
4321 Hartwick Road 
Suite 501 
College Park, MD 20740  
Phone: 301-403-8329 
Fax: 301-403-8342 
E-mail: ewish@cesar.umd.edu 
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APPENDIX B. WEB SITES1 CONTAINING DATA  
 AND INFORMATION DISCUSSED  
 IN THIS PUBLICATION 
 
 
 
 
 
 
 
 
 
 
 
                                                 
1All Web addresses given in this appendix are current as of November 2005. 
1.  National Institute on Drug Abuse 
(NIDA)
2.  The Office of National Drug Control 
Policy (ONDCP)
3.  Office of Applied Studies (OAS), 
Substance Abuse and Mental Health
Services Administration (SAMHSA)
4.  Drug Enforcement Administration
¾ Intelligence Division
¾ Diversion Control Division
5.  National Drug Intelligence Center
(NDIC)
7. Centers for Disease Control and
Prevention (CDC)
¾ National Center for Chronic Disease
Prevention and Health Promotion
¾ National Center for HIV, STD, 
and TB Prevention
6. Federal Bureau of Investigation,
Uniform Crime Reports
8. American Association of Poison
Control Centers (AAPCC)
9. Other Web Sites:
¾ USACops
¾ U.S. Customs and Border Protection
¾ U.S. Census Bureau 
U.S. Census Bureau
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National Institute on Drug Abuse (NIDA) 
 
Web address:  http://www.nida.nih.gov  
NIDA supports intramural and extramural research on all aspects of drug abuse and addiction.  The extramural 
program supports scientists in universities and research centers around the country and abroad in conducting a wide 
range of basic, clinical, and epidemiologic studies to increase understanding of drug addiction and improve methods 
of preventing and treating it. 
 
Soon after its inception in 1974, NIDA launched the Community Epidemiology Work Group (CEWG) and the 
Monitoring the Future (MTF) surveys to assess drug abuse patterns and track nationwide trends. 
 
This Web site provides access to data/information produced by five ongoing NIDA drug abuse data sources (CEWG 
and MTF) and links to data sources supported by other agencies and institutions.  These other data sources include 
Computer Retrieval of Information on Science Projects (CRISP), a searchable database of federally funded 
biomedical research projects being conducted at universities, hospitals, and other research institutions. This 
database includes NIDA grantees who are conducting drug abuse research. 
 
Monitoring the Future (MTF) Survey is conducted by the University of Michigan’s Institute for Social Research (ISR) 
and funded by NIDA.  MTF has tracked 12th graders’ illicit drug use and attitudes towards drugs since 1975.  In 1991, 
8th and 10th graders were added to the study.  The 2004 study surveyed 49,500 students in 406 schools across the 
Nation about their lifetime use, past-year use, past-month use, and daily use of drugs, alcohol, and cigarettes and 
smokeless tobacco. 
 
Additional information about the MTF survey, related publications, and press releases, as well as links to other ISR 
research projects can be found at www.monitoringthefuture.org.   
 
NIDA sponsors and conducts epidemiologic research to monitor and assess the complex and constantly changing 
phenomenon of drug abuse.  The Community Epidemiology Work Group, established by NIDA in 1976, provides 
ongoing community-level surveillance of drug abuse through the collection and analysis of epidemiologic and 
ethnographic data.  The CEWG meets semiannually to review epidemiologic and ethnographic data from 20 U.S. 
metropolitan areas and the State of Texas. 
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CEWG members representing the areas rely on multiple sources of information, including the types listed below: 
 
• Survey findings 
• Drug abuse treatment admissions and discharges 
• Drug-related deaths 
• Emergency department drug abuse episodes 
• Public health data 
• AIDS cases associated with injection drug use 
• Drug-related arrests 
• Forensic laboratory analyses 
• Price and purity levels (of illicit drugs) 
• Ethnographic research 
• Qualitative information 
 
Each data source is a potential drug abuse indicator.  By comparing and assessing data from different sources 
concurrently, members obtain a more comprehensive view of drug abuse patterns and trends.  One source can 
complement and support another.  Each data source may also represent different populations of users and the 
agencies that serve their needs. Interpretation of indicator data, therefore, requires an understanding of the strengths 
and weaknesses of each data source and variables within each database. 
 
CEWG Meeting Reports are based on data/information reported at biannual meetings.  At the meetings, CEWG 
members present data on drug abuse from a variety of city, State, Federal, and other sources.  These data are 
enhanced with information gathered through qualitative methods.  From each meeting stem the following 
publications: 
 
• Epidemiologic Trends in Drug Abuse – Advance Report 
• Volume I:  Highlights and Executive Summary 
• Volume II:  Proceedings of the Epidemiology Work Group on Drug Abuse 
 
These reports are available online at www.nida.nih.gov/about/organization/cewg/Reports.html. 
 
The Computer Retrieval of Information on Scientific Projects (CRISP) is a searchable database of federally 
funded biomedical research projects conducted at universities, hospitals, and other research institutions.  The 
database, maintained by the Office of Extramural Research at the National Institutes of Health, includes projects 
funded not only by NIDA but also by the National Institutes of Health (NIH), Substance Abuse and Mental Health 
Services Administration (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug 
Administration (FDA), Centers for Disease Control and Prevention (CDC), Agency for Health Care Research and 
Quality (AHRQ), and Office of Assistant Secretary of Health (OASH). Users, including the public, can use the CRISP 
interface to search for emerging trends and techniques or to identify specific projects and/or investigators.  CRISP 
can be viewed at http://crisp.cit.nih.gov. 
 
Related Links with other NIDA constituent organizations, grantees, and government sites of interest are also 
available. 
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The Office of National Drug Control Policy (ONDCP) 
 
Web address:  http://www.whitehousedrugpolicy.gov  
 
ONDCP is a component of the White House resources under the Office of the President.  Initiated in 1988 by the 
Anti-Drug Abuse Act, ONDCP establishes policies, priorities, and objectives to reduce the illicit use, manufacturing, 
trafficking, crime, and health consequences directly related to the abuse of drugs.  The ONDCP Web site provides 
the public with an array of data/information on substance abuse. 
 
Drug Facts provides data and information on specific drugs and drug-abusing populations, and the subcategories of 
specific drugs.  
 
Information is also provided on a wide range of topics, including the extent of drug use, health effects, treatment, 
arrest and sentencing, production and trafficking, legislation, street terms, and other links. 
 
ONDCP Major Cities Initiative 
 
The Major Cities Initiative develops and supports the leadership in 25 targeted cities—particularly in the areas of 
drug prevention, drug treatment, and public safety—to enhance cooperation and accomplish significant improvement 
in key measures of drug use in each city.  A State-of-the-City Profile for each targeted city can be accessed by 
selecting a city from the map or the drop down menu.   
 
High-Intensity Drug-Trafficking Areas (HIDTA) 
 
The HIDTA program provides Federal resources to areas within the United States that exhibit serious drug trafficking 
problems. The HIDTA link directs one to a map showing HIDTA sites and to individual HIDTA summaries for each 
site. 
 
State and Local Profiles, Contacts, and Resources 
 
The State and Local link on the Home Page allows the user to access each State’s profile, contact information, and 
various other resources with respect to drug policy information.  The drop box (like the HIDTA page’s drop box) 
transfers the user to the specific State information page, which consists of links to the information. 
 
Science and Technology is a link to Research, which is a link to the comprehensive list of Research, Science, and 
Technology resources. 
 
Related Links to other sites offers a listing of other Web pages that provides drug abuse data/information.  These 
links take the user to completely different Web pages that are not created or maintained by the Office of National 
Drug Control Policy.   
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Office of Applied Studies (OAS), 
Substance Abuse and Mental Health Services 
Administration (SAMHSA) 
 
Web site:  http://www.oas.samhsa.gov 
 
SAMHSA is the lead Federal agency within the Department of Health and Human Services for improving access to 
quality substance abuse prevention, addiction treatment, and mental health services in the United States.  OAS, an 
office within SAMHSA, is the primary source of national data on the prevalence, treatment, and consequences of 
substance abuse. Data are collected on the Nation’s treatment systems and outcomes.  These data are intended to 
serve as statistical indicators of progress in the field and to provide a better understanding of the nature and extent of 
substance abuse in order to improve prevention and treatment services and reduce substance abuse in this country.  
Data from the OAS data systems are available to the public, researchers, and other interested persons through 
published and Web site reports.  OAS produces several publication series that provide national and State data on 
alcohol, tobacco, and illegal drug use and their correlates and consequences.  In addition, persons may do their own 
data analysis using the Substance Abuse and Mental Health Data Archives (SAMHDA) system that provides for 
data analysis either online or by downloading public use tapes.  Additional information about SAMHDA and how it can 
be used is provided in a section below. 
 
Data/information can be obtained from the following OAS sources on the Web site: 
 
Latest Data  This link provides access to recently released reports, by data system and time period (e.g., year). 
 
National Survey on Drug Use and Health (NSDUH) Previously called the National Household Survey on Drug 
Abuse, NSDUH reports on the prevalence patterns and consequences of drug and alcohol use and abuse in the 
general U.S. civilian noninstitutionalized population age 12 and older.  Data are collected on the use of illicit drugs, 
nonmedical use of licit drugs, and use of alcohol and tobacco products.  The survey is conducted annually and is 
designed to produce drug and alcohol use incidence and prevalence estimates.  Data are also collected periodically 
on special topics, such as criminal behavior, treatment, mental health, and attitudes about drugs.  Incidence data 
describe emerging patterns of substance abuse, particularly among young people.  Incidence estimates are based on 
retrospective reports of age of first use of particular substances by respondents interviewed.  Incidence rates are 
reported as the number of new users per 1,000 potential (persons who have not yet used the substance) users. Data 
are reported nationally, and findings on selected variables are reported by State and periodically by substate areas. 
 
Drug and Alcohol Services Information System (DASIS), the primary source of national data on substance abuse 
treatment, has three components: 
 
• Substance Abuse Treatment Facility Locator provides names/addresses of local providers and of Single 
State Agencies. Facility Locator information is available at http://findtreatment.samhsa.gov. 
 
• National Survey of Substance Abuse Treatment Services (N-SSATS)  Treatment data are collected on 
location, patient characteristics, services offered, and numbers of clients in public and private alcohol and 
drug abuse treatment in the 50 States, the District of Columbia, and other U.S. jurisdictions.  N-SSATS is a 
point-prevalence survey collecting data collected on and for a particular (reference) date.  See also 
http://www.drugabusestatistics.samhsa.gov. 
 
• Treatment Episode Data Set (TEDS) is minimum data set that includes demographic and substance abuse 
characteristics of admissions to substance abuse treatment. These data are routinely collected by State 
administrative systems and submitted to SAMHSA in a standard format.  Some States also report discharge 
status data.  The most recent data reported by States, the District of Columbia, and Puerto Rico are 
presented by primary substance of abuse, according to gender, age, and race/ethnicity. See 
http://www.drugabusestatistics.samhsa.gov. 
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Drug Abuse Warning Network (DAWN) is a public health surveillance system that collects and reports data on: 
• Drug-related hospital emergency department cases 
• Drug-related deaths reported by medical examiners 
 
DAWN data are both local (metropolitan area) and national in scope.  A scientific sample of hospitals, by geographic 
area, participates in DAWN.  Eligible hospitals include non-Federal, short-term, general hospitals that operate 24-
hour emergency departments.  Types of drugs covered in DAWN include illegal drugs, prescription and over-the-
counter medications, dietary supplements, non-pharmaceutical inhalants, and alcohol.  Data are collected through a 
retrospective review of patient medical records and decedent case files.  OAS publishes national and metropolitan 
area estimates of drug-related emergency department visits each year.  Mortality data are published annually for 
each participating jurisdiction.  SAMHSA is required to collect DAWN data under Section 505 of the Public Health 
Service Act (42 U.S.C. 290aa-4). Both DAWN systems were redesigned in 2003, and data from 2002 and before 
cannot be compared with those from 2003 and subsequent years. See http://DAWNinfo.samhsa.gov. 
 
Substance Abuse and Mental Health Data Archive (SAMHDA) provides ready access to substance abuse and 
mental health research data and promotes the sharing of these data among researchers, academics, policymakers, 
service providers, and others.  The online analysis system allows one to run both simple and complex analyses, 
recode and compute new variables, subset variables, or cases for downloading, and run Quick Tables.  One objective 
is to increase the use of the data in understanding and assessing substance abuse and mental health problems and 
the impact of related treatment systems.  The data archive is also intended to expand the variety of media on which 
data are available and to make the data available in a user-friendly format.  The Web site features a data analysis 
system (DAS) that allows users to conduct analyses on selected datasets within the archive.  SAMHDA also provides 
user support through e-mail and a toll-free helpline. 
 
 
 
 
 
 
 
 
 
 
Drug Enforcement Administration (DEA) 
 
Intelligence Division 
 
Web address:  http://www.usdoj.gov/dea/programs/intelligence.htm 
 
In coordination with Federal, State, local, and foreign law enforcement organizations, the DEA collects, analyzes, and 
disseminates drug-related intelligence.  The DEA Intelligence Program gathers information that leads to drug seizures 
and arrests and provides policymakers with drug and drug trend information upon which program decisions can be 
made.  The DEA’s intelligence missions are to: 
 
• Collect and produce intelligence in support of the Administrator and other Federal, State, and local agencies 
• Establish and maintain close working relationships with all agencies that produce or use narcotics intelligence 
• Increase the efficiency in the reporting, analysis, storage, retrieval, and exchange of such information 
• Continue review of the narcotics intelligence effort to identify and correct deficiencies 
 
The DEA Intelligence System includes domestic field divisions; district, resident, and foreign officers; the El Paso 
Intelligence Center; and the Intelligence Division at DEA Headquarters. 
 
Stats and Facts is the link to State Fact Sheets for the 50 States and Washington, DC. Fact Sheets include the most 
recent information about the general drug situation (e.g., trafficking, availability, and abuse of particular drugs) and 
more detailed information about specific drugs (e.g., seizures) in each area. 
 
Drug Information provides descriptions and up-to-date information (including reports) on more than 50 drugs. 
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Diversion Control Program (DEA) 
 
Web address:  http://www.deadiversion.usdoj/gov 
 
The DEA Office of Diversion Control (ODC) is responsible for assessing and addressing the diversion of controlled 
pharmaceuticals and controlled chemicals.  ODC staff include diversion investigators, special agents, chemists, 
pharmacologists, and program analysts. The activities of this office include field management oversight; coordination 
of major investigations; drafting and promulgating of regulations; legal control of drugs and chemicals not previously 
under Federal control; control of imports and exports of drugs and chemicals; computerized monitoring and tracking; 
the distribution of certain controlled substances; and providing distribution intelligence to the States.  Data/information 
on drugs and drug distribution are collected and reported on the Web site. 
 
Publications through which diversion data/information are reported include Informational Brochures, Manuals, 
Newsletters, Press Releases, and Program Reports.  
 
Drugs/Chemicals of Concern provides data/information on a variety of prescription and over-the-counter drugs 
including fentanyl, hydrocodone, hydromorphone, ketamine, oxycodone, salvia divinorum, and tramadol. 
 
ARCOS is the link for the Automation of Reports and Consolidated Orders System that monitors the flow of DEA 
controlled substances from their point of manufacture, through commercial distribution channels, to point of sale or 
distribution at the dispensing/retail levels.  The information is used to identify the diversion of controlled substances 
into illicit channels of distribution.  ARCOS retail drug distribution data are reported (PDF format) by Zip Code and 
State.  These data can be accessed directly at retail drug summary. 
 
NFLIS is the link for the National Forensic Laboratory Information System that systematically collects results from 
solid dosage drug analyses conducted by State and local forensic laboratories across the country.  These data are 
used to monitor and assess drug abuse and trafficking in the U.S., including the diversion of legally manufactured 
drugs into illegal markets.  NFLIS laboratory results, validated by chemical analysis, have a degree of validity.  
Approximately 300 State and local forensic laboratories perform nearly 2 million drug analyses each year. 
 
DEA Field Offices 
 
To obtain drug intelligence data for your area, first contact the appropriate DEA division office. You will then be 
directed to an agent covering your community. 
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Atlanta Division 
(404) 893-7000 
Offices 
Augusta, GA 
Columbus, GA 
Macon, GA 
Rome, GA 
Savannah, GA 
Asheville, NC 
Charlotte, NC 
Greensboro, NC 
Raleigh, NC 
Wilmington, NC 
Beaufort, SC 
Charleston, SC 
Columbia, SC 
Florence, SC 
Greenville, SC 
Chattanooga, TN 
Jackson, TN 
Johnson City, TN 
Knoxville, TN 
Memphis, TN 
Nashville, TN 
Boston Division 
(617) 557-2100 
Offices 
Bridgeport, CT 
Hartford, CT 
New Haven, CT 
New Bedford, MA 
Springfield, MA 
Bangor, ME 
Portland, ME 
Manchester, NH 
Portsmouth, NH 
Providence, RI 
Burlington, VT 
Caribbean Division 
(787) 775-1815 
Offices 
Bridgetown, Barbados 
Santo-Domingo, D.R. 
Port-au-Prince, Haiti 
Kingston, Jamaica 
Curacao, Neth. Ant. 
Ponce, Puerto Rico 
Port of Spain, Trinadad & 
Tobago 
St. Thomas, VI 
St. Croix, VI 
Chicago Division 
(312) 353-7875 
Offices 
Rockford, IL 
Springfield, IL 
Evansville, IN 
Ft. Wayne, IN 
Indianapolis, IN 
Merrillville, IN 
Minneapolis/St. Paul, 
MN 
Bismarck, ND 
Fargo, ND 
Green Bay, WI 
Madison, WI 
Milwaukee, WI 
Dallas Division 
(214) 366-6900 
Offices 
McAlester, OK 
Oklahoma City, OK 
Tulsa, OK 
Amarillo, TX 
Ft. Worth, TX 
Lubbock, TX 
Tyler, TX 
Denver Division 
(303) 705-7300 
Offices 
Colorado Springs, CO 
Glenwood Springs, CO 
Grand Junction, CO 
Steamboat Springs, CO 
Billings, MT 
Missoula, MT 
Salt Lake City, UT 
St. George, UT 
Casper, WY 
Cheyenne, WY 
Detroit Division 
(313) 234-4000 
Offices 
Kalamazoo, MI 
Lexington, KY 
London, KY 
Louisville, KY 
Madisonville, KY 
Lansing, MI 
Grand Rapids, MI 
Saginaw, MI 
Cincinnati, OH 
Cleveland, OH 
Columbus, OH 
Dayton, OH 
Toledo, OH 
Youngstown, OH 
El Paso Division 
(915) 832-6000 
Offices 
Albuquerque, NM 
Las Cruces, NM 
Alpine, TX 
Midland, TX 
Houston Division 
(713) 693-3000 
Offices 
Austin, TX 
Beaumont, TX 
Brownsville, TX 
Corpus Christi, TX 
Del Rio, TX 
Eagle Pass, TX 
Galveston, TX 
Laredo, TX 
McAllen, TX 
San Antonio, TX 
Waco, TX 
Los Angeles Division 
(213) 621-6700 
Offices 
Riverside, CA 
Santa Ana, CA 
Ventura, CA 
Guam 
Hilo, HI 
Honolulu, HI 
Maui, HI 
Lake Tahoe, NV 
Las Vegas, NV 
Reno, NV 
Miami Division 
(305) 994-4870 
Offices 
Freeport, Bahamas 
Nassau, Bahamas 
Ft. Lauderdale, FL 
Ft. Myers, FL 
Gainesville, FL 
Jacksonville, FL 
Key Largo, FL 
Key West, FL 
Orlando, FL 
Panama City, FL 
Pensacola, FL 
Port St. Lucie, FL 
Tallahassee, FL 
Tampa, FL 
Titusville, FL 
W. Palm Beach, FL 
New Jersey Division 
(973) 776-1100  
Offices 
Atlantic City, NJ 
Camden, NJ 
Paterson, NJ 
New Orleans Division 
(504) 840-1100 
Offices 
Birmingham, AL 
Huntsville, AL 
Mobile, AL 
Montgomery, AL 
Fayetteville, AR 
Ft. Smith, AR 
Little Rock, AR 
Baton Rouge, LA 
Lafayette, LA 
Monroe, LA 
Shreveport, LA 
Gulfport, MS 
Jackson, MS 
Oxford, MS 
New York Division 
(212) 337-3900 
Offices 
Albany, NY 
Buffalo, NY 
Long Island, NY 
Plattsburgh, NY 
Rochester, NY 
Syracuse, NY 
Westchester Cty, NY 
Philadelphia Division 
(215) 861-3474 
Offices 
Dover, DE 
Wilmington, DE 
Allentown, PA 
Harrisburg, PA 
Pittsburgh, PA 
Scranton, PA 
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Phoenix Division 
(602) 664-5600 
Offices 
Flagstaff, AZ 
Lake Havasu City, AZ 
Nogales, AZ 
Sierra Vista, AZ 
Tucson, AZ 
Yuma, AZ  
San Diego Division 
(858) 616-4100 
Offices 
Carlsbad, CA 
Imperial County, CA 
San Ysidro, CA  
San Francisco 
Division 
(415) 436-7900 
Offices 
Bakersfield, CA 
Fresno, CA 
Modesto, CA 
Oakland, CA 
Redding, CA 
Sacramento, CA 
San Jose, CA 
Santa Rosa, CA 
Seattle Division 
(206) 553-5443 
Offices 
Anchorage, AK 
Fairbanks, AK 
Boise, ID 
Bend, OR 
Eugene, OR 
Medford, OR 
Portland, OR 
Salem, OR 
Blaine, WA 
Spokane, WA 
Tacoma, WA 
Tri-Cities, WA 
Yakima, WA 
St. Louis Division 
(314) 538-4600 
Offices 
Cedar Rapids, IA 
Des Moines, IA 
Sioux City, IA 
Carbondale, IL 
Fairview Hts., IL 
Quad Cities, IL 
Garden City, KS 
Kansas City, KS 
Topeka, KS 
Wichita, KS 
Cape Giradeau, MO 
Jefferson City, MO 
Springfield, MO 
North Platte, NE 
Omaha, NE 
Rapid City, SD 
Sioux Falls, SD 
Washington, DC 
Division 
(202) 305-8500 
Offices 
Baltimore, MD 
Hagerstown, MD 
Salisbury, MD 
Bristol, VA 
Hampton, VA 
Norfolk, VA 
Richmond, VA 
Roanoke, VA 
Winchester, VA 
Charleston, WV 
Clarksburg, WV 
Wheeling, WV 
 
 
 
 
 
 
 
 
 
 
National Drug Intelligence Center (NDIC) 
 
Web address:  http://www.usdoj.gov/ndic/index.htm 
 
NDIC was established in 1993 as a component of the U.S. Department of Justice (DOJ) to be a focal point for 
counter-drug intelligence.  It gathers intelligence on drug production and drug use and assesses the threat of illicit 
substances by geographic area. 
 
National and State threat assessment reports can be found under Publications.  
 
The National Drug Threat Assessment is an annual NDIC report on national drug trafficking and abuse trends 
within the United States.  The report identifies “drug threats,” monitors fluctuations in drug consumption levels, and 
tracks drug availability by geographic market.  It includes current quantitative and qualitative information on 
availability, demand, production, cultivation, transportation, and distribution, as well as the effects of particular drugs. 
 
State Drug Threat Assessment reports provide detailed threat assessments of drug patterns and trends in a 
particular State.  Each report identifies the primary drug threats in the State and gives a detailed overview of the most 
current trends by drug type. State reports are periodically updated. 
 
Bulletins and Briefs are responses to new trends or high-priority drug issues.  They are quickly transmitted to law 
enforcement and intelligence officials to warn them of emerging drug, drug patterns, and trends. 
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Federal Bureau of Investigation (FBI) 
Uniform Crime Reports (UCR) 
 
Web address:  http://www.fbi.gov/ucr/ucr.htm/  
 
The FBI compiles crime data collected from more than 17,000 law enforcement agencies annually to form the data 
set known as the Uniform Crime Report (UCR). 
 
These data include arrests for drug abuse violations by State and county and also the demographics for arrestees 
(i.e., age, sex, and race). 
 
Data pertaining to drug abuse violation arrests are collected in specific drug categories by type of arrest (i.e., Sales 
and Manufacturing or Possession).  The drug categories include Opium or Cocaine and Derivatives, Marijuana, 
Synthetic Narcotics, and Other Dangerous Narcotic Drugs. 
 
UCR Reports available on the FBI Web site include data by State but not by county.  To obtain the most recent 
reports that include county data, one should contact the State law enforcement agency responsible for reporting UCR 
data to the FBI.  Generally, hard copies of the most recent State UCR report can be obtained from the State agency. 
 
 
 
 
 
 
 
Centers for Disease Control and Prevention (CDC) 
 
National Center for Chronic Disease Prevention 
and Health Promotion 
 
Web address:  http://www.cdc.gov/HealthyYouth/YRBS/ 
 
CDC, a component of the Department of Health and Human Services, is the lead Federal agency for protecting the 
health and safety of people, providing credible information to enhance health decisions, and promoting health through 
partnerships.  It carries out this role through disease prevention and control, environmental health, and health 
promotion and education activities. 
 
Youth Risk Behavior Surveillance System (YRBSS) 
 
The YRBSS, developed in 1990, monitors health risk behaviors that contribute markedly to the leading causes of 
death, disability, and social problems among youth and young adults in the United States.  These behaviors include 
tobacco use, alcohol use, and other drug use. 
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The YRBSS is designed to: 
 
• Determine the prevalence of health risk behaviors 
• Assess whether health risk behaviors increase, decrease, or stay the same over time 
• Examine the co-occurrence of health risk behaviors 
• Provide comparable national, State, and local data 
• Provide comparable data among subpopulations of youth 
• Monitor progress toward achieving the Healthy People 2010 objectives and other program indicators 
 
The YRBSS includes national, State, and local school-based surveys of representative samples of 9th through 12th 
grade students.  The Youth Risk Behavior Survey (YRBS) is conducted every 2 years, usually during the spring 
semester.  The national survey, conducted by CDC, provides data representative of high school students in public 
and private schools in the United States.  The State and local surveys, conducted by departments of health and 
education, provide data representative of the State or local school district. 
 
At-A-Glance Report:  Assessing Health Risk Behaviors Among Young People:  Youth Risk Behavior 
Surveillance System, 2004 
 
 
National Center for HIV, STD, and TB Prevention 
 
Web address:  http://www.cdc.gov/hiv/stats/hasrlink.htm/ 
           http://www.cdc.gov/hiv/stats/hasr1402/website.htm 
 
The CDC Web sites include HIV/AIDS data by region but not by State, county, or city.  State and territorial health 
departments use local HIV/AIDS surveillance programs to report surveillance data to CDC.  These are the best 
sources of local HIV/AIDS, hepatitis B, and hepatitis C data. 
 
The Morbidity and Mortality Weekly Report (MMWR) series includes provisional weekly data based on reports to 
CDC by State health departments.  Data are provisional because of delayed reporting and the ongoing revision of 
information. 
 
The HIV/AIDS Surveillance Supplemental Report is an annual report on persons with diagnoses of HIV infection 
and AIDS, persons living with a diagnosis of HIV infection or AIDS, reported cases of HIV/AIDS and AIDS, and 
deaths among persons with AIDS, by race/ethnicity, in the United States 
http://www.cdc.gov/hiv/stats/hasrlink.htm. 
 
Estimated Numbers of Persons Living with HIV infection (not AIDS) by exposure category and year and by 
race/ethnicity and age. 
 
HIV/AIDS exposure categories by gender include: 
 
• Injection drug use 
• Male-to-male sexual contact and injection drug use 
• Heterosexual contact 
 
Acute Hepatitis  http://www.cdc.gov/ncidod/diseases/hepatitis/resource/index.htm (Hepatitis Surveillance 
Report).   This recent report is largely national data, however, Figure 12 shows the Incidence of Acute Hepatitis B by 
Region (Northwest, Northeast, etc.) and Figure 13 shows the same by county.  
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American Association of Poison Control Centers 
(AAPCC) 
 
Web site:  http://www.aapcc.org/ 
 
AAPCC is a nationwide association of Poison Control Centers in the United States.  It collects, analyzes, and reports 
on poisoning data submitted by centers. 
 
Find Your Poison Center  Local centers can be identified by clicking on a map of States, by entering a zip code or 
by directory. 
 
Poisoning Data can be accessed directly. 
 
Poison Center Survey Results are through annual reports. 
 
 
 
 
Other Web Sites 
 
 
 
 
USACOPS 
 
Web address:  http://www.usacops.com/  
 
USACOPS, a national directory of law enforcement agencies in the United States, is supported by donations.  
Contact information (person in charge, address, and telephone numbers) can be accessed for local (county/city) 
police departments and sheriffs’ offices. 
 
It is possible to obtain information on drug arrests (cases) for particular drugs (trafficking, production, availability, and 
cost). 
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U.S. Customs and Border Protection (CBP) 
U.S. Department of Homeland Security 
 
Web address:  http://www.cbp.gov/ (Formerly, U.S. Customs site); click on News Releases. 
 
This Web site contains CBP news releases by date.  
 
 
 
 
 
 
 
U.S. Census Bureau 
 
Web address:  http://www.census.gov; click on American FactFinder™ 
 
This Web site contains census data by geographic area on population size and sociodemographic population 
characteristics. 
U.S. Census Bureau
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